

Ref: NLL/CS/2019-102

Dated: 22/08/2019

To

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Notice of Annual General Meeting, Annual Report and Remote e-voting Instructions.

Sir's,

Pursuant to Regulation 30 and 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of the Annual Report for the financial year ended on 31.03.2019, containing therein, inter alia,:


1. Notice of 24th Annual General Meeting.
2. Standalone financial statements, Directors' and Auditors' Reports thereon
3. Consolidated financial statements and Auditors Report thereon
4. Corporate Governance Report
5. Management Discussion and Analysis Report
6. E-voting instructions.

This is for your information and records please.

Thanking you,

Yours Sincerely,

For Nectar Lifesciences Limited



(Sukriti Saini)

Company Secretary

Encl. as above

ANNUAL REPORT 2018-2019



Nectar Lifesciences Ltd.

SERVING HUMANITY, SAVING LIVES

Disclaimer

In this annual report, we have disclosed forward-looking information to help investors comprehend our prospects and take informed investment decisions. This report is based on certain forward-looking statements that we periodically make to anticipate results based on the managements's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should know or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, or estimated projected. We undertake no obligation to publicly update any forward-looking statements, whether as a results of new information, future events or otherwise.

Contents

Notice	01
Report on Corporate Governance	16
Profit & Loss Account	45
Notes	49

Directors' Report	07
Auditors' Report	40
Cash Flow Statement	46
Consolidated Financial Statements	62

Management Discussion and Analysis	11
Balance Sheet	44
Accounting Policies	47
Statement of Subsidiary Companies	84

NOTICE
Nectar Lifesciences Limited
(Corporate Identification Number: L24232PB1995PLC016664)
Registered Office: Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab
Email : cs@neclife.com, **Website :** www.neclife.com
Phone : +91-01762-308000, **Fax :** +91-01762- 308135

(Note: The business of this Meeting may be transacted through electronic voting system)

NOTICE is hereby given that the 24th Annual General Meeting of Nectar Lifesciences Limited will be held at the registered office and works of the company at Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab on Saturday, September 28, 2019 at 10.00 A.M. to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Standalone Financial Statements of the Company for the year ended March 31, 2019 and the Reports of the Board of Directors and Auditors thereon and Consolidated Financial Statements of the Company for the year ended March 31, 2019 and the Report of Auditors thereon.
2. To declare Final Dividend @5% i.e. Re. 0.05/- per equity share for the financial year ended on March 31, 2019.
3. To appoint a Director in place of Dr. Dinesh Dua (DIN – 02436706), who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

4. To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary** Resolution:

“**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made thereunder (including any statutory modification(s) or re-enactment thereof, for the time being in force), the remuneration payable to V. KUMAR & ASSOCIATES (Firm registration no. 100137), appointed by the Board of Directors as Cost Auditors to conduct the audit of the cost records of the Company for the financial year ending March 31, 2020, amounting to Rs. 2,00,000/- (Rupees Two Lacs only) as also the payment of tax(es) as applicable and re-imbursment of out of pocket expenses incurred in connection with the aforesaid audit, be and is hereby ratified and confirmed.

FURTHER RESOLVED THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

5. To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary** Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 152, read with Schedule IV to the Companies Act, 2013 ('Act') and any other applicable provisions of the Act and the Rules made thereunder and Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), including any statutory amendment(s) or re-enactment(s) thereof, Dr. Rupinder Tewari (DIN 07009485), who was appointed as an Additional Director of the Company by the Board of Directors in terms of Section 161(1) of the Act and the Articles of Association of the Company and whose term of office expires at the Annual General Meeting and who has submitted a declaration that he meets the criteria for independent

as provided in Section 149(6) of the Act and LODR Regulations, be and is hereby appointed as an Independent Director of the Company to hold office for a term of five years i.e. upto February 11, 2024, and shall not be liable to retire by rotation.

FURTHER RESOLVED THAT Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be deemed proper and expedient to give effect to this Resolution.”

6. To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special** Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 203 and read with Schedule V and any other applicable provisions of the Companies Act, 2013 and the rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) (hereinafter referred to as, “the Act”) and pursuant to the provisions of Memorandum and Articles of Association and subject to the approval of Central Government, if necessary, the consent of the members be and is hereby accorded to the re-appointment of Dr. Dinesh Dua (DIN - 02436706) as a Wholetime Director, designated as Chief Executive Officer & Director of the company for a period of One Year w.e.f. October 14, 2019 on the terms and conditions including remuneration as are set out herein below:

- a. **Salary:** Rs. 738,462.00 (Rupees Seven Lacs Thirty Eight Thousand Four Hundred and Sixty Two only) per month and inclusive of perquisites of leave travel.
- b. He is also entitling to bonus equivalent to his one month salary in a financial year, proportionately to his tenure in a year.
- c. **Other Perquisites:** He shall be entitled to personal accident insurance, club fees, company maintained car, telephone and such other perquisites in accordance with the company's rules, the monetary value of such perquisites to be determined in accordance with the Income Tax Rules, 1962, being restricted to Rs. 1.00 lacs per annum.

FURTHER RESOLVED THAT Board of Directors be and is hereby authorised to alter and vary such terms of appointment and remuneration so as to not to exceed the limits specified in Schedule V to the Companies Act, 2013.”

7. To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special** Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 152, read with Schedule IV to the Companies Act, 2013 ('Act') and any other applicable provisions of the Act and the Rules made thereunder and Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), including any statutory amendment(s) or re-enactment(s) thereof, Dr. (Maj. Gen.) Shamsher Singh Chauhan, VSM (DIN 02954776), who was appointed as an Independent Director of the Company by the Members and whose first term of office expires on September 29, 2019 and who has submitted a declaration that he meets the criteria for

independent as provided in Section 149(6) of the Act and LODR Regulations and who has attained the age of 75 years, be and is hereby re-appointed as an Independent Director of the Company to hold office for a second term of five years i.e. upto September 29, 2024, and shall not be liable to retire by rotation.”

FURTHER RESOLVED THAT Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be deemed proper and expedient to give effect to this Resolution.”

8. To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special** Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 152, read with Schedule IV to the Companies Act, 2013 (‘Act’) and any other applicable provisions of the Act and the Rules made thereunder and Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’), including any statutory amendment(s) or re-enactment(s) thereof, Mr. Ajay Swaroop (DIN – 02291700), who was appointed as an Independent Director of the Company by the Members and whose first term of office expires on September 29, 2019 and who has submitted a declaration that he meets the criteria for independent as provided in Section 149(6) of the Act and LODR Regulations, be and is hereby re-appointed as an Independent Director of the Company to hold office for a second term of five years i.e. upto September 29, 2024, and shall not be liable to retire by rotation.”

FURTHER RESOLVED THAT Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be deemed proper and expedient to give effect to this Resolution.”

By order of the Board of Directors
of **Nectar Lifesciences Limited**

Date : 14.08.2019
Place : Chandigarh

(Dinesh Dua)
Chief Executive Officer & Director

IMPORTANT NOTES:

1. **MEMBER ENTITLED TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING (‘AGM’) IS ENTITLED TO APPOINT A PROXY/ PROXIES TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF. SUCH A PROXY/ PROXIES NEED NOT BE A MEMBER OF THE COMPANY.** A person can act as proxy on behalf of members not exceeding fifty (50) and holding in the aggregate not more than ten per cent of the total share capital of the Company. A member holding more than ten per cent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.

The instrument of Proxy in order to be effective, should be deposited at the Registered Office of the Company, duly completed and signed, not less than 48 hours before the commencement of the AGM. A Proxy form is sent herewith. Proxies submitted on behalf of the companies, societies etc., must be supported by an appropriate resolution/authority, as applicable.

2. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (‘Act’), which sets out details relating to Special Business at the meeting, is annexed hereto. Details under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (hereinafter referred as ‘LODR Regulations’)

and under Secretarial Standard-2 issued by Institute of Company Secretaries of India, in respect of the Directors seeking appointment/re-appointment at the AGM, also contained in Explanatory Statement pursuant to Section 102 of the Act. The Directors have furnished the requisite declarations for their appointment/re-appointment.

3. The register of members and the share transfer books of the company will remain closed from September 22, 2019 to September 28, 2019 (Both days inclusive) in accordance with the provisions of the Act and the LODR Regulations, for the purpose of AGM and determining names of the shareholders eligible for dividend on equity shares, if declared. The dividend, if declared at the AGM, will be paid:
- (i) For equity shares held in physical form - those shareholders whose names will appear in the Register of Members on the close of the day on September 21, 2019.
- (ii) For equity shares held in dematerialised form - those beneficiaries, whose names are furnished by the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as beneficial owner on close of day on September 21, 2019.
4. Members holding shares in dematerialised form are requested to ensure that addresses furnished by them to their respective Depository Participants are correct and up-to-date, so that the correspondence from company could reach them promptly. However, the Members holding shares in physical form may notify the same to the Registrar and Share Transfer Agent of the Company.
5. Reserve Bank of India has introduced Electronic Clearing Service (NECS) for facilitating crediting of dividend directly to the shareholder’s bank account. This facility eliminates loss of dividend warrants sent by post due to pilferage in transit, delay in receipt of dividend warrants and ensures quick credit of the dividend. Members holding shares in dematerialised form are requested to notify / update their ECS details to / with their respective Depository Participants.

The Securities and Exchange Board of India (SEBI) has mandated the submission of PAN by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts.

SEBI has by its circular dated 20th April, 2018 mandated that the companies through their Registrar and Transfer Agents (RTA) take special efforts for collecting copies of PAN and bank account details for the holders holding securities in physical form. Those security holders whose folio(s) do not have complete details relating to their Permanent Account Number (PAN) and Bank Account, or where there is any change in the bank account details provided earlier, have to compulsorily furnish the details to RTA/ Company for registration/ updation.

6. Members who are holding shares in physical form are hereby informed that SEBI has amended regulation 40 of SEBI (LODR) Regulations, 2015 vide Notification dated June 8, 2018 and in terms of said notification except in case of transmission or transposition of securities, requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository.
7. Electronic copy of the Annual Report for 2018-19 is being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) for communication

purposes. For members who have not registered their email address, physical copies of the Annual Report for 2018-19 is being sent in the permitted mode.

8. Members may also note that the Notice of the 24th AGM and the Annual Report for 2018-19 will also be available on the Company's website www.neclife.com for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours on working days.
9. Members who hold shares in dematerialized form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the meeting. Corporate members intending to send their authorised representatives to attend and vote at the Meeting pursuant to Section 113 of the Companies Act, 2013 are requested to send, a certified true copy of the board resolution authorising their representative to attend and vote on their behalf at the Meeting.
10. Members desirous of having any information as regards accounts are requested to write to the company at least Seven days in advance so as to enable the Management to keep the information ready.
11. All documents referred to in the accompanying Notice and the Explanatory Statement shall be open for inspection at the Registered Office and Corporate Office of the Company during normal business hours (9.00 am to 5.00 pm) on all working days except Saturdays and Sundays, up to and including the date of the AGM of the Company. The details of above offices are given in this Annual Report.
12. Pursuant to the provisions of Section 124 and 125 of the Companies Act, 2013, the details of unpaid/unclaimed dividends lying with the Company as on the last AGM of the Company is available on the website of the Company.
13. Members are informed that the dividend amount for the year ended 2011-12 remaining unclaimed shall become due for transfer on November 5, 2019 to the Investor Education and Protection Fund (IEPF) established by the Central Government in terms of the Companies Act, 2013. Members are requested to note that no claim shall lie against the Company in respect of any amount of dividend remaining unclaimed / unpaid for a period of 7 years from the dates they became first due for payment.

The Company has already sent reminders to those members having shares in respect of which dividend remains unpaid or unclaimed for seven consecutive years or more from the date of transfer to unpaid dividend account, are required to be transferred to the IEPF Suspense Account. Details of such shareholders are also uploaded as per the requirements, on the Company's website www.neclife.com.

Members, who have not encashed their dividend, are advised to write to the Company or Registrar and Share Transfer Agent of the company Karvy Fintech Private Limited ("Karvy") immediately claiming dividends declared by the Company. Any member, who has not claimed dividend in respect of the financial year ended 2011-12 onwards, is requested to approach the Company/the Registrar and Share Transfer Agents of the Company in this respect.

The Company has already transferred all shares (in respect of which dividend has not been paid or claimed for seven consecutive years or more in respect Dividend upto 2010-11) to designated Demat Account of the IEPF maintained with

NSDL. Members who have so far not claimed or collected their dividends for the said period may claim their dividend and shares from the Investor Education and Protection Fund, by submitting an application in the prescribed form.

14. Members of the Company had approved the appointment of M/s. Ashwani K. Gupta & Associates, Chartered Accountants, as the Statutory Auditors at the 22nd AGM of the Company which is valid till 27th AGM of the Company. In accordance with the Companies (Amendment) Act, 2017, enforced on May 7, 2018 by Ministry of Corporate Affairs, the appointment of Statutory Auditors is not required to be ratified at every AGM.
15. Pursuant to Section 108 of Act read with Rule 20 of Companies (Management and Administration) Rules, 2014, the Company is pleased to provide members' facility to exercise their right to vote at the 24th AGM by electronic means (remote e-voting) and the business may be transacted through remote e-voting services provided by Karvy Fintech Private Limited ("Karvy"). The Members, whose names appear in the Register of Members / list of Beneficial Owners on the close of the day on Saturday, September 21, 2019 (cut-off date), i.e. the date prior to the commencement of book closure, are entitled to vote on the Resolutions set forth in this Notice. The voting rights of Members for e-voting and for physical voting at the meeting shall be in proportion to the paid up value of their shares in the equity share capital of the Company as on cut-off date.

The remote e-voting facility will be available at the link <https://evoting.karvy.com> during the following voting period:

Commencement of remote e-voting: FROM 9.00 a.m. on Wednesday, September 25, 2019

End of remote e-voting: TO 5.00 p.m. on Friday, September 27, 2019.

The remote e-voting will not be allowed beyond the aforesaid date and time and the e-voting module shall be disabled by Karvy upon expiry of aforesaid period.

In terms of provisions of Section 107 of the Companies Act, 2013, since the Company is providing the facility of remote e-voting to the shareholders, there shall be no voting by show of hands at the AGM. The facility for ballot / polling paper shall be made available at the Meeting and the members attending the Meeting who have not cast their vote by remote e-voting shall be able to vote at the Meeting through ballot / polling paper. The shareholders can opt for only one mode of voting i.e. remote e-voting or physical polling at the meeting. In case of voting by both the modes, vote casted through remote e-voting will be considered final and voting through physical ballot will not be considered. The members who have cast their vote by remote e-voting may also attend the Meeting.

The login ID and password for e-voting along with process and manner for generating or receiving the password and for casting of vote in a secure manner (remote e-voting instructions), is being sent alongwith this notice through permitted mode. Any person, who becomes member of the Company after dispatch of the Notice of the meeting and holding shares as on the cut-off date, may obtain the User Id and password in the manner as mentioned remote e-voting instructions. The persons, who have received this notice and e-voting details, ceased to be a Member as on the cut-off date should treat this and e-voting details Notice for information purposes only. The remote e-voting instructions are also available on the website of the company at www.neclife.com.

The Company has appointed Mr. Prince Chadha, Practising Company Secretary (C.P. No. 12409), as Scrutinizer to scrutinize the physical voting and remote e-voting process in a fair and transparent manner and he has communicated his willingness to be appointed and will be available for same purpose. He has also confirmed that in case of any emergency and he could not attend AGM, he shall be represented by CA Gaganpreet Garg, Chartered Accountant, who shall act as Scrutinizer for e-voting and polling on resolutions to be passed at the forthcoming AGM of the Company.

After the conclusion of voting at the general meeting, the scrutiniser shall, immediately first count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses (who shall not be in the employment of the company). Thereafter, Scrutinizer shall give a consolidated report, specifying the total votes cast in favour or against, if any, within forty eight hours of conclusion of the meeting, to the Chairman or a person authorised by him in writing who shall countersign the same. The Chairman or a person authorised by him in writing shall declare the result of the voting forthwith. The results declared shall be available on the website of the Company (www.neclife.com) and on the website of the Karvy (<https://evoting.karvy.com>). The results shall simultaneously be communicated to the Stock Exchanges. The resolutions will be deemed to be passed on the date of AGM subject to receipt of the requisite number of votes in favour of the resolutions.

16. KPRISM- Mobile service application by Karvy:

Members are requested to note that, Registrar and Share Transfer Agent, Karvy has launched a new mobile application - KPRISM and website <https://kprism.karvy.com> for online service to shareholders.

Members can download the mobile application, register yourself (onetime) for availing host of services viz., consolidated portfolio view serviced by Karvy, Dividends status etc. Through the Mobile app, members can download Annual reports, standard forms and keep track of upcoming General Meetings, IPO allotment status and dividend disbursements. The mobile application is available for download from Android Play Store. Alternatively visit the link <https://kprism.karvy.com/app/> to download the mobile application.

EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 AND INFORMATION PURSUANT TO REGULATION 36(3) OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARD – 2, ISSUED BY INSTITUTE OF COMPANY SECRETARIES OF INDIA.

Item No. 4

The Board, on the recommendation of the Audit Committee, has approved the appointment of V. KUMAR & ASSOCIATES (Firm registration no. 100137), Cost Accountants as the Cost Auditors to conduct the audit of the cost records of the Company for the financial year ending March 31, 2020 on the remuneration of Rs. 2 lacs. In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors has to be ratified by the shareholders of the Company.

Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out in the Notice for ratification of the remuneration

payable to the Cost Auditors for the financial year ending March 31, 2020. The Board recommends the Ordinary Resolution set out at Item no. 4 of the Notice for the approval of the Members.

None of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution.

Item No. 5

Based on recommendation of Nomination and Remuneration Committee and pursuant of provisions of Section 149, 150, 152, Schedule IV and other applicable provisions of the Companies Act, 2013 and LODR Regulations, the Board of Directors in their meeting held on February 11, 2019 have appointed Dr. Rupinder Tewari (DIN 07009485) as an additional director in the capacity of Independent Director of the company and he vacates his office at the ensuing Annual General Meeting. The Board has proposed the reappointment of Dr. Rupinder Tewari as an Independent Director at this Annual General Meeting of the Company for term of 5 years with effect from February 11, 2019, whose period of office shall not be liable to determination by retirement of directors by rotation.

Dr. Rupinder Tewari, aged 63 years, is a Professor and Coordinator in centre of Microbial Biotechnology, Panjab University, Chandigarh. A qualified B.Sc (Hons. School), M.Sc (Hons. School), Ph.D (Microbiology), Panjab University, Chandigarh (PU), Ph.D. (Microbiology) University of London, London, U.K. and Post Doctoral Fellow, Oakland University, Rochester, MI, USA (1986-87), Washington University, St. Louis, MO, USA (1987-90). He enjoys the experience of more than 40 years. Total research publications are 100, he has written 5 books on Microbiology and Biotechnology. He has also filed a patent (Rapid detection of typhoid).

He was senate member of PU from 2008 to 2016 and Dean (Faculty of Science) from 2012 to 2014. He is Founder & Chief-Coordinator, 'DST-Centre for Policy Research', PU, Chd. (2014-till date). He was also a Founder & Chief-Coordinator, BIRAC (GoI) sponsored 'Centre for Innovation Cluster in Biotechnology (CIC-B)' in PU, Chd. (2014-16). He also designed "Biotechnology Policy-2004" for U.T. (Chandigarh). He has expertise in Microbiology and Biotechnology.

He does not have any relationship with any other director of the company. He does not hold any equity share in the company. He is not director in any other company as on date.

The details of number of Board and committee meetings attended by him are given in Corporate Governance Report. The details of sitting fee drawn have been provided in the Corporate Governance Report, forming part of the Annual Report. He will be eligible for payment of sitting fee, as payable to other non-executive directors of the Company. The terms and conditions of appointment of Independent Directors have been disclosed on the website of the Company as required in terms of Regulation 46 of the LODR Regulations and available for inspection by the members at the registered office of the Company during business hours.

The company has received the declaration from him that he meets the criteria of Independence as per Section 149 of the Companies Act, 2013 and LODR Regulations. In the opinion of the Board, Dr. Tewari fulfils the conditions specified in the Companies Act, 2013, the Rules thereunder and the LODR Regulations for appointment as an Independent Director and that he is independent of the management of the Company. The Nomination and Remuneration Committee at its meeting held on May 25, 2019, evaluated the performance of all the Independent Directors including Dr. Tewari and concluded that his performance was satisfactory.

Dr. Tewari is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has given his consent to act as a Director.

Dr. Tewari has vast experience in research and will contribute immensely to the Board deliberations and the Company will be benefitted out of his vast experience in various fields of academics and research. The Board recommends the Ordinary Resolution set out in Item No. 5 of the accompanying Notice for approval by the Members.

Except Dr. Rupinder Tewari, none of the Directors and Key Managerial Personnel (KMPs) of the Company and their relatives is concerned or interested, financial or otherwise, in his re-appointment. He does not have any relation with any other directors or KMPs.

Item No. 3 and 6

The Statement for item no. 3 is provided, though strictly not required, as per Section 102 of the Act.

Dr. Dinesh Dua (DIN – 02436706), Director will retire by rotation in the forthcoming Annual General Meeting and being eligible, offer himself for reappointment. The Board recommends his reappointment as proposed in item no. 3. His term of office shall be liable to retire by rotation.

The Board of Directors vide resolution dated August 7, 2018 have re-appointed Dr. Dinesh Dua as a Director as well as Wholetime Director designated as Chief Executive Officer for a period of one year from October 14, 2018. As a result, his tenure, as a Wholetime Director, will expire on October 13, 2019. Therefore, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors in their meeting held on August 14, 2019, have decided to re-appoint Dr. Dinesh Dua as Wholetime Director designated as Chief Executive Officer & Director of the Company for a period of One year with effect from October 14, 2019 on the terms and conditions as set out in the proposed resolution.

The proposed remuneration as set out in the resolution is same as he is presently drawing, based on is revised remuneration with effect from September 1, 2018 and as approved by Nomination and Remuneration Committee and Board of Directors in their meeting held on August 14, 2019 pursuant to authority granted as per special resolution passed by members in their AGM held on September 28, 2019.

The appointment can be terminated by Dr. Dinesh Dua or the Company, by one party giving to the other 3(three) calendar months' notice in writing or by payment of a sum equivalent to basic salary for the notice period or part thereof in case of shorter notice or on such other terms as Board of Directors may think.

Dr. Dinesh Dua aged 64 years is MBA from IIM, Ahmedabad from 1979 batch. He has the experience of 39 years plus in varied industries like Sanofi Aventis, Hitech Labs and Berger Paints in middle to senior management positions. He works as Senior & Top Management positions in Reliance Industries, Jubilant Organosys Ltd., Zydus Cadila Healthcare Ltd. & Wochardt Ltd, and was CEO of Nectar Lifesciences Limited from 2007 to 2012. His last penultimate position was with a US Pharma MNC Akorn India P. Ltd. as Managing Director for 14 Months. He rejoined the Nectar Lifesciences Limited as a CEO & WTD from October 14, 2013.

He has expertise in Overall Business Management and Corporate Management. He does not hold any equity share in the Company.

His Directorships are as under:

Sr. No.	Name of the Company
1.	Pharmaceuticals Export Promotion Council of India
2.	Nectar Lifesciences UK Limited

He does not hold committee membership in any other company. The details of number of Board and committee meetings attended

by him are given in Corporate Governance Report. The details of remuneration drawn have been provided in the Corporate Governance Report, forming part of the Annual Report.

He is not disqualified from being appointed as Director in terms of Section 164 of the Act. In view of the provisions of Sections 196, 197, 203 and any other applicable provisions of the Companies Act, 2013, the Board recommends the Special Resolution of item no. 6 of the accompanying Notice for the approval of the Members.

Except Dr. Dinesh Dua, none of the Directors and Key Managerial Personnel (KMPs) of the Company and their relatives is concerned or interested, financial or otherwise, in his re-appointment. He does not have any relation with any other directors or KMPs.

Item No. 7

The first term of Dr. (Maj. Gen.) Shamsher Singh Chauhan, VSM (DIN 02954776), Independent Director will expire on September 29, 2019. Based on recommendation of Nomination and Remuneration Committee, the Board of Directors has proposed to re-appoint him as Independent Director for 2nd term for a period of 5 years. Pursuant to the provisions of Sections 149, 152 and other applicable provisions of the Act and LODR Regulations, approval of the members by way of a special resolution is required for reappointment of Independent Director for a second term and being he has also attained the age of 75 years. The Board recommends the special resolution for re-appointing him for a second term for a period upto September 29, 2024.

Dr. (Maj. Gen.) Shamsher Singh Chauhan, VSM, aged 81 years, retired after holding the most prestigious and highest professional appointment of Senior Consultant of the medicine and Allied Specialties/ Super Specialties in the Armed Forces from Ministry of Defence and Army Hospital (Research and Referral) Delhi. He has joined Defence forces on March 29, 1963 and superannuated on May 31, 1997.

He did his M.B.B.S. from Government M.G. Medical College Bhopal in 1961, did Advanced Course in Medicine from A.F.M.C. Pune in 1973, M.D. (Medicine) from Pune University in 1978 and F.I.C.P. from Indian College of Physicians Bombay in 1996. He also did management courses i.e., Medical Officers Senior Command Course from O.T.S.A.M.C. Centre Lucknow in 1977 and Senior Defence Management Course from College of Defence Management Secunderabad in 1993.

During his service tenure he was delegated twice as leader of the specialist's teams abroad. He has the distinction of active service in both 1965 and 1971 wars with Pakistan and also commanded the largest zonal hospital/ formation during insurgencies both in western and eastern threats. He had published over 30 papers/ articles in national and international journals. He was on the editorial boards of prestigious journal of Association of Physicians of India and Indian Academy of Clinical Medicine.

He does not hold any equity share in the Company. He also does not hold any directorship or committee membership in any other company. The details of number of Board and committee meetings attended by him are given in Corporate Governance Report. The details of sitting fee drawn have been provided in the Corporate Governance Report, forming part of the Annual Report. He will be eligible for payment of sitting fee, as payable to other non-executive directors of the Company.

The terms and conditions of appointment of Independent Directors have been disclosed on the website of the Company as required in

terms of Regulation 46 of the LODR Regulations and available for inspection by the members at the registered office of the Company during business hours.

The company has received a declaration from him that he meets the criteria of Independence as per Section 149 of the Companies Act, 2013 and LODR Regulations. In the opinion of the Board, Dr. Chauhan fulfils the conditions specified in the Companies Act, 2013, the Rules thereunder and the LODR Regulations 2015 for continuing as an Independent Director and that he is independent of the management of the Company. He is not disqualified from being a Director in terms of Section 164 of the Act.

Dr. Chauhan is on the Board of the Company in the Non-Executive Independent category since 2010 and has been contributing immensely to the Board deliberations and the Company is benefitted out of his vast experience in various fields of Management. The Board recommends the Special Resolution set out in Item No. 7 of the accompanying Notice for approval by the Members.

Except Dr. (Maj. Gen.) Shamsheer Singh Chauhan, VSM, none of the Directors and Key Managerial Personnel (KMPs) of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution. He does not have any relation with any other directors or KMPs.

Item No. 8

The first term of Mr. Ajay Swaroop (DIN – 02291700), Independent Director will expire on September 29, 2019. Based on recommendation of Nomination and Remuneration Committee, the Board of Directors has proposed to re-appoint him as Independent Director for 2nd term for a period of 5 years. Pursuant to the provisions of Sections 149, 152 and other applicable provisions of the Act and LODR Regulations, approval of the members by way of a special resolution is required for reappointment of Independent Director for a second term. The Board recommends the special resolution for re-appointing him for a second term for a period upto September 29, 2024.

Mr. Ajay Swaroop, aged 69 years, holds B.Com., M.A. (Economics) and C.A.I.I.B. degrees. He has retired as Chief General Manager of Chandigarh circle of State Bank of India comprising of Punjab, Haryana, Himachal, Jammu & Kashmir and Chandigarh (U.T.) after 37 years of long and varied service. At the time of retirement, he was

controlling Rs. 780,000 million of business, 1000 branches and 14000 employees.

He does not hold any equity share in the Company. He also does not hold any directorship or committee membership in any other company. The details of number of Board and committee meetings attended by him are given in Corporate Governance Report. The details of sitting fee drawn have been provided in the Corporate Governance Report, forming part of the Annual Report. He will be eligible for payment of sitting fee, as payable to other non-executive directors of the Company.

The terms and conditions of appointment of Independent Directors have been disclosed on the website of the Company as required in terms of Regulation 46 of the LODR Regulations and available for inspection by the members at the registered office of the Company during business hours.

The company has received a declaration from him that he meets the criteria of Independence as per Section 149 of the Companies Act, 2013 and LODR Regulations. In the opinion of the Board, Mr. Swaroop fulfils the conditions specified in the Companies Act, 2013, the Rules thereunder and the LODR Regulations 2015 for continuing as an Independent Director and that he is independent of the management of the Company. He is not disqualified from being a Director in terms of Section 164 of the Act.

Mr. Swaroop is on the Board of the Company in the Non-Executive Independent category since 2010 and has been contributing immensely to the Board deliberations and the Company is benefitted out of his vast experience in various fields of Management. The Board recommends the Special Resolution set out in Item No. 8 of the accompanying Notice for approval by the Members.

Except Mr. Ajay Swaroop, none of the Directors and Key Managerial Personnel (KMPs) of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution. He does not have any relation with any other directors or KMPs.

By order of the Board of Directors
of **Nectar Lifesciences Limited**

Date : 14.08.2019
Place : Chandigarh

(Dinesh Dua)
Chief Executive Officer & Director

BOARD OF DIRECTORS' REPORT OF NECTAR LIFESCIENCES LIMITED

Dear members,

Your Directors have pleasure in presenting the 24th Annual Report together with the audited accounts of Nectar Lifesciences Limited ('NLL' or 'NecLife' or 'Nectar' or 'the Company') for the financial year ended March 31, 2019.

Financial results

Rs. in Millions

	31-Mar-19	31-Mar-18
Gross Sales (Including GST)	31149.23	20,923.19
Other Income	60.40	60.36
Profit before interest and depreciation	2699.43	2,420.77
Interest	1481.34	1,152.02
Depreciation & Amortization	632.57	643.09
Profit before tax	585.52	625.66
Tax expenses	112.20	104.12
Profit after tax	473.32	521.54
Other Comprehensive income (Net of Taxes)	0.26	10.97
Profit after tax available for Appropriations	473.58	532.51

The company's revenue during Financial Year ('FY') 2018-19 stood at Rs. 3115/- Crores against 2092/- Crores in the previous year recording a very strong growth of 49%. Finance cost increased by 29% in this financial year to Rs 148/- Crores. The Profit after Tax has decreased by 11% as compared to last year due to high input costs.

The financial results of the company for the quarter ended on June 30, 2019 are available on the website of the company (URL: www.necLife.com).

Indian Accounting Standards (IndAS) and Secretarial Standards

The company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and accordingly, standalone and consolidated audited financial statements have been prepared in accordance with the recognition and measurement principles laid down in Ind AS and the other accounting principles generally accepted in India.

The Company is in Compliance of Secretarial Standards as issued by Institute of Company Secretaries of India.

Management Discussion and Analysis Report

The details of the Company's various operations and state of affairs and nature of business are discussed under **Management Discussion and Analysis Report**. The Management Discussion and Analysis of financial condition and result of operations of the Company for the year under review as required under Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), is given as Annexure 1 forms part of this report. Any disclosure not given in this report but disclosed in Annexure 1, shall be deemed to be reported in this report.

Corporate Governance

The Company aimed to conduct its affairs in an ethical manner. A separate Report on Corporate Governance is given as Annexure 2 forms part of this report. A certificate from the Company's Auditors regarding the Compliance of Conditions of Corporate Governance as stipulated under LODR Regulations is given in Annexure 3. Any disclosure not given in this report but disclosed in Annexure 2, shall be deemed to be reported in this report.

Share capital

The paid up equity share capital as on March 31, 2019 was Rs. 224.26 Millions. There was no public issue, rights issue, bonus issue or preferential issue, etc. during the year. The Company has not issued shares with differential voting rights, sweat equity shares, nor has it granted any stock options.

Global Depository Receipts (GDRs)

The Company has 46,000,000 equity shares of Rs. 1/- each underlying 46,000,000 Global Depository Receipts (GDRs). The GDRs are listed on:

Luxembourg Stock Exchange/ LuxSE
Société de la Bourse de Luxembourg S.A.
B.P. 165, L-2011 Luxembourg
Siège social, 11, av de la Porte-Neuve,
Telephone: (352) 47 79 36 – 1, Fax: (352) 47 32 98

Subsidiary companies

The company has wholly owned subsidiaries (WOS) namely Nectar Lifesciences UK Limited, incorporated in United Kingdom and Nectar Lifesciences US, LLC, incorporated in United States. There are negligible investments in Nectar Lifesciences UK Limited and no business activity has been carried out in it in financial year 2018-19 and till date in financial year 2019-20. Therefore, nothing is to report on the performance and financial position of Nectar Lifesciences UK Limited.

Due to uncertainty of Brexit, the company left with no choice but to shift its European Union (EU) incorporation & market authorization (MA) from United Kingdom (UK) to EU. Therefore, the company has incorporated a WOS namely NECLIFE PT, UNIPESAL LDA in Portugal on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited, which will eventually be dissolved. However, this shift will not have any impact on the business of the company.

However, the Nectar Lifesciences US, LLC doing the business operations of trading of pharmaceutical products. The company gained the profit of US\$ 28439.60 during the year under review as compared to profit of US\$ 10387.20 during last year.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013 (hereinafter referred as 'Act'), a statement containing salient features of financial statements of subsidiaries, associates and joint venture companies in Form AOC-1 is attached to the Financial Statements. The separate financial statements in respect of each of the subsidiary companies shall be kept open for inspection at the Registered Office of the Company during working hours for a period of 21 days before the date of the Annual General Meeting (AGM). Your Company will also make available these documents upon request by any Member of the Company interested in obtaining the same. The separate audited/ unaudited financial statements in respect of each of the subsidiary companies are also available on the website of your Company at www.necLife.com.

None of the subsidiaries is material as per Policy for determining Material Subsidiaries of the Company and LODR Regulations.

Consolidated financial Statements

As required under Section 129 of the Act and LODR Regulations, a consolidated financial statements for the year ended on March 31, 2019 of the Company are attached.

Dividend

Your Directors are pleased to recommend a Final Dividend @ 5% i.e. Re. 0.05/- per equity shares of face value of Re. 1/- each aggregating to Rs. 11,213,048.50 for the year ended March 31, 2019. The final dividend, subject to the approval by the shareholders in the forthcoming Annual General Meeting and if declared, will be paid on or after October 3, 2019, to those members whose names appears in the register of members as on date of book closure. The register of members and the share transfer books of the Company will remain closed from September 22, 2019 to September 28, 2019 (Both days inclusive) for Annual General Meeting and payment of dividend, if declared, on equity shares.

The members may please refer to notes of Notice of AGM for information on shares/dividend transferred / proposed to be transferred to IEPF Authority.

The Board of Directors of your company, has decided not to transfer any amount to the Reserves for the year under review.

Directors and Key Managerial Persons

Dr. Dinesh Dua (DIN – 02436706), Director will retire by rotation in the forthcoming Annual General Meeting and being eligible, offer himself for reappointment. Based on recommendation of Nomination and Remuneration Committee, the Board recommends his reappointment as a Director.

Dr. Dinesh Dua has been re-appointed as Wholetime Director designated as Chief Executive Officer & Director by the Board of Directors in their meeting held on August 14, 2019 w.e.f. October 14, 2019 for a period of One year. Based on recommendation of Nomination and Remuneration Committee, the Board recommends his reappointment as a Wholetime Director.

Mr. Vijay J. Shah (DIN - 00747226), an Independent Director of the Company, due to certain eventualities, had not attended all the meetings of the Board of Directors of the Company held during the period of twelve months from June 27, 2017 to June 27, 2018. Accordingly, in view of the provisions of Section 167(1)(b) of the Companies Act, 2013, his office of Director in the Company had become vacant on June 27, 2018 i.e. he was ceased to be director on that date.

Based on recommendation of Nomination and Remuneration Committee, the Board of Directors on August 07, 2018, appointed Mr. Vijay J. Shah as an Additional Director in the capacity of Independent Director and members in their Annual General Meeting held on September 28, 2018 appointed him as regular independent director for a period up to August 07, 2023 for a second term. He had resigned from the Board from December 01, 2018 due to preoccupations and some other works.

Pursuant to section 32 of Export Import Bank of India Act, 1981 and Facility Agreement, the Export and Import Bank of India had appointed Ms. Meena Verma (DIN - 05283168) as their nominee director on the Board of Directors of the company with effect from February 11, 2019.

Ms. Meena Verma, aged 48 years, is a Management graduate, specializing in Finance and Marketing from the University of Poona. She has been associated with Export-Import Bank of India since 2005. Ms. Verma has worked in the Treasury and Accounts Group, where she handled fund raising and treasury management, including derivatives. Prior to joining Exim Bank, she had worked in similar areas with the National Housing Bank. Currently she is incharge

of Lines of Credit, a flagship programme of the Bank. Her areas of interest include meeting people, reading and travel.

She does not have any relationship with any other director of the company. She does not hold any equity share in the company.

She has certified that she was not disqualified to become a Director under the Companies Act, 2013 and not debarred from holding the office of Director by virtue of any Securities & Exchange Board of India (SEBI) Order or any other such authority.

Based on recommendation of Nomination and Remuneration Committee, the Board of Directors on February 11, 2019, appointed Dr. Rupinder Tewari (DIN 07009485) as an Additional Director in the capacity of Independent Director and he vacates his office at the ensuing Annual General Meeting. The Nomination and Remuneration Committee also proposed to re-appoint him as regular independent director for a first term. The Board recommends the appointment of Dr. Rupinder Tewari as regular independent director for a period up to February 11, 2024.

Mr. Harparkash Singh Gill (DIN – 06414839), President (Operations) & Director has resigned from the Board of Directors of the company from February 28, 2019 to make to proportionate of Non Independent Directors viz a viz Independent Directors.

The first term of Dr. (Maj. Gen.) Shamsher Singh Chauhan, VSM (DIN 02954776) and Mr. Ajay Swaroop (DIN – 02291700), Independent Directors will expire on September 29, 2019. Based on recommendation of Nomination and Remuneration Committee, the Board of Directors has proposed to re-appoint them as Independent Directors for 2nd term for a period of 5 years. Pursuant to the provisions of Sections 149, 152 and other applicable provisions of the Act and LODR Regulations, approval of the members by way of a special resolution is required for reappointment of Independent Directors for a second term. The Board recommends the special resolutions for re-appointing both of them for a second term for a period upto September 29, 2024.

As on the date of this report, the company has right proportionate of Independent Directors viz a viz Non-Independent Directors as per applicable provisions of Section 149 of the Act, and LODR Regulations.

The Company has received declarations from all the Independent Directors of the Company confirming that they meet with the criteria of independence as prescribed both under sub-section (6) of Section 149 of the Act, and under LODR Regulations.

Your Directors do hereby confirm that in the opinion of the board, the independent directors fulfill the conditions specified in the Act and LODR Regulations and are independent of the management.

Pursuant to the provisions of Section 203 of the Act, the key managerial personnel of the Company as on March 31, 2019 were as under:

Mr. Sanjiv Goyal, Chairman & Managing Director

Mr. Dinesh Dua, Wholetime Director designated as Chief Executive Officer & Director

Mr. Sandeep Goel, Chief Financial Officer

Ms. Ankita Jain, Company Secretary

Number of meetings of the board

Seven (7) meetings of the board were held during the year. The details of Directors and meeting held during the financial year 2018-2019 are provided in Corporate Governance Report which forms part of this report.

Directors' responsibility statement

The Directors confirm that:

- in the preparation of the annual accounts, the applicable accounting standards have been followed and that no material departures have been made from the same;
- they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profits of the Company for that period;
- they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- they have prepared the annual accounts on a going concern basis;
- they have laid down internal financial controls for the Company and such internal financial controls are adequate and operating effectively; and
- they have devised proper systems to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

Board evaluation

Pursuant to the provisions of the Act, and the corporate governance requirements as prescribed by LODR Regulations, the performance of the Board and committees was evaluated by the Board after seeking inputs from all the directors/ committee members on the basis of the criteria such as the Board/ committee composition and structure, effectiveness of board processes, information and functioning, etc.

The Board and the Nomination and Remuneration Committee ("NRC") reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the Chairman was also evaluated on the key aspects of his role. The performance evaluation forms of each of director get filled from all directors.

In a separate meeting of independent Directors, performance of non-independent directors, performance of the board as a whole and performance of the Chairman was evaluated.

Policy on directors' appointment and remuneration and other details

The Company's policy on directors' appointment and remuneration and other matters namely Nomination, Remuneration and Evaluation Policy as provided in Section 178(3) of the Act has been uploaded on the website of the company at <http://www.neclife.com/uploads/1549887491137395438.pdf>.

Committees of the Board

The Company constituted the Committees as per the provisions of Sections 177 and 178 of the Act and LODR Regulations. The composition, powers and duties of the Committees, during financial year 2018-19, are detailed out in the Corporate Governance Report which forms and part of this report. The Board of Directors accepted all recommendations of the Audit Committee.

Internal financial control systems and their adequacy

The company has adequate financial controls. The details in respect of internal financial control and their adequacy are included in the

Management Discussion & Analysis, which forms part of this report.

Auditors and Auditors' Report

M/s Ashwani K. Gupta & Associates, Chartered Accountants (ICAI Registration No. 003803N) were appointed as Statutory Auditors of your Company at the Annual General Meeting held on September 28, 2017 for a term of five consecutive years. In accordance with the Companies Amendment Act, 2017, enforced on 7th May, 2018 by the Ministry of Corporate Affairs, the appointment of Statutory Auditors is not required to be ratified at every Annual General Meeting.

The Report given by the Auditors on the financial statements of the Company is part of the Annual Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report.

Secretarial Auditor and Secretarial Audit Report

During the year, Secretarial Audit was carried out by Mr. Prince Chadha of P. Chadha & Associates., Practicing Company Secretary, the Secretarial Auditor of the company for the Financial Year 2018-19. There were no qualifications, reservation or adverse remarks given by Secretarial Auditors of the Company. The Secretarial Audit Report is appended as an Annexure 4 to this report.

The Company has undertaken an audit for the financial year 2018-19 for all applicable compliances as per Securities and Exchange Board of India Regulations and Circulars/Guidelines issued thereunder. The Annual Secretarial Compliance Report has been submitted to the stock exchanges within 60 days of the end of the financial year.

Cost Records and Audit

The Company is required to maintain of cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 and accordingly such accounts and records are made and maintained.

The company has appointed Dr. Vimal Kumar (Membership No. 9982) prop. of M/s V. Kumar and Associates, SCO, 124-125, Sector 34A, Chandigarh, Cost and Works Accountants as the Cost Auditors of the Company for the financial year 2019-20.

The Cost Audit Reports for the financial year 2017-18 have been filed on September 26, 2018 being within 50 days of date of report i.e. August 07, 2018 with late filing fee. However, the last date for filing of Cost Audit Report was extended to December 31, 2018 by ministry of Corporate Affairs vide circular dated December 10, 2018.

The Cost Auditor shall forward the Cost Audit Report for the financial year 2018-19 by September 30, 2019. The report will be filed with Ministry of Corporate Affairs within 30 days of date of Cost Audit Report.

Risk management

The development and implementation of risk management policy has been covered in the management discussion and analysis, which forms part of this report.

Though not mandatory, the Company has constituted a Risk Management Committee with Dr. Dinesh Dua as the Chairman and Mr. Harparkash Singh as a member to, inter-alia:

- to formulate and recommend to the Board, a Risk Management Policy which shall indicate the activities such as identification of risks and mitigation strategy thereof;
- to recommend the Board about risk assessment and minimization procedures ; and
- monitoring and reviewing of the risk management plan to the Board.

The audit committee has additional oversight in the area of financial risks and controls. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis.

Particulars of loans, guarantees and investments

The company has not given any loan or provide guarantee as per Section 186 of the Act, however, the amount receivable from subsidiaries and the investments under section 186 of the Act are given in the Financial Statements forming part of the Annual Report.

Transactions with related parties

Information on transactions with related parties pursuant to Section 134(3)(h) of the Act read with rule 8(2) of the Companies (Accounts) Rules, 2014 are given in Annexure 5 in Form AOC-2 and the same forms part of this report. Further details about these transactions are provided in Report on Corporate Governance.

Corporate social responsibility

The brief outline of the Corporate Social Responsibility (CSR) Policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in Annexure 6 of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014. The policy is available on the website of the Company.

Annual Return and Extract of annual return

As provided under Section 92(3) of the Act, the extract of annual return is given in Annexure 7 in the prescribed Form MGT-9, which forms part of this report. The MGT-9 (Extract of Annual Return) and MGT-7 (Annual Return) are also available on the website of the company at <http://www.neclife.com/uploads/15643824461382466477.pdf> and <http://www.neclife.com/uploads/1564580929548712790.pdf>, respectively.

Employees

The information required under Section 197 of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is attached as Annexure 8. In terms of first proviso to Section 136 of the Act, the Report and Accounts are being sent to the Members and others entitled thereto, excluding the information on employees' particulars as required pursuant to provisions of Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The said information is available for inspection by the Members at the Registered Office of the Company during business hours on working days of the Company up to the date of the ensuing AGM. If any Member is interested in obtaining a copy thereof, such Member may write to the Company Secretary in this regard.

Fixed deposits

During the year under Report, your Company did not accept any deposits from the public in terms the provisions of Companies Act, 2013.

Disclosure requirements

- As per LODR Regulations, corporate governance report with auditors' certificate thereon and management discussion and analysis are attached, which form part of this report.
- Details of the familiarization programme of the independent directors are available on the website of the Company (URL: www.neclife.com).
- Policy for determining material subsidiaries of the Company is available on the website of the Company (URL: www.neclife.com).
- Policy on dealing with related party transactions is available on the website of the Company (URL: www.neclife.com).
- The Whistle Blower Policy to provide Vigil Mechanism for employees including directors is available on the website of the Company (URL: www.neclife.com).

Committee and Policy against Sexual Harassment at Workplace

The company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The company has made the Anti Sexual Harassment Policy under above referred Act for all individuals working for Nectar at all levels and grades, including senior executives, officers, employees (whether permanent, fixed-term or temporary), consultants, contractors, trainees, staff, casual workers, interns. As per policy any aggrieved woman employee who feels and is being sexually harassed directly or indirectly may make a complaint of the alleged incident to any member of the Committee constituted for this purpose.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

- a. number of complaints filed during the financial year 2018-19 - NIL
- b. number of complaints disposed off during the financial year - N.A.
- c. number of complaints pending as on March 31, 2019 - NIL

Energy, technology and foreign exchange

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under the Act, are provided in Annexure 9 to this Report.

Acknowledgement

Your Directors would like to express their sincere and grateful appreciation for the assistance and cooperation received from bankers and government authorities and also thank the shareholders for the confidence reposed by them in the Company and looks forward to their valuable support in the future plans of the Company.

Your Directors also thank its agents, the medical professionals and its customers for their continued patronage to the Company's products.

For and on behalf of the Board of Directors
Of Nectar Lifesciences Limited

(Sanjiv Goyal)
Chairman and Managing Director

Place : Chandigarh
Date : 14.08.2019

Annexure 1 of Board of Directors' Report Management Discussion & Analysis

ECONOMIC BACKGROUND

Indian Economy is the fastest growing major economy in the world and is expected to be one of the top three economic powers of the world over the next 10-15 years, backed by its strong democracy and partnerships. India's GDP is estimated to have increased 7.2 per cent in 2017-18 and 7 per cent in 2018-19. India has retained its position as the third largest startup base in the world with over 4,750 technology start-ups. [Source: Ibfef.org]

India has been ranked 11th in the Global FDI Confidence Index 2018, making it the 2nd highest ranked emerging market for FDI. FDI equity inflows to India reached US\$ 33.49 billion during 2018-19 while the cumulative FDI equity inflows to the country from April 2000 to December 2018 reached US\$ 409.15 billion. During 2018-19 merchandise exports from India have increased 8.85 per cent year-on-year to US\$ 298.47 billion, while services exports have grown 8.54 per cent year-on-year to US\$ 185.51 billion. [Source: Ibfef.org]

Healthcare market in India is expected to reach US\$372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. The government's expenditure on the health sector has grown to 1.4 per cent in FY18 from 1.2 per cent in FY14. The Government of India is planning to increase public health spending to 2.5 per cent of the country's GDP by 2025. [Source: Ibfef.org]

INDIAN PHARMACEUTICAL INDUSTRY

Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK. The pharmaceutical sector in India was valued at US\$ 33 billion in 2017. India's domestic pharmaceutical market turnover reached Rs 129,015 crore (US\$ 18.12 billion) in 2018, growing 9.4 per cent year-on-year (in Rs) from Rs 116,389 crore (US\$ 17.87 billion) in 2017. In February 2019, the Indian pharmaceutical market grew by 10 per cent year-on-year. [Source: Ibfef.org]

Indian drugs are exported to more than 200 countries in the world, with the US as the key market. Generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. India's pharmaceutical exports stood at US\$ 17.28 billion in FY18 and US\$ 19.14 billion in FY19. In FY18, 31 per cent of these exports from India went to the US. Pharmaceutical exports include bulk drugs, intermediates, drug formulations, biological, Ayush & herbal products and surgicals. [Source: Ibfef.org]

Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. Drug Controller General of India (DCGI) started a single-window facility to provide consents, approvals and other information. The move is aimed at giving a push to the Make in India initiative. [Source: Ibfef.org]

The National Health Protection Scheme is largest government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US\$ 7,723.2) per family per year for secondary and tertiary care hospitalization. [Source: Ibfef.org]

The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit

the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

GLOBAL PHARMACEUTICAL MARKET

The global market for pharmaceuticals reached \$1.2 trillion in 2018, up \$100 billion from 2017, Going forward, the global market will grow by 4-5% CAGR, reaching \$1.5 trillion. This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year. [Source: pharmaceuticalcommerce.com]

The US has the largest pharmaceutical market in the world with a value of \$339,694 million USD followed by Japan (\$94,025 million USD) and China (\$86,774 million USD). Factors affecting the pharmaceutical market size include disease prevalence, drug affordability, consumer attitudes, government policies and some supply-side factors. [Source: worldatlas.com]

Pharmacovigilance has become important in the industry as well in monitoring unrecognized drug risks, recognition of pre-disposing factors, and refuting spurious safety claims of drugs. In recent decades, pharmaceutical companies themselves have established their monitoring units to further the safety of their products.

The US FDA has increased its focus to further accelerate approval cycle of generics after having seen a significant improvement in the approval timelines under the Generic Drug User Fee Act (GDUFA). Specifically, clearer guidelines and faster approvals on complex generics will be beneficial for the Indian Pharmaceutical players.

ABOUT THE COMPANY

Nectar Lifesciences Limited ('NLL' or 'NECLIFE') is an integrated pharmaceutical organization incorporated in 1995 based in Chandigarh, Punjab India. NLL has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, -APIs and Formulations to meet the diverse requirements of its customer base in India and over 84 countries worldwide.

Nectar Lifesciences Ltd. is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. In a short span of existence, NLL was ranked one organization amongst mid-sized Pharmaceutical companies in India as per "Fortune Next 500" in 2017 & was among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per "Bio-Spectrum Asia Pacific" 2016 besides being one of the top amongst Indian Bulk Drug manufacturers in India.

NLL has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. NLL currently has a strong hold of API & Formulation with 11 State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

With leading Global capacities of some of the Cephalosporin molecules and strong tie ups Nectar has been experiencing a growth in this segment. With an expertise in R&D, Nectar is also working on new generation Cephalosporin molecules to be a globally dedicated Cephalosporin player. Our API facility have global regulatory

accreditations like USFDA, EUGMP INFARMED, COFEPRIS, KFDDA, PMDA, MCC, ANVISA Brazil and others. The FDF facility in Baddi also has been recognized & approved by regulatory bodies like INFARMED Portugal for European Union, ANVISA Brazil, OGYI Hungary for European Union, Pharmacy & Poison Board Kenya, NMRC Namibia, NDA Uganda, TFDA and others. NLL's major breakthrough was its strategic step towards making an entry in Europe through its formulations. NLL has filed two of its major Cephalosporin Formulations in Europe and expect commercialization in the Q1 of FY 21.

API's & Intermediates

With leading global capacity for some of the Cephalosporin Molecules, NLL is one of the leading manufacturers of Cephalosporin range of products possessing core strength in Manufacturing (Both oral and Sterile API's) and one of the few companies in India possessing both Lyophilisation and Crystallization facilities.

NLL offers highest standards of CGMP to satisfy both EU and USFDA requirements. Production is carried out in discrete production units, each unit coupled to a dedicated fully isolated finishing suite. NLL strictly maintains Total Quality System (TQS) controls throughout the entire production cycle from raw materials through to packaging and dispatch.

Glass lined, stainless steel and MSGL reaction are configured for multi product synthesis at the 500kg to multi tone scale of operations. Purified water is used throughout the site. Solids separation and drying is carried out in a range of tray ovens, stainless steel vacuum blender driers and stainless steel pressure filters/driers

All the API & Intermediate manufacturing sites are fully compliance with International environmental regulations. NLL continues to demonstrate its commitment to its customers through significant investment in additional production facilities thus enhancing the capability and quality of service available.

Currently NLL's API business explores one of the most stringent markets of the world like EU, Mexico, LATAM, SEA, CIS etc besides overall exports to over 70 countries across the world.

FINISHED DOSAGE FORMS (Formulations)

NLL boasts of state of the art facilities having latest technology & equipments from best in class vendors across the world. NLL's strong compliance and quality orientation leads to producing products of highest quality conforming to stringent regulatory guidelines of various authorities like USFDA, EDQM, MHRA, MCC etc.

NLL participates only in Exports for single dosage forms whereas in India which is a predominantly Fixed Dosage Combinations Market has come under hammer of regulators & is sub judice.

Our capacities are global capacities and geared to cater volumes of high quality finished dosage forms for world markets. Currently NLL sells its formulations in High End Row markets like South East Asia, LATAM, CIS, Africa and EU.

DIAGNOSTICS

Rapid Diagnostic Tests or Lateral Flow Assays are used to rapidly diagnose wide variety of medical conditions. They are usually the First Step in diagnostic testing. At Rapikit, we work each day to provide Technologically Advanced & Best Diagnostic Testing to pave way for Healthier World. Rapikit specializes in development & production of high quality lateral flow diagnostics. We offer a broad portfolio of Rapid Lateral Flow assays that can be interpreted visually. The principle of a basic Rapid Diagnostic Test utilizes a sandwich design to detect a specific analyte in the test specimen. Which means the analyte is bound between two components, i.e. antibody – antigen – antibody;

or antigen – antibody – antibody (bold indicates target analyte). At Rapikit, extensive research and Time goes in Quality Testing of each kit. RDTs are quick and easy to perform, suitable for preliminary or emergency medical screening and for use in medical facilities with limited resources.

MENTHOL

In a highly unorganized and fragmented menthol industry, Nectar has created a niche with its pharma-centric approach and a highly organized setup.

- Nectar has excellent state of the art facilities in North India. Our infrastructure enables us to produce high quality products, batch after batch, in strict adherence to global standards for our prized domestic and international customers.
- Right from sourcing of the natural raw material to world-class production practices to specialized packaging, our products pass through stringent quality control checks, carried under GMP norms, supervised by experienced and skilled manpower.
- With global sized processing capacities, Nectar has emerged as a leader in the Menthol Arena. NLL has taken global leadership in Pharmaceutical grade Menthol.

Our manufacturing facilities have the following certifications:

- GMP (Issued by World Health Organization - COPP)
- ISO 9001:2008 - Quality Management
- ISO 22000:2005 - Food Safety Management
- ISO 14001: 2004 - Environment Management Systems
- ISO 50001: 2011 – Energy Management System
- OHSAS 18001: 2007 - Occupational Health and Safety
- FSSAI, KOSHER & HALAL
- Nectar was the first company to file a US Drug Master File (DMF) for Natural menthol
- Approved by University of Georgia, Centre for Isotope studies -C14

EMPTY HARD GELATIN CAPSULES (EHGC)

Indian EHGC market is estimated at approx 64 billion capsules in absolute production terms. NLL has invested in a State-of-the-art Empty Hard Gelatin Capsules manufacturing facility. This Unit replicates the pharma value – orientation into its processes and systems to manufacture globally benchmarked products finding US and EU acceptance as well. The unit is completely based on pharma concept & is the only unit to follow unique concept of SMSR (Single Machine Single Room). NLL currently has a production capacity of 4 billion capsule shells. NLL is amongst top 5 EHGC manufacturers in India catering to both domestic & overseas markets.

Nectar's two-piece double lock gelatin capsules are manufactured in compliance with cGMP requirements of US FDA and EDQM norms and ISO 9001:2008 guidelines. NLL currently offers capsules in various 5 sizes (0, 0e1, 1, 2, 3) with all color and printing options. NLL specially caters to customized needs of BSE-Free shells without sulfites, sodium or ethylene oxide. Nectar has recently launched two new innovative products in EHGC – menthol capsules (NexxicapMintyTM) and pearl capsule (NexxicapPearlTM).

REGULATORY FILINGS

NLL has filed 44 Drug Master Files (DMFs) till date in highly regulated markets like US, EU, Japan, Korea, Canada and South Africa for its Cephalosporin APIs, intermediates, capsules shells and menthol. NLL has also filed a number of Formulations dossiers to some of the high-end markets and expects quick approvals for the same. NLL intends to file more ANDAs and EU dossiers for its cephalosporin range of products along with many more API DMFs. Currently NLL has filed 15 ANDAs in United States

FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

Financial results

Rs. in Millions

	31-Mar-19	31-Mar-18
Gross Sales (Including GST)	31149.23	20,923.19
Other Income	60.40	60.36
Profit before interest and depreciation	2699.43	2,420.77
Interest	1481.34	1,152.02
Depreciation & Amortization	632.57	643.09
Profit before tax	585.52	625.66
Tax expenses	112.20	104.12
Profit after tax	473.32	521.54
Other Comprehensive income (Net of Taxes)	0.26	10.97
Profit after tax available for Appropriations	473.58	532.51

The company's revenue during Financial Year ('FY') 2018-19 stood at Rs. 3115/- Crores against 2092/- Crores in the previous year recording a very strong growth of 49%. Finance cost increased by 29% in this financial year to Rs 148/- Crores. The Profit after Tax has decreased by 11% as compared to last year due to high input costs.

	FY19	FY18
EBITDA Margin (%)	9.69%	12.74%
PBT Margin (%)	2.10%	3.29%
PAT Margin (%)	1.70%	2.75%

Return on Net worth (PAT/Net Worth)

FY19	FY18	Detailed Explanation
4.28%	4.93%	Due to depreciation of rupee against USD the company incurred a foreign exchange loss of Rs. 20.50 Cr during the year against a forex gain of Rs. 4.31 Cr. in FY 2018 affecting the profitability adversely.

Details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore:

Key financial ratios	FY19	FY18	% Change		Detailed Explanation in case change is more than 25%:
(i) Debtors Turnover	5.5487	3.4182	62.33	(Credit Sales/Average Accounts Receivable.)	The Debtors turnover ratio has improved due to lower credit period in the menthol sales.
(ii) Inventory Turnover	3.4060	2.4345	39.91	(Cost of Goods Sold / Average Inventory)	Due to better inventory management the inventory turnover ratio has increased.
(iii) Interest Coverage Ratio	1.3953	1.5431	- 9.58	(EBIT/Interest)	Not Applicable (N.A.)
(iv) Current Ratio	1.2834	1.2681	1.21	(Current Assets/Current Liabilities)	N.A.
(v) Debt Equity Ratio	0.1499	0.2079	- 27.90	(Long Term Debt/Equity)	Debt equity ratio has improved due to repayment of sizeable long term loan.
(vi) Operating Profit Margin (%)	7.20%	9.04%	- 20.35	(Operating Margin / Net Sale)	Due to depreciation of rupee against USD the company incurred a foreign exchange loss of Rs. 20.50 Cr during the year against a forex gain of Rs. 4.31 Cr. in FY 2018 affecting the profitability adversely.
(vii) Net Profit Margin (%)	1.70%	2.75%	- 38.18	(PAT / Net Sale)	

OPPORTUNITIES AND THREATS

- Anti-infective/Microbial and Antibiotics are the largest therapy areas amongst all the therapy areas globally. Currently valued at US\$ 100 Bio in Formulations with cephalosporin's constituting the largest segment in this therapy area valued at US\$ 21 Bio. Out of this US\$ 21 Bio, US\$ 8 Bio pertains to Pen-G Gen 1 & 2.
- NLL's addressable market is Non Pen-G valued at US\$ 13 Bio in late Gen 2, Gen 3, Gen 4 & Gen 5 molecules.
- For NLL, a threat has become an opportunity in the sense that whole world is worried about Anti-Microbial Resistance (AMR) but till date not a single instance of AMR exhibited in any molecule in Cephalosporin range that NLL manufactures in the market.
- Therefore, the real threat of AMR pertains to other classes of Infection which will continue to shrink and is an opportunity for NLL to rephrase its molecule. As anti-infectives are here to stay for Alleviation from infections.
- The real threat is general perception of people, Media and Doctor Community which needs to be educated about the phenomenon of judicious use of Antibiotics particularly cephalosporins rather than indiscriminate the growing economy, therefore NLL is party to the alleviation campaign to ensure its cephalosporin's continue to be used in a judicious manner.

OUTLOOK

In 2020, drug pricing pressure from regulators, patients, politicians and payers will remain and aggressive negotiation tactics to drive down drug prices are expected.

Despite a trade war between the US and China, it is not a surprise that China is still viewed as a huge market opportunity for the pharmaceutical industry. China has a large population with a growing middle class and it has become a leader in R&D innovation for medicine, particularly regenerative medicine and perhaps even gene editing based on the news from late 2018.

China is beginning to open up to India, particularly in view of collaboration between Pharmexcil and China Chamber of Commerce for Import and Export of Health and Medicinal Products (CCMPHIE) under Minister of Commerce recently.

China is the second largest market valued at US \$ 128 Bio with export prices being 4 – 5 times of that in domestic market prices.

NLL will start further registration of their 2 API's already approved in China. NLL also expects all 7 API's to be approved in China. Number of ANDA's inspected in 2014 were 8 orals and 6 injectables. In orals there were no observations but in steriles there were some observations.

USFDA since 2014 have their sterile inspection under revision to improve on Aseptic Practices.

INTERNAL CONTROL SYSTEM & ADEQUACY

The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and ensure reliability of financial reporting. It maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations. All operations are governed through automated internal business controls, centralized global process framework and integrated key support functions. Quarterly tracking of annual quality objectives is done using QMS (quality management software), and any concerns are immediately flagged for effective addressing.

The system of internal controls monitors and ensures process for:

- Prudent financial control
- Accountability and integrity
- Automated control procedures

All transactions are recorded and reported in accordance with the Indian Accounting Standards. The internal auditors for different locations submit reports and updates. The Audit Committee of the Board review reports submitted by the independent internal auditors and monitor follow-up and corrective action.

DEVELOPMENTS IN HUMAN RESOURCE

NLL is a professionally managed company with highly competent and committed industry professionals forming a tight-knit team of dedicated colleagues. As part of its investment in learning and development, the Company has re-crafted its human resource philosophy. In brief, they are iterated below:

- Attract, build and retain right talent at all levels
- Create and nurture a performance culture through continuous capability building performance measurement and leveraging of IT
- Foster leadership at all levels through trust, empowerment and openness
- Strengthen collaborative approach for business excellence
- Promote a vibrant work culture based on innovation and to incentivize people based on productivity/outstanding performance

NLL has aligned its human resources learning and development to the needs of a growing and fast track organization. Year-on-year as the organization catapults ahead to meet its newest strategies and challenges, the immediate impact is felt on its processes, technology and most importantly its people. The very same people have to now perform with a certain sense of urgency, do more with less, be assertive yet be compliant and feel the heat of increase in their

RISKS AND CONCERNS:

RISK	RISK DESCRIPTION	MITIGATION PLAN
COMPETITION RISK	RISK Company faces competition from pharmaceutical companies from India and other parts of the world. These competitor companies bring new products in the market which can affect the Company's market share and revenue.	Company identifies unmet medical needs of patients, develop those products in R&D and launch innovative and customized products ahead of competition.
REGULATORY RISK	Company has to comply with extant laws and regulations prevailing in the country of its operations. These regulations can affect the development, manufacturing, approval, marketing and distribution of its products. Changes in the country's laws or regulations also throw new challenges of compliance.	Company has established a strong quality assurance mechanism and compliance monitoring network to ensure compliance. It also organizes regular training for its employees to update them on new developments.

span of control. This presupposes skilling the existing manpower to perform at their optimum best. The shop floor resources are hence encouraged to stay focused on key development areas as they are the doers, and hence are required to maintain the necessary cGMP compliance levels. Shop floor executives are continuously trained and groomed in the area of compliance, supported adequately to raise their competence, confidence and anytime readiness.

Safety Standards

The Company has established a safety, health and environment policy that is a planned series of controls and a few safety practices which need to be established for the protection of every employee.

Whistle Blower Policy

The company has made the Whistle Blower Policy for the employees of the company by which employees can report to the management, the instances of unethical behavior, actual or suspected, fraud or violation of the company's code of conduct or ethics policy. As per policy:

- No unfair treatment will be meted out to a Whistle Blower by virtue of his/her having reported a Protected Disclosure under this Policy.
- The Company, as a policy, condemns any kind of discrimination, harassment, victimization or any other unfair employment practice being adopted against Whistle Blowers.
- Complete protection will, therefore, be given to Whistle Blowers against any unfair practice like retaliation, threat or intimidation of termination/suspension of service, disciplinary action, transfer, demotion, refusal of promotion, or the like including any direct or indirect use of authority to obstruct the Whistle Blower's right to continue to perform his duties/functions including making further Protected Disclosure.

Employee Welfare

NLL undertakes following activities as a part of Employee Welfare services:

- Safety Services
- Safety training and publicity week
- Personal protective equipment
- Basic Facilities for Welfare of Employees
- Ambulatory services at workplace
- Sports day

The total numbers of employees are provided in Board of Directors' Report

BUSINESS RISKS AT NECTAR LIFESCIENCES LIMITED:

Some of the key existing and emerging risks affecting NLL's business are listed below:

RISK	RISK DESCRIPTION	MITIGATION PLAN
GLOBAL ECONOMIC VOLATILITY RISK	Company has business dealings in many countries. Each of these markets presents a different economic and political risk along with the ever present threat of natural disasters.	Company has established a strong quality assurance mechanism and compliance monitoring network to ensure compliance. It also organizes regular training for its employees to update them on new developments.
PATENT PROTECTION RISKS	Protection for patents, protect trade secrets and other proprietary information and operate without infringing on the intellectual property rights of other Pharma companies	NLL's success depends on a dedicated team of scientists whose primary task is to ensure that the products are manufactured using only non-infringing processes and related compliances by reviewing and monitoring IPR issues continuously.
RAW-MATERIAL IMPORT RISKS	NLL's dependency on China market for import of raw-material	NLL's dependency on China market is gradually coming down and minimizing risk of import disruptions, short supplies and production bottlenecks due to unforeseen changes in government regulations & economic policies of China. Continuous efforts are being made to create newer second sources of supplies and to develop alternative vendors.
PEOPLE RISKS	Maintaining good industrial & employee relations.	NLL's success depends largely upon an effective HR strategy that includes recruitment, learning & development, succession planning and retention of competent personnel. The HR strategy is aligned to business plan and growth of the Company
FINANCIAL RISKS	Foreign exchange fluctuations.	NLL is predominately an export oriented company. At the same time, the Company is having sizable imports/ working capital in foreign currency to fund the export oriented projects. As such, the Company's growing exports and its collections provide the natural hedge to the imports and working capital
COMMODITY RISKS	Prices are a function of demand and supply and the Company faced similar changes.	Exposure to market risk with respect to commodity prices primarily arises from the Company's purchases. There are commodity products whose prices may fluctuate significantly over short periods of time and generally fluctuate in line with commodity cycle. Sharp fluctuations in commodity prices may create significant business challenges that can affect production costs, product pricing, earnings and credit availability. As a safeguard measure, company purchases the raw material against orders in hand. The company has a strong export base to provide the required natural hedge for the raw material procurement. The open positions, if any, on either side, are hedged through commodity exchanges, if available.

For and on behalf of the Board of Directors
Of Nectar Lifesciences Limited

(Sanjiv Goyal)
Chairman and Managing Director

Place : Chandigarh
Date : 14.08.2019

Annexure 2 of Board of Directors' Report Report on Corporate Governance

Nectar Lifesciences' philosophy on Corporate Governance

Nectar Lifesciences Limited is committed to maximise the wealth of its shareholders, besides catering to the interests of its customers, employees and associates, with the highest standards of professionalism, integrity, accountability, fairness, following its values, transparency at all levels, social responsiveness and business ethics.

The Company's governance practices go beyond the statutory and regulatory requirements as it tries its best endeavour to follow the spirit of good governance in addition to regulatory requirements with a mission to alleviate human suffering with excellent global quality & affordable medicines created with a spirit of innovation, entrepreneurship & sustainability to create a better tomorrow.

The vision of the Company is: **"To become India's leading Global Lifesciences Company, which creates value for all stakeholders by offering excellence in product quality standards, services and commitment."**

The company is in compliance with corporate governance requirements specified in Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred as 'LODR Regulations'). Any disclosure not given in this report but disclosed in Board of Directors Report or its annexures, shall be deemed to be reported in this report.

The Company's compliances of Corporate Governance guidelines, as per LODR Regulations, are as under; however, this report is to be read with Board's Report and all its annexures for more clarity on corporate governance practices of the company:

I. Board of Directors

Composition and Responsibilities

The size and composition of the Board commensurate with the Company's future growth plans and also conforms to the requirements of the Corporate Governance Code under the LODR Regulations. The Company had total 8 Directors on the Board as on March 31, 2019, comprising two directors (including the Chairman) who are Executive Directors, two Non-Independent & Non-Executive director and remaining four are Non-Executive & Independent Directors (including a woman independent director).

The Board of the Company has devised a policy for orderly succession for appointments to the Board and to Senior Management.

The responsibilities of the Board include charting out business plans; devising corporate strategy; brand equity; formulation of policies; new initiatives; other management matters; performance review and control and ensuring that the targeted objectives are met on a consistent basis. In all, the Board of Directors of Nectar believes to ensure compliance of all the applicable laws of the land, in letter as well as in spirit.

Information as per LODR Regulations has been placed before the Board for its consideration. The Board reviews material compliances of all extant laws applicable to the Company as affirmed by the Management.

None of the Directors on the Board holds the office of:

- i) Director in more than 20 companies or
- ii) Director in more than 10 public companies including private companies which are holding or subsidiaries of public companies or
- iii) Director of more than 8 listed companies or
- iv) Independent Director of more than 7 listed companies or
- v) Independent Director of more than 3 listed companies in case of director who is Wholetime director of a listed company or
- vi) Memberships in Committees of the Board in more than 10 Committees or
- vii) Chairmanship of more than 5 Audit Committees and Stakeholders Relationship Committees.

Non-executive directors' compensation

Apart from receiving sitting fee for attending the meetings of the Board/committees, there were no pecuniary relationships or transactions between the Company and the Non-Executive and Independent Directors.

Number of meetings of the Board

During the financial year 2018-2019, Seven Board meetings were held on May 28, 2018, June 15, 2018, August 07, 2018, November 14, 2018, December 19, 2018, February 11, 2019 and March 14, 2019.

The names and categories of the Directors on the Board, their attendance at the Board meetings during the financial year 2018-19 and at the last Annual General Meeting (AGM), as also the number of directorship, committee memberships and committee chairmanship held by them in other companies are given below:

Name and designation of Directors	Category of Director	Number of Board Meetings attended	Attendance at the last AGM	Number of outside Directorship held as on March 31, 2019	Number of Board Committees of other companies in which	
					Member	Chairman
Mr. Sanjiv Goyal (Chairman and Managing Director)	Promoter & Executive Director	7	Not Present	3	Nil	N.A.
Dr. Dinesh Dua (Chief Executive Officer and Director)	Non Promoter & Executive Director	6	Present	1	Nil	N.A.
Mr. Vijay J. Shah (Director) (his office get vacated on June 27, 2018, reappointed on August 07, 2018 and resigned from December 01, 2018)	Independent & Non-executive Director	Nil	Not Present	N.A.	N.A.	N.A.
Mr. Vivek Sett (Nominee Director of Private Equity Investor)	Non-Independent & Non-executive Director	2	Not Present	8	1	Nil
Dr. (Maj. Gen.) S. S. Chauhan, VSM, Retd. (Director)	Independent & Non-executive Director	7	Present	Nil	N.A.	N.A.

Name and designation of Directors	Category of Director	Number of Board Meetings attended	Attendance at the last AGM	Number of outside Directorship held as on March 31, 2019	Number of Board Committees of other companies in which	
					Member	Chairman
Mr. Ajay Swaroop (Director)	Independent & Non-executive Director	6	Not Present	Nil	N.A.	N.A.
Mr. Harparkash Singh Gill (President (Operations) & Director) (Resigned from February 28, 2019)	Non Promoter & Executive Director	1	Present	N.A.	N.A.	N.A.
Ms. Guljit Sethi (Director)	Independent & Non-executive Director	3	Present	3	Nil	N.A.
Ms. Meena Verma (Nominee Director of Financial Institution w.e.f. February 11, 2019)	Non-Independent & Non-executive Director	1	N.A.	Nil	N.A.	N.A.
Dr. Rupinder Tewari (Additional Director w.e.f. February 11, 2019)	Independent & Non-executive Director	1	N.A.	1	1	0

N.A. stands for Not Applicable.

Mr. Vijay J. Shah had resigned from the Board from December 01, 2018 due to preoccupations and some other works. As per the resignation letter received by the company from Mr. Vijay J. Shah, there is no other reason provided for resignation in the letter except preoccupation of some other work.

Further, as per the amendments LODR Regulations, the requirement of

- detailed reason and
- confirmation by director that there are no other material reasons other than those provided are to be provided in case of resignation of Independent Director on or after April 1, 2019.

The directors are not inter se related to each other.

The Directorship of Directors of the Company in listed entities other than Nectar Lifesciences Limited is as under:

Name of Directors	Name of Listed Entities other than Nectar Lifesciences Limited	Category of Directorship
Mr. Sanjiv Goyal	Nil	N.A.
Dr. Dinesh Dua	Nil	N.A.
Mr. Vivek Sett	Nil	N.A.
Dr. (Maj. Gen.) S. S. Chauhan, VSM, Retd.	Nil	N.A.
Mr. Ajay Swaroop	Nil	N.A.
Ms. Guljit Sethi	Nil	N.A.
Ms. Meena Verma	Nil	N.A.
Dr. Rupinder Tewari	Venus Remedies Limited (Resigned w.e.f. May 24, 2019)	Independent Director

II. Code of Conduct

The Board of Directors adopted the Code of Conduct as per the provisions under LODR Regulations. The same has been posted on the Company's website www.necolife.com. All Board members and senior management personnel affirmed compliance with the Code. A declaration to this effect signed by Dr. Dinesh Dua, Chief Executive Officer & Director is attached to this Report.

III. Audit Committee

During the financial year 2018-19, the Audit Committee comprised of three directors including Ms. Guljit Sethi as a Chairman of Audit Committee with Dr. (Maj. Gen.) S. S. Chauhan, VSM (Retd.) and Dr. Dinesh Dua as members.

Ms. Guljit Sethi graduated in Economics (Hons.), did full time MBA from Jamnalal Bajaj Institute, Mumbai University and a PhD. fellowship from University of Pune. She has a career spanning 36

years in international business, strategic alliances including joint ventures and domestic marketing of pharmaceuticals, polymers with leading corporates. She fulfils the requirement that the one member of Audit Committee must have financial management expertise.

Dr. (Maj. Gen.) S. S. Chauhan, VSM (Retd.) retired after holding the most prestigious and highest professional appointment of Senior Consultant Medicine as Head of the medicine and Allied Specialties/ Super Specialties in the Armed Forces from Ministry of Defence and Army Hospital (Research and Referral) Delhi. Apart from holding many medical degrees, he also did Senior Defence Management Course from College of Defence Management Secunderabad in 1993. Dr. Dinesh Dua is MBA from IIM, Ahmedabad from 1979 batch. He has the experience of 38 years plus in varied industries in middle to senior management positions. Thus, the members are well versed with financial systems and have the ability to read and understand basic financial statements.

The terms of reference to the Audit Committee are in compliance to Section 177 of Companies Act, 2013 and LODR Regulations and other applicable laws, which, inter-alia, includes:

- Oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - Matters required being included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
 - Changes, if any, in accounting policies and practices and reasons for the same;
 - Major accounting entries involving estimates based on the exercise of judgment by management;
 - Significant adjustments made in the financial statements arising out of audit findings;
 - Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions;
 - Modified opinion(s) in the draft audit report;

- (5) Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- (6) Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- (7) Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- (8) Approval or any subsequent modification of transactions of the listed entity with related parties;
- (9) Scrutiny of inter-corporate loans and investments;
- (10) Valuation of undertakings or assets of the listed entity, wherever it is necessary;
- (11) Evaluation of internal financial controls and risk management systems;
- (12) Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems;
- (13) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- (14) Discussion with internal auditors of any significant findings and follow up there on;
- (15) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- (16) Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- (17) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- (18) To review the functioning of the whistle blower mechanism;
- (19) Approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;
- (20) Valuation of undertakings or assets of the company, wherever, it is necessary.
- (21) Reviewing management discussion and analysis of financial condition and results of operations;
- (22) Reviewing statement of significant related party transactions (as defined by the audit committee), submitted by management;
- (23) Reviewing management letters / letters of internal control weaknesses issued by the statutory auditors;
- (24) Reviewing internal audit reports relating to internal control weaknesses;
- (25) Reviewing the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
- (26) Reviewing statement of deviations:
 - (a) Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
 - (b) Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).
- 27) Reviewing loan and investment in subsidiaries.

During the year under review, four meetings of the Audit Committee were held, the dates being May 28, 2018, August 07, 2018, November 14, 2018 and February 11, 2019.

Annual Report 2018-19/ 18

The attendance of the members/permanent invitee at the Audit Committee meetings was as follows:

Name	Category of member of Committee	Number of meetings held during the tenure of each member	Number of meetings attended during the year
Ms. Guljit Sethi (Chairman)	Independent & Non-executive Director	4	4
Dr. (Maj. Gen.) S. S. Chauhan, VSM (Retd.) (Member)	Independent & Non-executive Director	4	4
Dr. Dinesh Dua (Member)	Chief Executive Officer & Director	4	4

Mr. Sandeep Goel, Chief Financial Officer and Mr. Ravi Kant Aggarwal, Vice President (Accounts) of the Company and representatives from M/s Ashwani K. Gupta & Associates, Chartered Accountants, statutory auditors of the Company, as considered appropriate, attended the meetings as permanent invitees, while Company Secretary, acts as the Secretary to the Committee.

IV. Nomination and Remuneration Committee

During the financial year 2018-19 the Nomination and Remuneration Committee comprised of three directors including Dr. (Maj. Gen.) S. S. Chauhan, VSM, (Retd.) as its Chairman and Ms. Guljit Sethi and Mr. Ajay Swaroop as its members

During the financial year ended on March 31, 2019, three meetings were held of the committee on May 28, 2018, August 07, 2018 and February 11, 2019.

The attendance of the members of Nomination and Remuneration Committee meetings was as follows:

Name	Category of member of Committee	Number of meetings held during the tenure of each member	Number of meetings attended during the year
Dr. (Maj. Gen.) S. S. Chauhan, VSM (Retd.) (Chairman)	Independent & Non-executive Director	3	3
Mr. Ajay Swaroop (Member)	Independent & Non-executive Director	3	2
Ms. Guljit Sethi (Member)	Independent & Non-executive Director	3	3

The terms of reference Nomination and Remuneration Committee are as under:

- i) to formulate the criteria for determining qualifications, positive attributes and independence of a director
- ii) to the Board a policy, relating to the remuneration for the directors, key managerial personnel and other employees and while formulating the policy ensure that—
 - (a) the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully;
 - (b) relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
 - (c) remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term

performance objectives appropriate to the working of the company and its goals:

- iii) Formulation of criteria for evaluation of Independent Directors and the Board;
- iv) Devising a policy on Board diversity;
- v) Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal.
- vi) As specified in the provisions of the Section 178 of the Companies Act, 2013 and Regulation 19 and Part D of Schedule II of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Nomination, Remuneration and Evaluation Policy is formulated by the Nomination and Remuneration Committee and approved by the Board. The weblink of said Policy has been provided in Board's report.

The details of remuneration of Directors are given in disclosures part of this Report.

The performance evaluation criteria for Independent Directors are disclosed in Directors' report.

V. Stakeholders' Relationship Committee

The Stakeholders' Relationship committee of the company is constituted with three directors including Mr. Ajay Swaroop as its Chairman and Mr. Sanjiv Goyal and Dr. Dinesh Dua as its members.

Company Secretary, acts as the Secretary of the Committee and also the Compliance officer of the Company. The Committee focuses on strengthening investor relations and performs the following functions:

- (i) Approves and monitors transfers, transmission, splitting and consolidation of securities, issue of share certificate upon rematerialisation requests and issue of duplicate share certificates;
- (ii) Looks into various issues relating to shareholders including redressal of complaints relating to transfer of shares, non-receipt of annual reports and dividends, among others;
- (iii) Ensures compliance of the Code of Conduct for prevention of insider trading formulated by the Company as per the Securities and Exchange Board of India Regulations.

As on March 31, 2019, 99.999% of the Company's shares are held in electronic (demat) form.

During the financial year ended on March 31, 2019, one meeting was held of the committee on August 07, 2018, which was attended by all its members.

All the complaints received during the year were duly redressed to the complete satisfaction of the respective shareholders expeditiously. The detail of complaints received and redressed follows:

Opening balance as on 01-04-2018	Received during the year	Complaints resolved during the year	Closing balance as on 31-03-2019
Nil	23	23	Nil

Quarter-wise details of complaints during 2018-19:

Quarter	Complaints pending at the beginning of the quarter	Complaints received during the quarter	Complaints resolved during the quarter	Complaints pending at the end of the quarter
April-June	Nil	2	2	Nil
July-September	Nil	12	12	Nil
October-December	Nil	5	5	Nil
January-March	Nil	4	4	Nil

Reconciliation of share capital Audit

The Company conducts a Reconciliation of Share Capital audit on a quarterly basis in accordance with requirements of Securities and Exchange Board of India (Depositories and Participants) Reg. 1996 and SEBI Circular No. D&CC/ FITTC/ Cir-16/2002 dated 31.12.2002. The Practicing Company Secretaries were appointed by the Company to conduct such audit. The Reconciliation of Share Capital Audit Report, which was submitted to the stock exchanges within the stipulated period, inter-alia certifies that the Company's equity shares held in the dematerialised form and in the physical form confirm with the issued and paid-up equity shares capital of the Company.

Secretarial Compliance Certificate

As per the provisions of the LODR Regulations, the company has obtained the Secretarial Compliance Certificate on half-yearly basis from Practicing Company Secretaries, to the effect that all transfer of shares among others, were effected within the stipulated time. The certificate was submitted with the stock exchanges within the prescribed time limit.

A half yearly Compliance Certificate duly signed by the Compliance officer of the company and the authorized representative of the Registrar and Share Transfer agent (RTA), with a confirmation that all activities of share transfer facility (both physical and electronic) are maintained by RTA, registered with the SEBI, is also filed with the Stock Exchanges.

Reporting as per para F of Schedule V of the LODR Regulations

As required under para F of Schedule V of the LODR Regulations, the details of shares in suspense account, i.e. shares issued pursuant to the public issues or any other issue which remain unclaimed are as under:

At the beginning of the year i.e. April 1, 2018	Aggregate number of shareholders	2
	Outstanding shares in the suspense account	500 equity shares of Re. 1/- each
Number of shareholders who approached issuer for transfer of shares from suspense account during the year		Nil
Number of shareholders to whom shares were transferred from suspense account during the year		Nil
Number of shares which are transferred to IEPF Authority pursuant to Sections 124(6) and 125 of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (IEPF) (Accounting, Audit, Transfer and Refund) Rules, 2016		Nil
At the end of the year i.e. March 31, 2019	Aggregate number of shareholders	2
	Outstanding shares in the suspense account	500 equity shares of Re. 1/- each

Further, the voting rights on these shares will remain frozen till the rightful owner of such shares claims the shares.

Compliances regarding insider trading

The Company had in place a 'Code of Conduct for Prevention of Insider Trading' and 'Code of Fair Disclosures', in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The codes referred above are placed on the Company's website www.neclife.com. The said codes were adhered during the year under review.

VI. Other committees

The details of other committees of Board, its members and date of their meeting are as under:

Name of the Committee	Members	Details
Management Committee	1. Mr. Sanjiv Goyal (Chairman) 2. Dr. Dinesh Dua (Member)	Two meetings of the Management committee were held on September 4, 2018 and November 30, 2018 and attended by all its members.
Corporate Social Responsibility Committee	1. Mr. Sanjiv Goyal (Chairman) 2. Dr. (Maj. Gen.) S. S. Chauhan, VSM (Member) 3. Dr. Dinesh Dua (Member)	Two meetings of the CSR committee were held on May 28, 2018 and November 14, 2018 and attended by all its members.
Risk Management Committee	1. Dr. Dinesh Dua (Chairman) 2. Mr. Harparkash Singh Gill (Member)	One meeting of the Risk Management committee was held on December 24, 2018 and attended by all its members.

The meetings of above committees are held as and when its members think appropriate or necessary to discuss the matters within their terms of reference.

Independent Directors' meeting:

During financial year 2018-19, One meeting of Independent Directors was held on August 07, 2018.

The attendance of the Independent Directors of their meetings was as follows:

Name	Category of member of Committee	Number of meetings held during the tenure of each member	Number of meetings attended during the year
Dr. (Maj. Gen.) S. S. Chauhan, VSM (Retd.) (Chairman)	Independent Director	1	1
Mr. Vijay J. Shah (Member)	Independent Director	1	0
Mr. Ajay Swaroop (Member)	Independent Director	1	1
Ms. Guljit Sethi (Member)	Independent Director	1	1
Dr. Rupinder Tewari (Member)	Independent Director	N.A.	N.A.

In compliance with Schedule IV to the Companies Act, 2013 and regulation 25(3) of the LODR Regulations, the independent directors held their separate meeting on August 14, 2019, without the attendance of non-independent directors and members of the Management, inter alia, to discuss the following:

- Noting of the report of performance evaluation for 2018-19 from Chairman of the Board;
- Review of the performance of non-independent directors and the Board;
- Review of the performance of the Chairperson of the Company;
- Assessment of the quality, quantity and timeliness of flow of information to the Board; and
- Review of informal meeting with Senior Management Personnel.

The independent directors present elected Dr. (Maj. Gen.) S. S. Chauhan, VSM as Chairman for the meeting. All independent directors, except Mr. Ajay Swaroop, were present at the meeting, deliberated on the above and expressed their satisfaction on each of the matters.

VII. General Body meetings

Details of the last three Annual General Meetings held

1. 23rd Annual General Meeting: September 28, 2018 at 10.00 am at the registered office and works of the Company i.e. Village Saidpura, Tehsil Derabassi, District S.A.S. Nagar (Mohali) Punjab

2. 22nd Annual General Meeting: September 28, 2017 at 10.00 am at the registered office and works of the Company i.e. Village Saidpura, Tehsil Derabassi, District S.A.S. Nagar (Mohali) Punjab
3. 21st Annual General Meeting: September 30, 2016 at 10.00 am at the registered office and works of the Company i.e. Village Saidpura, Tehsil Derabassi, District S.A.S. Nagar (Mohali) Punjab

Detail of special resolutions:

1. At the 23rd Annual General Meeting held on September 28, 2018, the following special resolutions were passed:
 - i) Re-appointment of Dr. Dinesh Dua Chief Executive Officer & Director and to approve his remuneration.
 - ii) For continuation of Dr. (Maj. Gen.) Shamsheer Singh Chauhan, VSM, who has attained the age of 75 years, as a Non-Executive Independent Director of the company.
 - iii) Re-appointment of Mr. Vijay J. Shah, as an Independent Director of the Company for 2nd term to hold office for a term of five years.
2. At the 22nd Annual General Meeting held on September 28, 2017, the following special resolutions were passed:
 - i) Re-appointment of Mr. Sanjiv Goyal, Chairman & Managing Director and to approve his remuneration.
 - ii) Re-appointment of Mr. Harparkash Singh Gill, President (Operations) & Director and to approve his remuneration.
3. At the 21st Annual General Meeting held on September 30, 2016, the following special resolutions were passed:
 - i) Re-appointment and revision in the remuneration of Mr. Harparkash Singh Gill, President (Operations) & Director.
 - ii) Revision in the remuneration of Dr. Dinesh Dua Chief Executive Officer & Director.

Apart from the said resolutions, there was no other special resolution passed at the above General Meetings. The resolutions of 21st, 22nd and 23rd Annual General Meeting are passed through e-voting as per section 108 of the Companies Act, 2013 and polling at the venue of General Meeting as per Section 109 of the Companies Act, 2013, in case of those members who did not participated by e-voting.

There was no resolution passed through postal ballot process during the last year.

No special resolution to be passed through postal ballot is proposed at the ensuing Annual General Meeting.

VIII Disclosures

- a. There was not any material non-compliance by the Company and no penalties, strictures imposed on the Company by stock exchanges or SEBI or any statutory authority, on any matter related to capital markets, during the 2016-17, 2017-18 and 2018-19. However, the company had submitted the audited financial results for the year ended on March 31, 2017 on June 27, 2017 which was 28 days after the prescribed period that was expired on May 30, 2017. National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) had imposed fine on the company for late submission of financial results for the financial year ended on March 31, 2017. The fine was 0.1% of listed capital and Rs. 5000/- per day for a period of delay, which amount to Rs. 364261/- for NSE and BSE each. Further, the BSE had also charged the service tax on the fine. The company had deposited the fine along with service tax, wherever applicable, which was acknowledged by NSE and BSE.
- b. The Company had adopted the whistle blower policy during 2014-15. The policy is available on URL: www.neclife.com. No employee has been denied access to the audit committee.
- c. i) Details of compliance with mandatory requirements is given elsewhere in this Report

ii) The Company has also complied with the discretionary requirements as under:

a) The Board

Since the Company has an executive Chairman, the requirement regarding non-executive Chairman is not applicable.

b) Un-Modified opinion(s) in audit report

The Company confirms that its financial statements are with unmodified audit opinion.

c) Reporting of Internal Auditor

The Internal Auditor reports directly to the Audit Committee.

d. **Related Party Transactions:** The details of all transactions, if any, with related parties are placed before the Audit committee and Board and wherever necessary approval of members has also obtained in their General Meeting.

There was not any loan or advances given by the company to its wholly owned subsidiaries. The Investments as on March 31, 2019, in Nectar Lifesciences USA LLC was USD 51950/- and in Nectar Lifesciences UK Limited was GBP 1/- only.

There were no materially significant transactions made by the Company with its promoters, Directors or the management and their subsidiaries or relatives, among others, that may have potential conflict with the interests of the Company at large. However, the general related party disclosures are given in the Notes on Accounts and Form AOC-2 attached to Board's Report.

The transaction with persons or entities belonging to the promoter/ promoter group which hold(s) 10% or more shareholding in the Company, if any, are provided in Notes of forming and part of Financial Statements of the company.

The Senior Management has confirmed to the Board that they have complied with the code of conduct which bar them to not to enter into any material financial and commercial transactions, where they had (or were deemed to have had) personal interest.

e. **Disclosure of accounting treatment:** In the preparations of financial statements, the Company followed the accounting standards issued under Companies (Indian Accounting Standards) Rules, 2015, as amended upto date, to the extent applicable.

f. **Disclosure of risk management:** The Company regularly informed the Board of Directors about the risk assessment, if any, along with recommendations to reduce the risk. The company has voluntarily constituted the Risk Management Committee which advised to Board about Risk Management Policy from time to time. The Board approved the Risk Management Policy as recommended by Risk Management Committee. Apart from it, Audit Committee also oversee the Risk Management framework of the company.

g. Remuneration of Directors: **The Non-Executive Directors are entitled to sitting fee of Rs. 10,000 per board meeting attended by them. The sitting fee of Rs. 1000 is paid to them for every Committee meeting attended by them. Apart from the sitting fee, the Non-Executive Directors did not have any material pecuniary relationship with the Company.**

During the financial year 2018-19, the Company paid the remuneration to Mr. Sanjiv Goyal, Chairman & Managing Director, Dr. Dinesh Dua, Chief Executive Officer & Director and Mr. Harparkash Singh Gill, President (Operation) & Director on the terms and conditions of their respective resolutions passed by the Board of Directors and members. The Company is not paying any sitting fee to its Executive Directors.

The details of Directors' remuneration for the financial year ended March 31, 2019:

Name and designation of Director	Sitting fee (Rs.)	Salaries and perquisites (Rs.)	Period of service	Number of shares held as on March 31, 2019
Mr. Sanjiv Goyal, Chairman and Managing Director	N.A.	18091940/-	5 years from June 01, 2017	55555600
Dr. Dinesh Dua, Chief Executive Officer & Director	N.A.	12306141/-	1 years from October 14, 2018	Nil
Mr. Harparkash Singh Gill, President Operations & Director	N.A.	3238412/-	2 years from November 01, 2017 and resigned on February 28, 2019	N.A.
Mr. Vijay J. Shah, Independent Director	Nil	N.A.	Upto August 7, 2023, but resigned with effect from December 1, 2018	N.A.
Mr. Vivek Sett, (Nominee Director of Private Equity Investor)	20000/-	N.A.	Non rotational Director	Nil
Dr. (Maj. Gen.) S. S. Chauhan, VSM, Independent Director	79000/-	N.A.	5 years from September 30, 2014.	Nil
Mr. Ajay Swaroop, Independent Director	63000/-	N.A.	5 years from September 30, 2014	Nil
Ms. Guljit Sethi Independent Director	37000/-	N.A.	Upto December 28, 2020.	Nil
Ms. Meena Verma (Nominee Director of Financial Institution)	10000/-	N.A.	No term specified.	Nil
Dr. Rupinder Tewari (Additional Director) Independent Director	10000/-	N.A.	Upto AGM	Nil

The Company did not provide any stock option to its directors and employees.

h. Details of the familiarization programme of the independent directors are available on the website of the Company (URL: www.neclife.com).

i. Policy for determining material subsidiaries of the Company is available on the website of the Company (URL: www.neclife.com).

j. Policy on dealing with related party transactions is available on the website of the Company (URL: www.neclife.com).

k. Commodity price risk or foreign exchange risk and hedging activities.

1. This activity is discussed in Management Discussion and Analysis Report under Risk Management.

2. Exposure of the listed entity to commodity and commodity risks faced by the entity throughout the year:

a. Total exposure of the listed entity to commodities in INR: The Value of total Inventory held by the Company for Raw Material, Work in Progress and Finished Goods (Including Stock in Trade) as on 31.03.2019 was Rs.914.53 Crores.

b. Exposure of the listed entity to various commodities:

Commodity Name (Inventory as on 31.03.19)	Exposure in INR (crores) towards the particular commodity	Exposure in Quantity (MT) terms towards the particular commodity	% of such exposure hedged through commodity derivatives				Total
			Domestic market		International market		
			OTC	Exchange	OTC	Exchange	
Raw Material	100.70	6,348.44	Nil	Nil	Nil	Nil	Nil
Work in Progress	599.33	4,646.55	Nil	Nil	Nil	Nil	Nil
Finished Goods	192.39	286.75	Nil	Nil	Nil	Nil	Nil
Misc. Stocks	22.11	Not ascertainable	Nil	Nil	Nil	Nil	Nil

- c. Commodity risks faced by the listed entity during the year and how they have been managed.

The commodity prices are determined through basic supply and demand factors in the marketplace and as a safeguard measure, company purchases the raw material against orders in hand. The company has a strong export base to provide the required natural hedge for the raw material procurement. The open positions, if any, on either side, are hedged through commodity exchanges, if available.

- I. Terms and conditions of Appointment of Independent Directors:** As per regulation 46(2) of SEBI Listing Regulations, 2015, the terms and conditions of appointment of independent directors are placed on the Company's website www.neclife.com. The maximum tenure of independent directors is in accordance with the Companies Act, 2013 and regulation 25(2) of the SEBI Listing Regulations, 2015.

A confirmation that in the opinion of the board, the independent directors fulfill the conditions specified in the LODR Regulations and are independent of the management has been provided in Directors Report.

- m. The company is in compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 of LODR Regulations.
- n. There is no credit rating obtained by the company or any revisions thereto during the financial year 2018-19, as there are no:
- debt instruments or
 - any fixed deposit programme or
 - any scheme or proposal of the company involving mobilization of funds, whether in India or abroad.
- o. Skills/expertise/competence identified by the board of directors as required in the context of its business(es) and sector(s) for it to function effectively and those actually available with the board are as under:

Skills/expertise/competence	Availability
1. All Round Leadership skills	Yes
2. Knowledge of domain of Pharmaceuticals, Science & Research	Yes
3. Overall familiarity about Finance, Accounting, Manufacturing, Quality Management Systems, Sales, marketing and business development	Yes
4. Risk management Awareness	Yes
5. Skills in regulations	Yes
6. OH&S (Occupational health and safety)	Yes

- p. There are no funds raised through public issue, rights issue, preferential issue etc. and therefore, Regulation 32 (4) of LODR Regulations is not applicable to company.

There are no funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of LODR Regulations.

- q. Certificate from Mr. Prince Chadha of P. Chadha & Associates., Practicing Company Secretary that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the SEBI or Ministry of Corporate Affairs or any such statutory authority is attached to this report.
- r. The board had accepted all recommendations or submissions of all committees of the board which are mandatorily required for the approval of the Board, in the financial year 2018-19.
- s. Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/ network entity of which the statutory auditor is a part are as Under:

The company has paid Rs. 21,00,000/- (excluding GST @ 18%) towards Statutory audit fees and Rs. 4,00,000/- (excluding GST @ 18%) towards Tax Audit fees to statutory auditors. No any other fees have been paid to statutory auditors for the company and/ or its subsidiaries.

IX. Means of communication

Quarterly results

The details of quarterly results are published are as under:

Quarter	English daily	Punjabi daily
April-June	<i>Business Standard</i> – All Editions	Desh Sewak
July-September	<i>Business Standard</i> – All Editions	Desh Sewak
October-December	<i>Business Standard</i> – All Editions	Desh Sewak
January - March	<i>Business Standard</i> – All Editions	Desh Sewak

The results are also displayed on the company's website www.neclife.com. The official news' are also displayed on the Company's website. Apart from the above, we also regularly provided the information to the Stock Exchanges as per the requirements of the LODR Regulations and the desired information can be accessed from the websites of the respective Stock Exchanges. Other than the annual accounts, the quarterly and half-yearly financial results are not sent to the household of each shareholder. The presentations made to institutional investors or analysts, if any, are also disclosed to the Stock Exchanges, simultaneously and hosted on the website of the company.

X. PARTICULARS OF APPOINTMENT / RE-APPOINTMENT OF DIRECTORS

The required information of directors on their appointment/ re-appointments is given in the explanatory statement under section 102 of the Companies Act, 2013 of Notice of ensuing Annual General Meeting.


XI. General Shareholder Information

- i. 24th Annual General Meeting
- Date Saturday, September 28, 2019
- Time 10.00 am
- Venue Registered Office and Works: Village Saidpura Tehsil Derabassi, District S.A.S. Nagar (Mohali) Punjab – 140507.
- ii. Financial year April 1, 2018 to March 31, 2019
- iii. Date of book closure September 22, 2019 to September 28, 2019 (Both days inclusive).
- iv. Dividend payment date By October 27, 2019
- v. The equity shares of Re. 1/-each of the Company are listed on
- The National Stock Exchange of India Limited (NSE)
Regd Office : "Exchange Plaza",
Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051,
Maharashtra, India
Tel : 91-22-26598100, 56418100
Fax : 91-22-26598237/38, 26598120
 - BSE Limited (BSE)
New Trading Ring, Rotunda Building,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001,
Maharashtra, India
Tel : 91-22-22721233, 22721234,
Fax : 91-22-22723677, 22722082/ 3132
- vi. Global Depository Receipts (GDRs) listed on Luxembourg Stock Exchange/ LuxSE Société de la Bourse de Luxembourg S.A. B.P. 165, L-2011 Luxembourg
Siège social, 11, av de la Porte-Neuve,
Telephone: (00352) 47 79 36 – 1,
Fax : (00352) 47 32 98
- vii. Listing fee The annual listing fees have been paid to the above exchanges and there is no outstanding payment towards the exchanges, as on date.


- viii. Equity shares' stock code BSE Code : 532649
/ symbol NSE Symbol : NECLIFE
- ix. GDRs common code 039031680
- x. ISIN of Company's equity shares: INE023H01027
- xi. ISIN of Company's GDRs US63975T1051
- xii. CUSIP of Company's GDRs 63975T 105
- xiii. Corporate Identification Number (CIN) L24232PB1995PLC016664
- xiv. Market price data:
The high and low prices of the Company's share (of Re. 1/- each) at BSE and NSE from April 1, 2018 to March 31, 2019 were as below:

Month	BSE			NSE		
	High (Rs.)	Low (Rs.)	Total Traded Quantity	High (Rs.)	Low (Rs.)	Total Traded Quantity
Apr-18	29.70	26.35	999,070	29.80	26.55	2,933,468
May-18	28.00	23.80	764,298	27.70	23.70	3,216,462
Jun-18	28.45	18.70	1,644,801	28.85	17.80	7,963,643
Jul-18	23.85	19.10	826,780	23.95	19.05	3,533,854
Aug-18	30.95	20.30	3,557,628	30.90	20.15	17,996,425
Sep-18	30.80	22.10	1,409,452	30.90	22.00	7,130,361
Oct-18	24.45	19.00	840,237	24.50	20.00	3,607,528
Nov-18	24.35	20.40	654,002	24.30	20.50	3,637,426
Dec-18	21.80	18.75	502,580	21.80	18.70	2,062,939
Jan-19	20.85	17.60	364,125	20.90	17.40	1,511,739
Feb-19	20.70	15.50	460,145	18.40	15.40	1,985,570
Mar-19	20.00	16.10	728,423	20.00	15.85	2,534,438

- xv. Performance of the Company's share price with BSE SENSEX and NSE Nifty
- a. Performance of the Company's share price at BSE in comparison with BSE SENSEX



- b. Performance of the Company's share price at NSE in comparison with NSE Nifty




- xvi. Registrar and Transfer Agents and contact person thereof
Karvy Fintech Private Limited
Unit: Nectar Lifesciences Limited
Karvy Selenium Tower B, Plot No. 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 Tel: (91-40) 67161527, Fax: (91-40) 23420814
Contact Person : Ms. Varalakshmi
E-mail: vlakshmi.p@karvy.com
- xvii. Address for correspondence at the Company
Nectar Lifesciences Limited
SCO 38-39, Sector 9-D, Chandigarh -160 009
Ph. No. 0172-3047777,3047701
Fax No. 0172-3047755
- xviii. Compliance Officer and contact person at the Company
Company Secretary
E-mail: cs@neclife.com
Website : www.neclife.com

- xix. Share transfer system
Almost 99.999% of the shares of the Company are held in dematerialised form. Transfers of these dematerialised shares are done through the depositories with no involvement of the Company. As regards transfer of shares held in physical form, the transfer documents can be lodged with the Registrar and Share Transfer Agent of the Company.
Transfers of shares in physical form are normally processed within 15 days from the date of receipt, if documents are complete in all respects. The Stakeholders' Relationship Committee approves the transfer and transmission of shares.

- xx. Distribution of shareholding
a) Class-wise distribution of equity shares as on March 31, 2019

Category (amount)	Number of cases	% of cases	Total shares	Nominal value of shares held (Rs.)	% of amount
1-5000	41572	97.21	23918657	23918657	10.67
5001- 10000	689	1.61	5191290	5191290	2.31
10001- 20000	267	0.62	3810976	3810976	1.70
20001- 30000	97	0.23	2400939	2400939	1.07
30001- 40000	42	0.10	1485912	1485912	0.66
40001- 50000	26	0.06	1195779	1195779	0.53
50001- 100000	37	0.09	2652318	2652318	1.18
100001 & Above	35	0.08	183605099	183605099	81.87
Total	42765	100.00	224260970	224260970	100.00

Distribution Schedule as on March 31, 2019




- b) Shareholding pattern as on March 31, 2019

Category	Number of Cases	Total shares	% to equity
Promoters	5	99468000	44.35
GDR	1	46000000	20.51
Resident Individuals & HUFs	41686	38356164	17.10
Foreign Companies	1	26000000	11.59
Bodies Corporate & Trusts	459	5920526	2.64
Foreign Portfolio Investors	5	5171122	2.31
Non Resident Indians	515	2655930	1.18
Indian Financial Institutions & Banks	4	183150	0.08

Category	Number of Cases	Total shares	% to equity
Clearing Members	79	160562	0.07
NBFC	9	311917	0.14
IEPF	1	33599	0.01
Total	42765	224260970	100.00

Shareholding Pattern as at March 31, 2019




xxi. Dematerialisation of shares and liquidity

The Company's shares are compulsory traded in dematerialized form. Equity shares of the Company representing 99.999% of the Company's share capital were dematerialised as on March 31, 2019.

The Distribution of shareholding of the Company as per the depository system as on March 31, 2019 was as under:

Sr.	Category	Number of holders	Total shares	% to equity
1	PHYSICAL	9	2300	0.001
2	N S D L	23912	161657479	72.085
3	C D S L	18844	62601191	27.914
	TOTAL	42765	224260970	100.000



Distribution of Shareholding as on March 31, 2019

The Company's shares are regularly traded on the National Stock Exchange of India Limited (NSE) and the BSE limited (BSE), in electronic form.

Under the depository system, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE023H01027.

xxii. Outstanding GDRs/ADRs/warrants or any convertible instruments, conversion date and likely impact on equity
GDRs: The Company has issued and allotted 46,000,000 equity shares of Re. 1/- each underlying 46,000,000 Global Depository Receipts (GDRs) of US\$ 0.76 each on 26.02.2010. The total proceeds from the GDRs issue was US\$ 34.96 Million. The GDRs are listed on:

Luxembourg Stock Exchange/ LuxSE
Société de la Bourse de Luxembourg S.A.
B.P. 165, L-2011 Luxembourg
Siège social, 11, av de la Porte-Neuve,
Telephone: (352) 47 79 36 – 1, Fax : (352) 47 32 98

The underlying equity shares, of the company are forms and part of paid up equity capital of Rs. 224,260,970/- comprising of 224,260,970 equity shares of Re. 1/- each.

- xxiii. Registered office location: Nectar Lifesciences Limited, Village: Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab
- xxiv. Plant locations:
1. Nectar Lifesciences Limited, Unit I, Village: Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab
 2. Nectar Lifesciences Limited, Unit II, Village: Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab
 3. Empty Hard Gelatin Capsule Unit, Village Bhatoli Kalan, Pargana Dharpur, Tehsil Nalagarh District Solan, (Himachal Pradesh)
 4. Formulation Unit, Village Bhatoli Kalan, Pargana Dharpur, Tehsil Nalagarh District Solan, (Himachal Pradesh)
 5. Narbada Industries, Plot No. 2, Lane No. 4, Phase II, SIDCO INDUSTRIAL COMPLEX Bari Brahmana, Jammu (J & K)

xxv. The shareholders / investors may please refer to Notes to Notice of AGM for information pertaining to Unpaid/ Unclaimed Dividend and share transferred to IEPF.

XII. CEO / CFO certification

As required under LODR Regulations the certificates duly signed by Chief Executive Officer & Director and Chief Financial Officer, were placed at the meeting of the Board of Directors held on May 25, 2019.

XIII. Report on corporate governance

This report, read together with the information given in the Directors' Report and the chapters on Management Discussion and Analysis and General Shareholder Information, constitute the compliance report on Corporate Governance during 2018-19. The Company has been regularly submitting the quarterly compliance report to the stock exchanges, as required under regulation 27 of the LODR Regulations, 2015 and placing at the meeting of the Board for their information and noting.

XIV. Auditor's certificate on compliance of conditions of Corporate Governance

Certificate from the auditors on compliance of conditions on Corporate Governance is enclosed along with the Directors' Report.

For and on behalf of the Board of Directors
of Nectar Lifesciences Limited

Place : Chandigarh
Date : 14.08.2019

(Sanjiv Goyal)
Chairman and Managing Director

**Declaration to the Compliance with code of conduct as per Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

I, Dinesh Dua, Chief Executive Officer & Director of Nectar Lifesciences Limited having its registered office at Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, do hereby certify that the Board of Directors has formulated the code of conduct as per the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Directors and Senior Management Personnel, which has been posted on the website of the company.

Further, it is hereby confirmed that all the Directors and Senior Management Personnel have complied with the code of conduct and a confirmation to this effect has been obtained from Directors and Senior Management Personnel for the financial year 2018-19.

For and on behalf of the Board of Directors
of Nectar Lifesciences Limited

(Dinesh Dua)
Chief Executive Officer & Director

Place : Chandigarh
Date : May 25, 2019

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS
(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,

The Members of
Nectar Lifesciences Limited
CIN – L24232PB1995PLC016664
Village: Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

I/We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Nectar Lifesciences Limited** having CIN **L24232PB1995PLC016664** and having registered office at **Village: Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab** (hereinafter referred to as 'the Company'), produced before me/us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10 (i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my/our opinion and to the best of my/our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me / us by the Company & its officers, I/We hereby certify that none of the Directors on the Board of the Company for the Financial Year ending on 31st March, 2019 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For P. Chadha & Associates
Company Secretaries

Prince Chadha
(Prop.)
M. No.: 32856
C.P. No.: 12409

Place : Chandigarh
Date : 25-05-2019

Annexure 3 of Board of Directors' Report Auditor's Report on Corporate Governance

To

The members of
Nectar Lifesciences Limited

We have examined the compliance of conditions of Corporate Governance by Nectar Lifesciences Limited for the year ended March 31, 2019, as stipulated in Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The compliance of the conditions of Corporate Governance is the responsibility of the management. Our examination was limited to a review of procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance as stipulated in the said Regulations. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to explanations given to us by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Based on the records maintained & certified by the Secretary of the Company, there are no investor grievances pending against the Company for a period exceeding one month.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For M/s **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(Ashwani K Gupta)
PARTNER
M.No.: 082808

Place : Chandigarh
Date : 25.05.2019

Annexure 4 of Board of Directors' Report

To,

The Members,

NECTAR LIFESCIENCES LIMITED

Registered office: Village Saidpura,
Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali)
Punjab – 140507

Our Secretarial Audit Report (Form MR-3) of even date is to be read along with this letter:

1. Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure the correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of law, rules, regulations and happening of event etc.
5. The compliance of provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit reports is neither an assurances as to the future viability neither of Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

For **P. Chadha & Associates**
Practising Company Secretaries

(Prince Chadha)
ACS 32856,
CP 12409

Date : 25-05-2019
Place : Chandigarh

SECRETARIAL AUDIT REPORT

Form no. MR-3

For the Financial Year ended March 31, 2019

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rule, 2014]

To,

The Members,

Nectar Lifesciences Limited

Registered office: Village Saidpura,

Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali)

Punjab – 140507

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and adherence to good corporate practices by Nectar Lifesciences Limited (“the listed entity”) having Corporate Identification Number (CIN) L24232PB1995PLC016664 and registered office at Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab (hereinafter called ‘the company’). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on our verification of the Company’s books, papers, minutes book, forms and returns filed and other records maintained by the company and also the information provided by the company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the company has, during the audit period covering the financial year ended on March 31, 2019 complied with statutory provisions listed hereunder and also that company has proper Board-processes and compliance- mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

- (A) We have examined the books, papers, minute books, forms and returns filed and other records maintained by the company for the financial year ended March 31, 2019 according to the provisions of:
1. The Companies Act, 2013 (The Act) and the rules made there under;
 2. The Securities Contract (Regulation) Act, 1956 (‘SCRA’) and the rules made there under;
 3. The Depositories Act, 1996 and Regulations and Bye-laws framed there under;
 4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct investment and External Commercials Borrowings;
 5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992(‘SEBI Act’):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended upto date;
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended upto date; and
 - c) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with clients as amended upto date;
 6. During the period under review, the Company has complied with the provision of the following acts and as reported by Management of the company to us there is no material proceedings, litigation pending in any Court or Department in respect of these Acts and no penalty has been imposed on Company under the following Act:
 - (i) Drugs and Cosmetics Act, 1940
 - (ii) Narcotic Drugs & Psychotropic Substances Act, 1985
 - (iii) The Environment (Protection) Act, 1986
 - (iv) Air (Prevention and Control of Pollution) Act, 1981
 - (v) The Water (Prevention and Control of Pollution) Act, 1974
 - (vi) Solvent and Petroleum Products storage under Petroleum Act, 1934
 - (vii) Electricity Act, 2003 and Rules and Regulations thereof.
 - (viii) Factories Act, 1948
 - (ix) Indian Boilers Act, 1923
 - (x) Standards of Weights & Measure Act ,1976
 - (xi) GST (Goods & Service Tax) Laws, Excise Laws, Sales Tax Laws
 - (xii) Customs Act, 1962
 - (xiii) Income Tax Act, 1961.
 - (xiv) Hazardous waste and other Wastes (Management, Handling & Tran boundary Movement) Rules-2016
 - (xv) Petroleum Act, 1934
 - (xvi) Food Safety and Standards Act, 2006

-
- (xvii) Employee's Provident Funds and Miscellaneous Provision Act, 1952
 - (xviii) The Employee's State Insurance Act, 1948
 - (xix) The Employment Exchange (Compulsory Notification of Vacancies) Act, 1959 & Rules
 - (xx) Industrial Employment (Standing Order) Act, 1946
 - (xxi) The Maternity Benefit Act, 1961
 - (xxii) Punjab Welfare Fund Act, 1965
 - (xxiii) Equal Remuneration Act, 1976
 - (xxiv) The Workmen's Compensation Act, 1923
 - (xxv) The Minimum Wages Act, 1948
 - (xxvi) The Payment of Wages Act, 1936
 - (xxvii) The Payment of Gratuity Act, 1972
 - (xxviii) The Payment of Bonus Act, 1965
 - (xxix) The Contract Labour (Regulation & Abolition) Act, 1970 & Rules
 - (xxx) Punjab Industrial Establishment (National & Festival, Holidays, Sick & Casual Leave) Rules, 1966.
 - (xxxi) Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

(B) We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial standards with regard to Meeting of Board of Directors (SS-1) and General Meetings (SS-2) issued by the institute of company Secretaries of India;
- (ii) The Securities and Exchange Board of India (Listing Obligation Disclosure Requirements) Regulations, 2015;
During the period under review, the Company has generally complied with the provision of the Acts, Rules, Regulations, Guidelines and Standards etc.
During the period under review, the provision of the following Regulations (as enumerated in the prescribed format of Form MR-3) were not applicable to the Company:
 - (i) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
 - (ii) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;
 - (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - (iv) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefit) Regulations, 2014; and
 - (v) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008.

We further report that the board of directors of the company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the board of directors that took place during the period under review were carried out in compliance with the provisions of the relevant act.

We further report that adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting. Three Board meetings were called on June 15, 2018, December 19, 2018 and March 14, 2019 on shorter notice after due compliance and obtaining requisite consents to transact some urgent matter and the said meeting was attended by a independent director of the Company.

We further report that majority decisions are carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and process in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines referred to above.

We further report that during the audit period no specific events/ actions has taken place which has major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

**For P. Chadha & Associates
Practising Company Secretaries**

**(Prince Chadha)
ACS 32856,
CP 12409**

Date : 25-05-2019
Place : Chandigarh

Annexure 5 of Board of Directors' Report
Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship:	Mr. Aryan Goyal Relative of Director	Mr. Saurabh Goyal Relative of Director
(b) Nature of contracts/ arrangements/transactions:	Remuneration	Remuneration
(c) Duration of the contracts / arrangements/transactions:	He has been appointed under a contract of employment pursuant to which he may function according to directions as may be given by the Company from time to time. Contract will continue as long as he remains an employee as per the contract of employment Date of Resignation: November 30, 2018	He has been appointed under a contract of employment pursuant to which he may function according to directions as may be given by the Company from time to time. Contract will continue as long as he remains an employee as per the contract of employment Date of Resignation: November 30, 2018
(d) Salient terms of the contracts or arrangements or transactions including the value, if any:	(1) Salary: Rs. 650,000/- (Rupees Six Lacs and Fifty Thousand only) per month and be broken into various components as per HR policy of the company, with a provision for increase in salary of not more than Rs. 25000/- per annum over the previous year. (2) Perquisites: As per company's policy but not more than Rs. 5 lacs in a year.	Salary: (1) Rs. 400,000/- (Rupees Four Lacs only) per month, with a provision for increase in salary of not more than 25% per annum. (2) Perquisites: (a) Medical and accident insurance premium as per company rules. (b) Provision of car for official use. (c) Leaves/ Leave encashment in accordance with the leave rules of the Company from time to time. (d) Gratuity as per company policy.
(e) Justification for entering into such contracts or arrangements or transactions	Mr. Aryan Goyal hold a Bachelor degree in Chemical Engineering. He has a rich experience of 15 years in the pharmaceuticals industry. In Nectar Lifesciences Limited he was looking after chemical engineering function in factory.	Mr. Saurabh Goyal holds a Masters degree in International Management from King's College London, United Kingdom. He has a rich experience of 11 years in the marketing etc. In Nectar Lifesciences Limited he was looking after international marketing of Menthol.
(f) Date(s) of approval by the Board:	November 12, 2014	August 11, 2014
(g) Amount paid as advances, if any:	Not applicable	Not applicable
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188:	December 30, 2014	September 30, 2014
(i) Other details	Pursuant to authority granted by the Shareholders, the Nomination and Remuneration Committee and Board of Directors increased the monthly salary to Rs. 675000/- Per month from April 1, 2016, with bonus not exceeding of equivalent to his one month gross salary in a year as per HR manuals of the company and other terms and conditions will remain the same. Date of Resignation: November 30, 2018	Pursuant to authority granted by the Shareholders, the Nomination and Remuneration Committee and Board of Directors increased the monthly salary to Rs. 500000/- Per month from April 1, 2016, with bonus not exceeding of equivalent to his one month gross salary in a year as per HR manuals of the company and other terms and conditions will remain the same. Date of Resignation: November 30, 2018

2. Details of material contracts or arrangement or transactions at arm's length basis:

The company has not entered into any material contract or arrangement or transaction with its related parties which is at arm's length during financial year 2018-19. However, the details of non - material contract or arrangement or transaction with its related parties which are at arm's length during financial year 2018-19, has been given in the notes to the Financial Statements forming part of the Annual Report.

**For and on behalf of the Board of Directors
of Nectar Lifesciences Limited**

**(Sanjiv Goyal)
Chairman and Managing Director**

Place : Chandigarh
Date : 14.08.2019

Annexure 6 of Board of Directors' Report

REPORT ON CSR ACTIVITIES

1. A brief outline of the company's CSR Policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs:

Nectar Lifesciences Limited (hereinafter referred as NLL or 'the Company') believes that the actions of the organization and its community are highly inter-dependent. Through constant and collaborative interactions with our external stakeholders, NLL strives to become an asset in the communities. As our CSR we actively implement Projects and initiatives for the betterment of society, communities, and the environment.

Company's Corporate Social Responsibility (CSR) Committee has formulated and recommended to the Board, a Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company, which has been approved by the Board. The CSR Policy may be accessed on the Company's website at the link: <http://www.neclife.com/uploads/15129926051621224044.pdf>

The objective of this policy is to do continuously and consistently:

- Initiate projects that benefit communities;
- Encourage an increased commitment from employees towards CSR activities and volunteering.
- Generate goodwill in communities where NLL operates or are likely to operate;

A brief overview of company's CSR projects and programs is as under:

- (i) Environment sustainability: The Company has identified the renewable energy project as one of its major project of CSR activities. This helps in improving energy efficiency and to reduce environmental emissions thereby establishing a strong foundation for a corporate green house gas management programme. In order to achieve this mission of reducing environmental emissions, the company started its **power plant** also called as Neclife Biomass Cogeneration Project. This agro-based power generation plant runs on husk and can be switched over to 10 other feed stocks if there is a need.
- (ii) Nectar Lifesciences Charitable Foundation which is engaged in promoting education and employment enhancing vocational skills among women to help them in earning their livelihood. It runs an institute under the name of Nectar Polytechnic for Women in Derabassi, Punjab providing opportunity to the underprivileged girls.
- The mission of the institute is to elevate its status to a centre of excellence in women's technical education by a conscious & consistent enhancement of its performance. The company's indirect aim is also to bring about an improvement in boys and girls sex ratio in Punjab. The program focuses on enrolling girls belonging to underprivileged section of society, other backward classes, migrant laborers and the ones below poverty line.
- (iii) Safe Drinking Water: The lack of safe drinking water is a major public health issue, particularly in developing countries where majority of diseases are waterborne. Under this project, the company is identifying areas and provides necessary equipments for safe drinking water.
- (iv) Promoting Healthcare and Preventive Healthcare: Preventive healthcare has not been inculcated in Indian society and in rural areas in particular, causing untold suffering. The company lays further emphasis on preventive healthcare, one of the most important human development indicators with an aim to address the needs of all sections of society.
- (v) Relief/ Donations: Your Company has always been at the forefront in responding to its call for national duty and has contributed generous amounts for Eradicating hunger, poverty, malnutrition and Welfare of Animals.

The Company would also undertake other need based initiatives in compliance with Schedule VII to the Act.

2. The composition of the CSR Committee.

Please refer to Corporate Governance Report for composition of CSR committee.

		Rs. in Millions
3.	Average net profit of the company for last three financial years:	621.94
4.	Prescribed CSR Expenditure (two percent of the amount as in item 3 above):	12.44
5.	Details of CSR spent during the financial year.	
	a. Total amount to be spent for the financial year	12.44
	b. Total amount spent for the financial year	26.14
	c. Amount unspent, if any:	N.A.

d. Manner in which the amount spent during the financial year is detailed below:

1	2	3	4	5	6	7	8
Sr. No.	CSR project or activity identified	Sector in which the project is covered	Projects or programs (1) Local area or other (2) Specify the State and district where projects or programs were undertaken.	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs Sub-heads: (1) Direct expenditure on projects or programs. (2) Overheads:	Cumulative expenditure upto to the reporting period	Amount spent: Direct or through implementing agency
1	Renewable Energy Project	Environmental sustainability, ecological balance and conservation of natural resources	Local at Derabassi, Distt. S.A.S. Nagar Punjab	14.00	13.97	13.97	Direct
2	Nectar Lifesciences Charitable Foundation and Payment to Education Institutions	Promoting education and employment and women empowerment	Local at Derabassi, Distt. S.A.S. Nagar Punjab and Chandigarh	2.59	2.59	2.59	Direct and through implementing agency ^I
3	Payment to Govt. and Trusts and Kerala Flood Relief	Eradicating hunger, poverty, malnutrition and providing Safe Drinking Water	PAN India	5.42	5.42	5.42	Direct and through implementing agency ^{II}
4	Payment to Medical Institutions.	Promoting preventive healthcare	PAN India	4.03	4.03	4.03	Through implementing agencies ^{III}
5	Payment for Gausewa	Animal Welfare	Haryana & Punjab	0.13	0.13	0.13	Through implementing agencies ^{IV}
	Direct Expenditure			26.17	26.14	26.14	
	Overheads				Nil	Nil	
	Total			26.17	26.14	26.14	

I Expenditure of Rs. 1.54 Million incurred directly through Nectar Lifesciences Charitable Foundation, Rs. 1.00 Millions to Shri Dhanwantry Educational Society (Regd.) Chandigarh and Rs. 0.05 Millions to Govt College, Derabassi (Punjab).

II Expenditure of Rs. 0.15 Million incurred directly towards Kerala Flood Relief, Rs. 5.10 Million to Mata Vaishno Devi Shrine Board, Katra, Rs. 0.12 Millions to Govt. Institute of Mentally Retarded children, Chandigarh & Govt. Rehabilitation Institute for Intellectual Disabilities, Chandigarh and Rs. 0.05 Million to Shiv Gauri Sewa Mandal, Baddi, Himachal Pradesh.

III Expenditure of Rs. 1.10 Millions to Shri Saibaba Sansthan Trust, Shirdi, Rs. 0.24 Millions to Sahayta Charitable Welfare Society, Chandigarh, Rs.2.28 Millions to Shri Sainath Hospital, Shirdi, Rs. 0.40 Millions to Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh and Rs. 0.01 Millions to Green Star Welfare Club, Derabassi (Punjab).

IV Expenditure incurred through Panchkula Gaushala Trust, Panchkula.

6. In case the company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board Report:

Not Applicable

7. RESPONSIBILITY STATEMENT

The Responsibility Statement of the CSR Committee of the Board of Directors of the Company, is reproduced below:

'The implementation and monitoring of Corporate Social Responsibility (CSR) Policy, is in compliance with CSR objectives and policy of the Company.'

Dr. Dinesh Dua,
Chief Executive Officer & Director

Mr. Sanjiv Goyal,
Chairman & Managing Director
(Chairman CSR Committee)

Place : Chandigarh
Date : 14.08.2019

Annexure 7 of Board of Directors' Report

FormNo.MGT-9

EXTRACT OF ANNUAL RETURN

As on the financial year ended on 31.03.2019

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

1	CIN:	L24232PB1995PLC016664
2	Registration Date	June 27, 1995
3	Name of the Company	NECTAR LIFESCIENCES LIMITED
4	Category/Sub-Category of the Company	Public Limited Company
5	Address of the Registered Office and contact details	VILLAGE SAIDPURA, TEHSIL DERABASSI, DISTT. S.A.S NAGAR, MOHALI (PUNJAB), Ph.01762-308000.
6	Whether listed company Yes/No	YES
7	Name, Address and Contact details of Registrar and Transfer Agent, if any	Karvy Fintech Private Limited Karvy Selenium, Tower – B, Plot No. 31-32, Gachibowli, Financial District Nanakramguda, Hyderabad – 500 032 Tel. (91 40) 67161527, Fax: (91 40) 23420814

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

S. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1	Drugs and Pharmaceuticals	2100	99.98%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES –

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of Shares Held	Applicable Section
1	Nectar Lifesciences UK Limited	N.A	Subsidiary	100	2(87)
2	Nectar Lifesciences US LLC	N.A	Subsidiary	100	2(87)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

CATEGORY SHAREHOLDER	OF	NO. OF SHARES HELD AT THE BEGINNING OF THE YEAR 01-04-2018				NO. OF SHARES HELD AT THE END OF THE YEAR 31-03-2019				% CHANGE DURING THE YEAR
		DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)
(A) PROMOTER AND PROMOTER GROUP										
(a)	Individual /HUF	99,468,000	-	99,468,000	44.35	99,468,000	-	99,468,000	44.35	-
(b)	Central Government/ State Government(s)	-	-	-	-	-	-	-	-	-
(c)	Bodies Corporate	-	-	-	-	-	-	-	-	-
(d)	Financial Institutions / Banks	-	-	-	-	-	-	-	-	-
(e)	Others	-	-	-	-	-	-	-	-	-
	Sub-Total A(1) :	99,468,000	-	99,468,000	44.35	99,468,000	-	99,468,000	44.35	-
2 FOREIGN										
(a)	Individuals (NRIs/ Foreign Individuals)	-	-	-	-	-	-	-	-	-
(b)	Bodies Corporate	-	-	-	-	-	-	-	-	-
(c)	Institutions	-	-	-	-	-	-	-	-	-
(d)	Qualified Foreign Investor	-	-	-	-	-	-	-	-	-
(e)	Others	-	-	-	-	-	-	-	-	-
	Sub-Total A(2) :	-	-	-	-	-	-	-	-	-
	Total A=A(1)+A(2)	99,468,000	-	99,468,000	44.35	99,468,000	-	99,468,000	44.35	-
(B) PUBLIC SHAREHOLDING										
(1) INSTITUTIONS										
(a)	Mutual Funds /UTI	0	0	0	0.00	0	0	0	0.00	0.00
(b)	Financial Institutions / Banks	139153	0	139153	0.06	183150	0	183150	0.08	0.02

CATEGORY OF SHAREHOLDER		NO. OF SHARES HELD AT THE BEGINNING OF THE YEAR 01-04-2018				NO. OF SHARES HELD AT THE END OF THE YEAR 31-03-2019				% CHANGE DURING THE YEAR
		DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)
(c)	Central Government / State Government(s)	0	0	0	0.00	0	0	0	0.00	0.00
(d)	Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
(e)	Insurance Companies	500000	0	500000	0.22	0	0	0	0.00	-0.22
(f)	Foreign Institutional Investors	6024020	0	6024020	2.69	5171122	0	5171122	2.31	-0.38
(g)	Foreign Venture Capital Investors	0	0	0	0.00	0	0	0	0.00	0.00
(h)	Foreign Body Corporate	26000000	0	26000000	11.59	26000000	0	26000000	11.59	0.00
(i)	Others	0	0	0	0.00	0	0	0	0.00	0.00
	Sub-Total B(1) :	32663173	0	32663173	14.56	31354272	0	31354272	13.98	-0.58
(2)	NON-INSTITUTIONS									
(a)	Bodies Corporate	6678143	510	6678653	2.98	5919191	510	5919701	2.64	-0.34
(b)	Individuals									
	(i) Individuals holding nominal share capital upto Rs.1 lakh	34659202	1800	34661002	15.46	36374868	1790	36376658	16.22	0.77
	(ii) Individuals holding nominal share capital in excess of Rs.1 lakh	2093259	0	2093259	0.93	1979506	0	1979506	0.88	-0.05
(c)	Others									
	CLEARING MEMBERS	322439	0	322439	0.14	160562	0	160562	0.07	-0.07
	I E P F	20863	0	20863	0.01	33599	0	33599	0.01	0.01
	NBFC	125953	0	125953	0.06	311917	0	311917	0.14	0.08
	NON RESIDENT INDIANS	1008359	0	1008359	0.45	1394568	0	1394568	0.62	0.17
	NRI NON-REPATRIATION	1218444	0	1218444	0.54	1261362	0	1261362	0.56	0.02
	TRUSTS	825	0	825	0.00	825	0	825	0.00	0.00
(d)	Qualified Foreign Investor	0	0	0	0.00	0	0	0	0.00	0.00
	Sub-Total B(2) :	46127487	2310	46129797	20.57	47436398	2300	47438698	21.15	0.58
	Total B=B(1)+B(2) :	78790660	2310	78792970	35.13	78790670	2300	78792970	35.13	0.00
	Total (A+B) :	178258660	2310	178260970	79.49	178258670	2300	178260970	79.49	0.00
(C)	Shares held by custodians, against which Depository Receipts have been issued									
1.	Promoter and Promoter Group	46000000	0	46000000	20.51	46000000	0	46000000	20.51	0.00
2.	Public									
	GRAND TOTAL (A+B+C) :	224258660	2310	224260970	100.00	224258670	2300	224260970	100.00	0.00

ii) Shareholding of Promoters and Promoters Group

S. No.	Share holder's Name	Share holding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of Shares	%of total Shares of the company	%of Shares Pledged/ encumbered to total shares	No. of Shares	%of total Shares of the company	%of Shares Pledged/ encumbered to total shares	
1	Mr. Sanjiv Goyal	55555600	24.77	-	55555600	24.77	24.77	-
2	Sanjiv (HUF)	43379400	19.34	9.36	43379400	19.34	-	-
3	Mr. Aryan Goyal	290000	0.13	-	290000	0.13	-	-
4	Mr. Saurabh Goyal	243000	0.11	-	243000	0.11	-	-
	Total	99468000	44.35	9.36	99468000	44.35	24.77	-

Note: For change in pledged shares, please see next point (iii)

iii) Change in Promoters' Shareholding (please specify, if there is no change)

There are no changes in the Promoters shareholding during the financial year 2018-19. However, on repayment of loan by the company the pledge on 21000000 equity shares representing 09.36% of Share Capital of the Company of one of promoter Sanjiv HUF has been closed in July, 2018. Further, a fresh Pledge has been created on the 55555600 equity shares representing 24.77% of Share Capital of the Company of Mr. Sanjiv Goyal in July, 2018 for collateral of fresh loan taken by the company from IFCI Limited.

iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

S. No.	Name of the Share Holder	Date	Reason	Increase/ Decrease in share holding	% of total shares of the company	Cumulative Shareholding during the Year	
						No of Shares	% of total shares of the company
1	NSR DIRECT PE MAURITIUS LLC	Opening Balance		Nil		26000000	11.59
		Closing Balance		movement during the year		26000000	11.59
2	INGAIN TRADERS, LLC	Opening Balance		Nil		2387012	1.06
		Closing Balance		movement during the year		2387012	1.06
3	RELIGARE FINVEST LTD	Opening Balance		Nil		1717484	0.77
		Closing Balance		movement during the year		1717484	0.77
4	LSV EMERGING MARKETS SMALL CAP EQUITY FUND, LP	Opening Balance		Nil		1584500	0.71
		Closing Balance		movement during the year		1584500	0.71
5	RAMAN KAPUR	Opening Balance		Nil		1000000	0.45
		Closing Balance		movement during the year		1000000	0.45
6	SOURABH HEMRAJ BORA	Opening Balance				903953	0.40
		13/04/2018	Sale	(13341)	(0.01)	890612	0.40
		27/04/2018	Sale	(7750)	(0.00)	882862	0.39
		01/06/2018	Purchase	50000	0.02	932862	0.42
		22/06/2018	Purchase	7818	0.00	940680	0.42
		13/07/2018	Sale	(43204)	(0.02)	897476	0.40
		03/08/2018	Sale	(232907)	(0.10)	664569	0.30
		14/09/2018	Purchase	22000	0.01	686569	0.31
		12/10/2018	Sale	(56900)	(0.03)	629669	0.28
		19/10/2018	Purchase	595	0.00	630264	0.28
		28/12/2018	Purchase	14908	0.01	645172	0.29
		04/01/2019	Purchase	8153	0.00	653325	0.29
		25/01/2019	Purchase	36908	0.02	690233	0.31
		25/01/2019	Sale	(36908)	(0.02)	653325	0.29
		15/03/2019	Sale	(6790)	(0.00)	646535	0.29
		29/03/2019	Sale	(221225)	(0.10)	425310	0.19
	Closing Balance				425310	0.19	
7	MALTI SECURITIES PVT LTD	Opening Balance		Nil		900000	0.40
		Closing Balance		movement during the year		900000	0.40
8	GOVERNMENT OF THE PROVINCE OF ALBERTA MANAGED BY COMGEST S.A.	Opening Balance		Nil		501710	0.22
		Closing Balance		movement during the year		501710	0.22
9	GENERAL INSURANCE CORPORATION OF INDIA#	Opening Balance				500000	0.22
		31/08/2018	Sale	(132254)	(0.06)	367746	0.16
		07/09/2018	Sale	(367746)	(0.16)	0	0.00
		Closing Balance				0	0.00
10	ANGEL BROKING LIMITED#	Opening Balance				472467	0.21
		06/04/2018	Purchase	34718	0.02	507185	0.23
		06/04/2018	Sale	(102132)	0.05	405053	0.18
		13/04/2018	Purchase	41914	0.02	446967	0.20
		13/04/2018	Sale	(61072)	0.03	385895	0.17
		20/04/2018	Purchase	24239	0.01	410134	0.18
		20/04/2018	Sale	(10291)	0.00	399843	0.18
		27/04/2018	Purchase	18869	0.01	418712	0.19
		27/04/2018	Sale	(27588)	0.01	391124	0.17
		04/05/2018	Purchase	36915	0.02	428039	0.19
		04/05/2018	Sale	(18756)	0.01	409283	0.18
		11/05/2018	Purchase	8070	0.00	417353	0.19
		11/05/2018	Sale	(44442)	0.02	372911	0.17
		18/05/2018	Purchase	14495	0.01	387406	0.17
		18/05/2018	Sale	(13782)	0.01	373624	0.17
		25/05/2018	Purchase	18074	0.01	391698	0.17
		25/05/2018	Sale	(40882)	0.02	350816	0.16
		01/06/2018	Purchase	14890	0.01	365706	0.16
		01/06/2018	Sale	(24815)	0.01	340891	0.15
		08/06/2018	Purchase	11843	0.01	352734	0.16
		08/06/2018	Sale	(70389)	0.03	282345	0.13
		15/06/2018	Purchase	21370	0.01	303715	0.14
		15/06/2018	Sale	(25920)	0.01	277795	0.12
		22/06/2018	Purchase	22330	0.01	300125	0.13
		22/06/2018	Sale	(15337)	0.01	284788	0.13

S. No.	Name of the Share Holder	Date	Reason	Increase/ Decrease in share holding	% of total shares of the company	Cumulative Shareholding during the Year	
						No of Shares	% of total shares of the company
		29/06/2018	Purchase	6878	0.00	291666	0.13
		29/06/2018	Sale	(21958)	0.01	269708	0.12
		06/07/2018	Purchase	2459	0.00	272167	0.12
		06/07/2018	Sale	(17718)	0.01	254449	0.11
		13/07/2018	Purchase	19418	0.01	273867	0.12
		13/07/2018	Sale	(5903)	0.00	267964	0.12
		20/07/2018	Purchase	2970	0.00	270934	0.12
		20/07/2018	Sale	(15055)	0.01	255879	0.11
		27/07/2018	Purchase	22820	0.01	278699	0.12
		27/07/2018	Sale	(9016)	0.00	269683	0.12
		03/08/2018	Purchase	24785	0.01	294468	0.13
		03/08/2018	Sale	(1752)	0.00	292716	0.13
		10/08/2018	Purchase	6684	0.00	299400	0.13
		10/08/2018	Sale	(33204)	0.01	266196	0.12
		17/08/2018	Purchase	5642	0.00	271838	0.12
		17/08/2018	Sale	(10879)	0.00	260959	0.12
		24/08/2018	Purchase	43505	0.02	304464	0.14
		24/08/2018	Sale	(18261)	0.01	286203	0.13
		31/08/2018	Purchase	132866	0.06	419069	0.19
		31/08/2018	Sale	(23689)	0.01	395380	0.18
		07/09/2018	Purchase	55586	0.02	450966	0.20
		07/09/2018	Sale	(37412)	0.02	413554	0.18
		14/09/2018	Purchase	68363	0.03	481917	0.21
		14/09/2018	Sale	(11098)	0.00	470819	0.21
		21/09/2018	Purchase	30498	0.01	501317	0.22
		21/09/2018	Sale	(32405)	0.01	468912	0.21
		28/09/2018	Purchase	23316	0.01	492228	0.22
		28/09/2018	Sale	(34691)	0.02	457537	0.20
		29/09/2018	Sale	(30)	0.00	457507	0.20
		05/10/2018	Purchase	22473	0.01	479980	0.21
		05/10/2018	Sale	(34493)	0.02	445487	0.20
		12/10/2018	Purchase	43110	0.02	488597	0.22
		12/10/2018	Sale	(60659)	0.03	427938	0.19
		19/10/2018	Purchase	6831	0.00	434769	0.19
		19/10/2018	Sale	(12322)	0.01	422447	0.19
		26/10/2018	Purchase	7661	0.00	430108	0.19
		26/10/2018	Sale	(12818)	0.01	417290	0.19
		02/11/2018	Purchase	17901	0.01	435191	0.19
		02/11/2018	Sale	(17827)	0.01	417364	0.19
		09/11/2018	Purchase	21179	0.01	438543	0.20
		09/11/2018	Sale	(5584)	0.00	432959	0.19
		16/11/2018	Purchase	3005	0.00	435964	0.19
		16/11/2018	Sale	(50352)	0.02	385612	0.17
		23/11/2018	Purchase	13934	0.01	399546	0.18
		23/11/2018	Sale	(11922)	0.01	387624	0.17
		30/11/2018	Purchase	42859	0.02	430483	0.19
		30/11/2018	Sale	(55239)	0.02	375244	0.17
		07/12/2018	Purchase	39767	0.02	415011	0.19
		07/12/2018	Sale	(25080)	0.01	389931	0.17
		14/12/2018	Purchase	3750	0.00	393681	0.18
		14/12/2018	Sale	(41383)	0.02	352298	0.16
		21/12/2018	Purchase	7061	0.00	359359	0.16
		21/12/2018	Sale	(14758)	0.01	344601	0.15
		28/12/2018	Purchase	6811	0.00	351412	0.16
		28/12/2018	Sale	(11338)	0.01	340074	0.15
		31/12/2018	Purchase	13011	0.01	353085	0.16
		31/12/2018	Sale	(5486)	0.00	347599	0.15
		04/01/2019	Purchase	54023	0.02	401622	0.18
		04/01/2019	Sale	(8278)	0.00	393344	0.18

S. No.	Name of the Share Holder	Date	Reason	Increase/ Decrease in share holding	% of total shares of the company	Cumulative Shareholding during the Year	
						No of Shares	% of total shares of the company
		11/01/2019	Purchase	30303	0.01	423647	0.19
		11/01/2019	Sale	(57136)	0.03	366511	0.16
		18/01/2019	Purchase	25995	0.01	392506	0.18
		18/01/2019	Sale	(45236)	0.02	347270	0.15
		25/01/2019	Purchase	11706	0.01	358976	0.16
		25/01/2019	Sale	(67687)	0.03	291289	0.13
		01/02/2019	Purchase	7235	0.00	298524	0.13
		01/02/2019	Sale	(56669)	0.03	241855	0.11
		08/02/2019	Purchase	15626	0.01	257481	0.11
		08/02/2019	Sale	(17762)	0.01	239719	0.11
		15/02/2019	Purchase	9735	0.00	249454	0.11
		15/02/2019	Sale	(18926)	0.01	230528	0.10
		22/02/2019	Purchase	3704	0.00	234232	0.10
		22/02/2019	Sale	(3115)	0.00	231117	0.10
		01/03/2019	Purchase	9239	0.00	240356	0.11
		01/03/2019	Sale	(17228)	0.01	223128	0.10
		08/03/2019	Purchase	35389	0.02	258517	0.12
		08/03/2019	Sale	(25602)	0.01	232915	0.10
		15/03/2019	Purchase	18008	0.01	250923	0.11
		15/03/2019	Sale	(23915)	0.01	227008	0.10
		22/03/2019	Purchase	111126	0.05	338134	0.15
		22/03/2019	Sale	(116555)	0.05	221579	0.10
		29/03/2019	Purchase	31781	0.01	253360	0.11
		29/03/2019	Sale	(3549)	0.00	249811	0.11
		Closing Balance				249811	0.11
11	SHELL PENSIONS TRUST LIMITED AS TRUSTEE OF THE SHE*	Opening Balance		Nil movement during the year		361300	0.16
		Closing Balance				361300	0.16
12	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO*	Opening Balance		Nil movement during the year		336600	0.15
		Closing Balance				336600	0.15

Ceased to be in the list of Top 10 shareholders as on 31-03-2019. The same is reflected above since the shareholder was one of the Top 10 shareholders as on 01-04-2018.

* Not in the list of Top 10 shareholders as on 01-04-2018. The same has been reflected above since the shareholder was one of the Top 10 shareholders as on 31-03-2019

v) Shareholding of Directors and Key Managerial Personnel:

S. No.	For Each of the Directors and KMP	Share holding at the Beginning of the year		Cumulative Shareholding During the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Sanjiv Goyal, Chairman & Managing Director				
	At the beginning of the year	55555600	24.77	55555600	24.77
	Bought during the year	-	-	55555600	24.77
	Sold during the year	-	-	55555600	24.77
	At the end of the year	55555600	24.77	55555600	24.77
2.	Mr. Vijay J Shah, Director				
	At the beginning of the year	250	0.00	250	0.00
	Bought during the year	-	-	250	0.00
	Sold during the year	-	-	250	0.00
	Resigned w.e.f. December 1, 2018	250	0.00	250	0.00
3.	Mr. Sandeep Goel, CFO				
	At the beginning of the year	6760	0.00	6760	0.00
	Bought during the year	-	-	6760	0.00
	Sold during the year	-	-	6760	0.00
	At the end of the year	6760	0.00	6760	0.00

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

Rupees in Millions

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	9523.56	26.97	-	9550.53
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	33.62	-	-	33.62
Total (i+ii+iii)	9557.18	26.97	-	9584.15
Change in Indebtedness during the financial year				
- Addition	1154.55	0.40	-	1154.95
- Reduction	(1674.80)	(8.62)	-	(1683.42)
Net Change	(520.25)	(8.22)	-	(528.47)
Indebtedness at the end of the financial year				
i) Principal Amount	9015.74	18.75	-	9034.49
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	21.19	-	-	21.19
Total (i+ii+iii)	9036.93	18.75	-	9055.68

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Rupees in Lacs

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount
		Sanjiv Goyal	Dinesh Dua	H.P. Singh	
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	180.00	122.66	32.38	335.04
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0.92	0.40	-	1.32
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission - as % of profit - others, specify	-	-	-	-
5.	Others, please specify	-	-	-	-
	Total (A)	180.92	123.06	32.38	336.36
	Ceiling as per the Act (@ 10% of profits calculated under Section 198 of the Companies Act, 2013)				621.42

B. Remuneration to other directors:

Rupees in Lacs

Sr. No.	Particulars of Remuneration	Name of Directors				Total Amount
		Ajay Swaroop	Dr. (Maj Gen) SS Chauhan	Rupinder Tewari	Guljit Sethi	
1.	Independent Directors					
	- Fee for attending board and committee meetings	0.63	0.79	0.10	0.37	1.89
	- Commission	-	-	-	-	-
	- Others, please specify	-	-	-	-	-
	Total (1)	0.63	0.79	0.10	0.37	1.89
2.	Other Non-Executive Directors	Vivek Sett	Meena Verma (EXIM Bank)			
	- Fee for attending board committee meetings	0.20	0.10		-	0.30
	- Commission				-	-
	- Others, please specify				-	-
	Total (2)	0.20	0.10		-	0.30
	Total (B) = (1+2)					2.19
	Total Managerial Remuneration					338.55
	Over all Ceiling as per the Act (@ 11% of profits calculated under Section 198 of the Companies Act, 2013)					683.57

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Rupees in Lacs

Sl. No.	Particulars of Remuneration	Key Managerial Personnel		
		Company Secretary	CFO	Total
1.	Gross salary		-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	3.46	24.63	28.09
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	--	-	-
2.	Stock Option			
3.	Sweat Equity	-	-	-
4.	Commission - as % of profit - others, specify...	-	-	-
5.	Others, please specify	-	-	-
	Total	3.46	24.63	28.09
	Grand Total	3.46	24.63	28.09

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

There were no penalties, punishment or compounding of offences for breach of any section of Companies Act against the company or its directors or other officers in default, if any, during the year ended March 31, 2019.

For and on behalf of the Board of Directors
of Nectar Lifesciences Limited

(Sanjiv Goyal)

Chairman and Managing Director

Place : Chandigarh

Date : 14.08.2019

Annexure 8 of Board of Directors' Report

Statement of Disclosure of Remuneration under Section 197 of Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

1. Ratio of the remuneration of each Wholtime Director to the median remuneration of the Employees of the Company for the Financial Year 2018-19, the percentage increase in remuneration of Managing Director, Wholtime Directors (WTD), Chief Financial Officer and Company Secretary during the Financial Year 2018-19.

S. No.	Name of the Director/ KMP	Designation	Ratio of Remuneration of each Director to median remuneration of Employees	Percentage increase in Remuneration
1.	Sanjiv Goyal	Chairman & Managing Director	77:1	3.71%
2.	Dinesh Dua	WTD & CEO	52:1	(-)26.16%
3.	Harparkash Singh Gill	WTD & President (Operations)*	15:1	Nil
4.	Sandeep Goel	Chief Financial Officer	Not Applicable	(-)6.39%
5.	Ankita Jain	Company Secretary**	Not Applicable	-

Note:

- a) The Non- Executive Directors of the Company are entitled for sitting fee only as per the statutory provisions. The details of remuneration of Non- Executive Directors are provided in the Corporate Governance Report. The ratio of remuneration and percentage increase for Non- Executive Directors Remuneration is therefore not considered for the purpose above.
- b) Percentage increase in remuneration indicates annual target total compensation increases, as approved by the Nomination and Remuneration Committee of the Company during the financial year 2018-2019.

* Mr. Harparkash Singh Gill has resigned from company as director with effect from 28-02-2019, however continued to be with the company on retainership basis on same remuneration, therefore, no change in his remuneration.

** In financial year 2017-18, Ms. Ankita Jain has joined on 11-11-2017, therefore her yearly remuneration is not comparable, however her monthly remuneration remains the same.

2. The percentage increase in the median remuneration of Employees for the financial year was 3.12%.
3. The Company has 1971 permanent Employees on the rolls of Company as on March 31, 2019.
4. **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:**
Average percentage increase made in the salaries of Employees other than the managerial personnel in the financial year was 4.85% whereas the increase (decrease) in the managerial remuneration was approximately (10.58%). The average increases every year is an outcome of Company's market competitiveness as well as prevailing market scenario. In keeping with our reward philosophy and benchmarking results, the increases this year reflect the market practice.
5. It is hereby affirmed that the remuneration paid during the year is as per the Remuneration Policy of the Company.

For and on behalf of the Board of Directors
of Nectar Lifesciences Limited

(Sanjiv Goyal)

Chairman and Managing Director

Place : Chandigarh

Date : 14.08.2019

Annexure 9 of Board of Directors' Report

Statement of particulars as prescribed under Rule 8 (3) of the Companies (Account) Rules, 2014

A) Conservation of energy

(i) Steps taken or impact on Conservation of energy

The company leaves a very small amount of carbon footprint as it has three agro based captive power plants of 6MW each, which are eco-friendly and they reduce the environmental emission thus establishing a strong foundation for a corporate greenhouse gas management program. These units also reduce the manufacturing cost.

Followings are the few more steps taken towards conservation of energy:

- Energy saved by operating VAM on 0.5 kg/cm² steam pressure.
- Improved the power factor by using APFC (Automatic Power Factor Controller)
- Recovered the condensate heat recovery from utility i.e. VAM (Vapor Absorption Machine), chilling and brine machine.
- Usage of O₂ analyzer to optimum use of air in boiler for power saving and better combustion.
- Replacement of LED lights in admin block and street lights.
- Compressed air distribution modification and loading and unloading pressure recalculate according to process requirement and save power.
- VFD (Variable Frequency Drive) installed on bigger motors more than 100 HP to save power.
- Liquid nitrogen is substituted with Mechanical refrigeration system /Mechanical Compression System (DX):- An appropriate solution adopted to reduce losses and make this process more efficient was conversion of Liquid Nitrogen to Mechanical vapor compression system by adopting:
 1. Refrigerant chosen was ammonia.
 2. Use of Brine as a cooling media.
- Replacement of conventional drying system of Menthol Crystals by using the cold air through the perforated tray with FBD. Cold air consumption is comparatively very less and loss of material is negligible.
- TETRA GENERATION: Low Pressure Steam turbine has been installed for De-aerator heating by replacing the Pressure Reducing Station (PRS).

(ii) Steps taken by the Company for utilising alternate sources of energy

Biomass mixed combination of rice husk, wild bushes and lantana bushes etc are being used instead of conventional fuels to generate power in power plants.

(iii) The capital investment on energy conservation equipments

Capital expenditure incurred on energy conservation equipments:

Rs. 16.60 Millions

B) Technology Absorption

(i) Efforts made towards technology absorption

Pharmatech up gradation and innovation is a way of life and like others our company is no different. New technologies are continuously developed and implemented without changing critical parameters so that there are no changes in the quality of the drugs. The company has informally tied up with global institutions for up gradation of Technologies who have already developed some systems for us and we are looking forward for more of such technologies to be developed. NLL has successfully scaled-up a technology which has been developed jointly under collaborative R&D programme with a big Japanese company at our R&D Centre.

(ii) The benefits derived like product improvement, cost reduction, product development and import reduction

NLL's R&D center is always on their toes and continuously refining the process for existing products and development for new molecules to maintain the sustainable growth and ensuring the profitability. The new products have been developed and launched for regular commercial production which expands the company's overall performance along with product portfolio, an achievement of research-based organization.

(iii) Information in case of imported technology (imports during last three years)

Not applicable

(iv) Expenditure on R & D

Total expenditure incurred on Research and Development:

Rs. 91.60 Millions

C) Foreign exchange earnings and outgo

(i) During the year 2018-19, the Company had exported its pharmaceutical products to 65 countries. Further, the Company is making all efforts to export its products to new countries & new markets and to expand its export portfolio.

(ii)	a)	Foreign exchange earned in terms of actual inflow during the financial year ended on March 31, 2019:	Rs. 10351.15 Millions
	b)	Foreign exchange outgo in terms of actual outflow during the financial year ended on March 31, 2019:	Rs. 7522.65 Millions

For and on behalf of the Board of Directors
of Nectar Lifesciences Limited

(Sanjiv Goyal)

Chairman and Managing Director

Place : Chandigarh

Date : 14.08.2019

INDEPENDENT AUDITOR'S REPORT

To the Members of

NECTAR LIFESCIENCES LIMITED

Report on the Audit of the Standalone Financial Statements

1. Opinion

We have audited the accompanying standalone financial statements of Nectar Lifesciences Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2019, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

2. Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

3. Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. In our opinion, there is no Key Audit Matter to be reported.

4. Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information

and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

5. Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit / loss (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is responsible for overseeing the Company's financial reporting process.

6. Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve

Standalone Financial Statements

collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

7. Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A", a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- (A) As required by Section 143(3) of the Act, based on our audit we report that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on March 31, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- (B) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements.
 - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
- (C) With respect to the matter to be included in the Auditors' Report under section 197(16):

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.

For **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(Ashwani K. Gupta)
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Standalone Financial Statements

ANNEXURE “A” TO THE AUDITORS’ REPORT

REFERRED TO IN PARAGRAPH 5 OF OUR REPORT TO THE MEMBERS OF NECTAR LIFESCIENCES LIMITED ON THE STANDLONE FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH 2019;

1. In respect of its fixed assets:
 - (a) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets on the basis of available information.
 - (b) The fixed assets were physically verified during the year by the Management in accordance with a regular programme of verification which, in our opinion, provides for physical verification of major portion of fixed assets at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
 - (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
2. In respect of its inventory:
 - (a) As explained to us, the inventories were physically verified during the year by the management at reasonable intervals. Inventories as at 31st March 2019 were also physically verified and valued by an independent firm of chartered accountants.
 - (b) As explained to us, the discrepancies noticed between the physical stocks and the books records were not material and have been properly dealt with in the books of accounts.
3. The Company has not granted any loan, secured or unsecured, to companies, firms, limited liability partnerships or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, provisions of clause 3 (iii) of the Companies (Auditor Reports) Order 2016 are not applicable to the Company.
4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Section 185 and 186 of the Act, with respect to the loans and investments made.
5. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits attracting the provisions of sections 73 to 76, or any other relevant provisions of the Companies Act, 2013.
6. We have broadly reviewed the cost records maintained by the Company, pursuant to the rules made by the Central Government U/s 148(1) of the Companies Act, 2013 and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
7. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees’ State Insurance, Investor Education and Protection Fund, Income Tax, Customs Duty, Excise Duty, Goods and Services Tax, Cess and other material statutory dues as applicable with the appropriate authorities in India. We are informed that there are no undisputed statutory dues as at the end of the year, which are outstanding for a period of more than six months from the date they became payable.
 - (b) According to the information and explanation given to us and as per records of the Company examined by us, there are no dues of Custom Duty, Goods and Services Tax and Cess which are outstanding as at 31st March, 2019 and which have not been deposited on account of any dispute. However, according to information and explanation given to us, the following dues of Excise duty, Income Tax and Service Tax have not been deposited by the Company on account of disputes as detailed below:

(Rs. In Millions*)

Statute	Nature of the Dues	Amount	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Income Tax	0.41	Assessment Year 01-02	Commissioner of Income Tax Appeal
Income Tax Act, 1961	Income Tax	2.34	Assessment Year 01-02	Commissioner of Income Tax Appeal
Income Tax Act, 1961	Income Tax	0.03	Assessment Year 03-04	Income Tax Appellate Tribunal, Delhi
Income Tax Act, 1961	Income Tax	0.19	Assessment Year 04-05	Income Tax Appellate Tribunal, Delhi
Income Tax Act, 1961	Income Tax	-**	Assessment Year 14-15	Income Tax Appellate Tribunal, Delhi
Central Excise Act, 1944	Excise Duty	1.05	Financial Year 07-09	Joint Secretary, Ministry of Finance, Delhi
Central Excise Act, 1944	Excise Duty	5.58	Financial Year 05-06	CESTAT, Chandigarh
Service Tax, 1994	Service Tax	5.78***	Financial Year 09-10	CESTAT, Chandigarh
Service Tax, 1994	Service Tax	0.84	Financial Year 2011-12	CESTAT, Chandigarh
Service Tax, 1994	Service Tax	0.08	Financial Year 2011-2012	CESTAT, Chandigarh

* Net of amounts deposited under protest

** In case of adverse judgment, MAT credit entitlement would reduce by 108.34 millions

*** In case demand is confirmed, penalty up to equivalent amount may be imposed.

8. According to the records of the Company examined by us and the information and explanations given to us, the Company has not defaulted in repayment of dues to any financial institution or bank or debenture holders as at the balance sheet date.
9. In our opinion and according to the information and explanations given to us, during the year the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and the term loans availed during the year have been applied for the purpose for which they were raised.
10. According to the information and explanation given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
11. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.
12. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the Order is not applicable.
13. According to the information and explanations given to us and based on our examination of the records of the Company,

Standalone Financial Statements

transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

14. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
15. According to the information and explanations given to us and based on our examination of the records the Company, the Company has not entered into non-cash transactions with

directors or persons connected with them. Accordingly, paragraph 3(xv) of the Order is not applicable.

16. According to information and explanations given to us, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934.

For **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(Ashwani K. Gupta)
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

ANNEXURE “B” TO THE AUDITORS’ REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **NECTAR LIFESCIENCES LIMITED** (“the Company”) as on 31 March 2019 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s

internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of change in conditions, or that the degree of compliance with the policies or procedure may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(Ashwani K. Gupta)
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

BALANCE SHEET As At 31st March 2019

Particulars	NOTE	As At March 31, 2019	As At March 31, 2018
ASSETS			
Non-Current Assets			
Property, plant and equipment	2.2	7,856.36	8,064.31
Capital work-in-progress		995.50	997.86
Intangible assets	2.3	391.82	459.24
Financial assets			
Investments	2.4	6.00	6.00
Trade receivables	2.5	48.09	36.81
Other financial assets	2.6	24.94	61.13
Other non-current assets	2.7	1,040.16	1,010.08
Total Non Current Assets		10,362.88	10,635.43
Current Assets			
Inventory	2.8	9,145.27	8,594.35
Financial assets			
Investments	2.4	5.05	5.10
Trade receivables	2.5	5,613.79	6,121.15
Cash and cash equivalents	2.9	205.80	89.08
Loans	2.10	3.82	3.79
Other financial assets	2.6	1,019.06	1,122.31
Other current assets	2.11	682.08	667.72
Total Current Assets		16,674.87	16,603.50
Total Assets		27,037.76	27,238.94
EQUITY AND LIABILITIES			
Equity			
Equity share capital	2.12	224.26	224.26
Other equity	2.13	10,822.11	10,362.03
Total Equity		11,046.37	10,586.29
Liabilities			
Non-Current Liabilities			
Financial liabilities			
Borrowings	2.14	1,655.90	2,200.76
Other financial liabilities	2.15	119.25	175.65
Other Non-Current Liability	2.16	8.71	8.96
Provisions	2.17	93.63	90.69
Deferred tax liabilities (net)	2.18	1,121.58	1,083.38
Total Non-Current Liabilities		2,999.07	3,559.44
Current Liabilities			
Financial liabilities			
Borrowings	2.14	6,359.69	6,340.83
Other financial liabilities	2.15	1,129.94	1,123.37
Trade payables			
Due to Micro ,Small & Medium Enterprises	2.19	44.43	29.67
Due to Others		5,263.39	5,364.57
Other current liabilities	2.20	96.23	110.66
Provisions	2.17	8.58	4.88
Current tax liabilities (net)		90.07	119.23
Total Current Liabilities		12,992.32	13,093.21
Total Equity and Liabilities		27,037.76	27,238.94
Significant Accounting Policies	1		
Notes to Financial Statements	2		

For **NECTAR LIFESCIENCES LIMITED**

Sanjiv Goyal Chairman & Managing Director
Dinesh Dua CEO & Whole Time Director

Sandeep Goel Chief Financial Officer
R.K. Aggarwal Vice President Accounts

Ankita Jain Company Secretary

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

STATEMENT OF PROFIT AND LOSS ACCOUNT for the Year Ended March 31, 2019

Particulars	NOTE	Year Ended March 31, 2019	Year Ended March 31, 2018
Continuing Operations			
Revenue from Operations (Gross)	2.21	31,149.23	20,923.19
Less: GST Recovered		3,299.93	1,924.06
Revenue from Operations (Net of GST)		<u>27,849.30</u>	<u>18,999.13</u>
Other Income (Net)	2.22	60.40	60.36
		<u>27,909.70</u>	<u>19,059.49</u>
Expenses			
Raw Material Consumed	2.23	22,253.17	13,816.39
Purchase of Stock in Trade (Traded Goods)		428.17	152.73
(Increase)/ Decrease in Inventories of Finished Goods, Stock-in-Process and Stock in Trade	2.24	(469.86)	(304.32)
Excise duty		-	243.81
Employees Benefits Expense	2.25	799.00	784.05
Finance Cost	2.26	1,481.34	1,152.02
Depreciation & Amortization	2.2 & 2.3	632.57	643.09
Other Expenses	2.27	2,199.78	1,946.06
		<u>27,324.18</u>	<u>18,433.83</u>
Profit before exceptional items & tax		585.52	625.66
Exceptional items		-	-
Profit/(Loss) before tax		<u>585.52</u>	<u>625.66</u>
Tax Expenses		112.20	104.11
Profit for the period		<u>473.32</u>	<u>521.55</u>
Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
Remeasurement of the net defined benefit liability/asset (Net of Tax)		0.26	10.97
Total Comprehensive income for the period		<u>473.58</u>	<u>532.51</u>
Earnings per equity share (Equity Shares of Re.1/- each fully paid up)			
Basic (Rs.)		2.11	2.33
Diluted (Rs.)		2.11	2.33
Significant Accounting Policies	1		
Notes to Financial Statements	2		

For **NECTAR LIFESCIENCES LIMITED**

Sanjiv Goyal Chairman & Managing Director
Dinesh Dua CEO & Whole Time Director

Sandeep Goel Chief Financial Officer
R.K. Aggarwal Vice President Accounts

Ankita Jain Company Secretary

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

CASH FLOW STATEMENT FOR YEAR ENDED 31st March 2019

PARTICULARS	As At March 31, 2019	As At March 31, 2018
CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before Tax & Extra Ordinary Items	585.52	625.66
Adjustments For :		
Depreciation & Amortization	632.57	643.09
Other Comprehensive Income (Net)	0.26	10.97
Other Comprehensive Income (Tax)	0.14	5.80
Provision for Doubtful debts/ Insurance Claims	5.36	2.85
Provision for Employees Retirement Benefits	6.64	4.36
Provision for Excise Duty On Finished Goods	-	(6.00)
Loss/ (Profit) on Sale of Fixed Assets	2.23	(3.43)
Profit on Sale / Restatement of Investment	0.04	(0.01)
Interest on Borrowings	1,481.34	1,152.02
Other Non-Operating Income	(59.59)	(52.21)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	2,654.51	2,383.10
Adjustments For :		
(Increase)/Decrease in Current Assets	45.30	(1,682.01)
Increase/(Decrease) in Current Liabilities	(104.26)	109.17
Increase/(Decrease) in Long Term Liabilities	(56.39)	(12.18)
Increase/ (Decrease) in Non Current Liabilities	(0.25)	(0.25)
(Increase)/ Decrease in Non Current Assets	(14.44)	(20.33)
CASH GENERATED FROM OPERATIONS	2,524.47	777.51
Direct Taxes Paid	(135.59)	(126.16)
CASH FLOW BEFORE EXTRA-ORDINARY ITEMS	2,388.88	651.35
Extra-Ordinary Items	-	-
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	2,388.88	651.35
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(381.27)	(331.63)
Interest Received	59.59	52.21
Dividend Received	0.00	0.00
Sale of Fixed Assets	24.20	4.09
Sale/(Purchase) of Investments	0.00	(1.00)
Other Financial Assets Received/ (Paid)	36.18	(18.03)
NET CASH USED IN INVESTING ACTIVITIES (B)	(261.30)	(294.35)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds/(Repayment) from Term Loans from Banks	(526.67)	739.33
Proceeds/(Repayment) from Working Capital Limits from Banks	18.86	37.42
Proceeds/(Repayment) from Vehicle Loans	(8.22)	(7.26)
Dividend Paid	(13.50)	(13.50)
Interest Paid	(1,481.34)	(1,152.02)
NET CASH GENERATED FROM FINANCING ACTIVITIES (C)	(2,010.87)	(396.02)
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	116.71	(39.02)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	89.08	128.10
CASH & CASH EQUIVALENTS AT THE CLOSE OF THE YEAR	205.80	89.08

For **NECTAR LIFESCIENCES LIMITED**

Sanjiv Goyal
Chairman & Managing Director

Dinesh Dua
CEO & Whole Time Director

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

1. SIGNIFICANT ACCOUNTING POLICIES

1.1 BASIS FOR PREPARATION OF FINANCIAL STATEMENTS

These financial statements have been prepared to comply with the Indian Accounting Standards (Ind AS). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

The financial statements are prepared on accrual basis under the historical cost convention. The financial statements are presented in Indian rupees rounded off to the nearest rupees in millions.

The Company has adopted all the Ind AS standards mandatorily applicable and the adoption was carried out in accordance with Ind AS 101 "First time adoption of Indian Accounting Standards". The transition was carried out from Indian Accounting Principles generally accepted in India as prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (IGAAP), which was the previous GAAP.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

1.2 USE OF ESTIMATES

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

1.3 PROPERTY, PLANT & EQUIPMENT

- i) Property, Plant & Equipment have been stated at cost, net of *cenvat*/ goods and service tax availed, but inclusive of attributable costs of bringing the assets to their working condition for their intended use, less depreciation and impairment loss, if any. Depreciation on assets is provided on straight line method in the manner prescribed in Schedule II to the Companies Act, 2013
- ii) Cost of leasehold assets is amortized over the period of the lease.

1.4 INTANGIBLE ASSETS

Intangible assets are stated at cost less accumulated amortization and impairment, wherever applicable. Intangible assets are amortized over their respective individual estimated useful lives on a straight line basis, from the date they are available for use. The estimated useful life of an identifiable asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The research costs are expensed as incurred. The development costs, which can be capitalized, include the cost of material, direct labour and overhead costs that are directly attributable to preparing the asset for its intended use.

1.5 INVESTMENTS

Investments are classified into current and long term investments. Long Term Investments are stated at cost and provision for diminution in value is made if decline is other than temporary in the opinion of the management. Current Investments are valued at cost and provision is made for decline in market value, if any.

1.6 REVENUE RECOGNITION

- i) Revenue from product sales is stated exclusive of returns, inter-division transfers, Sales Tax but includes Excise Duty and Goods and Service tax.
- ii) Dividend income is recognized as and when the right to receive is established.
- iii) Export benefits and other benefits are accounted for on accrual basis. Export entitlements are recognized as reduction from material consumption when the right to receive credit is established in respect of the exports made and when there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

1.7 FINANCIAL INSTRUMENTS

A. Initial recognition

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, that are not at fair value through profit or loss, are added to the fair value on initial recognition.

B. Subsequent measurement

a. Non-derivative financial instruments

- i. Financial assets carried at amortized cost
A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
- ii. Financial assets at fair value through other comprehensive income
A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company has made an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income based on its business model. Further, in cases where the Company has made an irrevocable election based on its business model, for its investments which are classified as equity instruments, the subsequent changes in fair value are recognized in other comprehensive income.
- iii. Financial assets at fair value through profit or loss
A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

Standalone Financial Statements

iv. Financial liabilities

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

v. Investment in subsidiaries

Investment in subsidiaries is carried at cost in the separate financial statements.

b. *Derivative financial instruments*

The Company holds derivative financial instruments such as foreign exchange forward and option contracts to mitigate the risk of changes in exchange rates on foreign currency exposures. The counterparty for these contracts is generally a bank.

C. **Derecognition of financial instruments**

The company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognized from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

D. **Fair value of financial instruments**

In determining the fair value of its financial instruments, the Company uses a variety of methods and assumptions that are based on market conditions and risks existing at each reporting date. The methods used to determine fair value include discounted cash flow analysis, available quoted market prices and dealer quotes. All methods of assessing fair value result in general approximation of value, and such value may never actually be realized.

1.8 INVENTORIES

i) Raw materials, Stores and Spares and Packing material

Lower of cost and net realizable value. Cost of inventory comprises all cost of purchase and other cost incurred in bringing the inventories to their present location and condition.

ii) Finished Goods and work in process

Lower of cost and net realizable value. Cost includes direct material, labour and proportionate manufacturing overheads.

iii) Traded goods

Lower of Cost and Net Realizable Value. Cost includes the purchase price and other associated costs directly incurred in bringing the inventory to its present location. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

1.9 FOREIGN EXCHANGE TRANSACTIONS

i) Initial Recognition

Investments in foreign entities are recorded at the exchange rate prevailing on the date of making the investment. Transactions denominated in foreign currencies are recorded at the exchange rates prevailing on the date of the transaction.

ii) Conversion

Monetary assets and liabilities denominated in foreign currencies, as at the balance sheet date, not covered by forward exchange contracts, are translated at year end rates.

iii) Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in the previous financial statements, are recognized as income or expense in the year in which they arise and as per Ind AS 21, exchange differences arising on account of consolidation with foreign operation, are recognized in Other Comprehensive Income. The exchange difference on foreign currency denominated long term borrowings relating to the acquisition of depreciable capital assets are adjusted in the carrying cost of such assets for current year. The Company has opted for voluntary exemption given in Ind AS-101, which allows first time adopter to continue its Indian GAAP policy for accounting of exchange difference arising on translation of long term foreign currency monetary items recognized in the financial statements for the period ending immediately before the beginning of the first Ind AS financial reporting period.

1.10 EMPLOYEE BENEFITS

i) Short Term Employee Benefits:

Employee benefits payable fully within twelve months of rendering the service are classified as short term employee benefits and are recognized in the period in which the employee renders the related service.

Contribution to the Provident Fund, which is a defined contribution scheme, is recognized as an expense in the profit and loss account in the period in which the contribution is due.

ii) Long Term Employee Benefits

Post Employment Benefits (Defined Benefit Plans)

The employee gratuity scheme is a defined benefit plan. The present value of the obligation under such defined benefit plan is determined at Balance Sheet date based on an actuarial valuation carried out by an independent actuary using the projected unit credit method. Actuarial gains and losses and past service cost are recognized immediately in other comprehensive income.

Long term employee benefit also comprises of compensated absences. These are measured based on actuarial valuations carried out by an independent actuary using the projected unit method at balance sheet date unless they are insignificant. Actuarial gains and losses and past service cost are recognized immediately in other comprehensive income.

1.11 CASH FLOW STATEMENT

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

1.12 DIVIDENDS

Final dividends on shares are recorded as a liability on the date of approval by the shareholders.

Standalone Financial Statements

1.13 OTHER INCOME

Other income is comprised primarily of interest income, dividend income and profit/ loss on sale of investment/ fixed assets. Dividend income is recognized when the right to receive payment is established.

1.14 BORROWING COSTS

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized. Other borrowing costs are recognized as an expense in the period in which they are incurred.

1.15 LEASES

Leases, where the lessor retains substantially all the risks and benefits of the ownership of the leased item are classified as operating leases. Lease rentals for assets taken on operating lease are charged to the profit and loss account in accordance with Indian Accounting Standard (Ind AS 19) on "Leases".

1.16 GOVERNMENT GRANTS AND SUBSIDIES

Grants and Subsidies are recognized when there is a reasonable assurance that the grant or subsidy will be received and that all underlying conditions will be complied with. When the grant or subsidy relates to an asset, such grant is recognized in Statement of Profit and Loss on a systematic basis over the useful life of the asset.

1.17 EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

1.18 IMPAIRMENT OF ASSETS

Management periodically assesses using external and internal sources whether there is an indication that an asset may be

impaired. Impairment occurs where the carrying value of future cash flows expected to arise from the continuing use of the assets and its eventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net sales price or present value as determined above.

1.19 INCOME TAXES

Income tax expense comprises current and deferred income tax. Income tax expense is recognized in net profit in the statement of profit and loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in other comprehensive income.

Current income tax for current and prior periods is recognized at the amount expected to be paid to or recovered from the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date. Deferred income tax assets and liabilities are recognized for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

2. NOTES TO FINANCIAL STATEMENTS

2.1 COMPANY OVERVIEW

Nectar Lifesciences Limited (CIN: L24232PB1995PLC016664) is an integrated pharmaceutical organization, incorporated in 1995, having its corporate office in Chandigarh and works in the states of Punjab and Himachal Pradesh. The Company has sustainable production systems to manufacture APIs and Formulations. With an expertise in R&D, the Company has been experiencing growth in this segment. The Company is also in the Menthol business and succeeded in both domestic and international markets. The Company has its primary listings on the BSE Limited and National Stock Exchange of India Limited.

Nectar Lifesciences Limited

(Rs. in Millions)

NOTE - 2.2 "PROPERTY, PLANT AND EQUIPMENT"

Particulars	GROSS BLOCK			DEPRECIATION					NET BLOCK	
	As At 01-Apr-18	Additions	Sale/ Deletion	As At 31-Mar-19	Up To 31-Mar-18	During the Year	Deletion/ Adjustments	Up To 31-Mar-19	As At 31-Mar-19	As At 31-Mar-18
Freehold Land & Site Development	955.95	2.52	25.54	932.93	-	-	-	-	932.93	955.95
Leasehold Land	3.27	-	-	3.27	0.41	0.04	-	0.45	2.82	2.87
Buildings	1,615.01	34.07	-	1,649.07	462.37	50.42	-	512.79	1,136.28	1,152.64
Tube Well	22.66	-	-	22.66	15.40	2.33	-	17.73	4.93	7.26
Plant & Machinery *	8,646.43	221.88	-	8,868.31	3,708.42	315.67	-	4,024.08	4,844.22	4,938.01
Boiler	170.70	-	-	170.70	92.08	8.93	-	101.02	69.68	78.62
Pollution Control Equipment	75.25	-	-	75.25	58.90	5.68	-	64.58	10.67	16.35
Laboratory	110.05	1.27	-	111.32	77.21	5.57	-	82.78	28.54	32.84
Miscellaneous Fixed Assets	1,500.04	29.84	-	1,529.89	696.05	70.40	-	766.45	763.44	804.00
Furniture & Fixture	100.71	0.32	-	101.03	71.72	6.39	-	78.11	22.92	29.00
Motor Vehicles	111.69	0.60	16.68	95.61	68.22	7.21	15.80	59.63	35.98	43.47
Computer	44.57	1.53	-	46.10	41.25	0.90	-	42.14	3.95	3.32
GRAND TOTAL	13,356.33	292.02	42.22	13,606.13	5,292.02	473.55	15.80	5,749.76	7,856.36	8,064.31
Previous Year	13,062.24	294.82	0.73	13,356.33	4,824.27	467.81	0.06	5,292.02	8,064.31	8,237.97

*includes addition on account of foreign exchange fluctuation on ECB amounting to Rs. 53.03 Millions (Previous Year addition of Rs. 2.14 Millions)

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.3 "INTANGIBLE ASSETS"

Opening Gross Block	1,207.22	1,147.13
Additions during the year	91.60	60.09
Closing Gross Block	1,298.82	1,207.22
Opening Accumulated amortization	747.98	572.70
Amortization during the year	159.03	175.28
Closing Accumulated amortization	907.00	747.98
Net Intangible Assets	391.82	459.24

NOTE - 2.4 "INVESTMENTS"

Non Current Investments

Investment in Equity Instruments

UNQUOTED

In Subsidiary Companies

1 Equity Share of 1 GBP Fully Paid Up In Nectar Lifesciences UK Ltd.-England [Absolute amount Rs. 75 (Previous Year Rs. 75)]	0.00	0.00
--	------	------

51,950 Equity Shares (Previous year 51,950 Equity Shares) of 1 USD Fully Paid Up In Nectar Lifesciences USA LLC	3.30	3.30
--	------	------

In Others

2,20,000 (Previous Year 2,20,000) Equity Shares of Rs. 10/- each Fully paid up In Mohali Green Environment Private Limited	2.20	2.20
---	------	------

50,000 Equity Shares of RS. 10/- each, fully paid up in Nimbua Greenfield (Punjab) Ltd.	0.50	0.50
--	------	------

20 Equity Shares of Rs. 50/- each in The Thane Janta Sahakari Bank Ltd [Absolute amount Rs. 1,000 (Previous Year Rs.1,000)]	0.00	0.00
---	------	------

Total - "A"	6.00	6.00
--------------------	-------------	-------------

Current Investments

Investment in Equity Instruments

QUOTED

5 Equity Shares of Re. 1/- each, Fully Paid Up In Aurobindo Pharma Ltd. [Absolute amount Rs. 314 (Previous Year Rs. 314)]	0.00	0.00
--	------	------

4,700 Equity Shares of Rs. 5/- each, Fully Paid Up In Parsvanath Developers Ltd.	1.31	1.31
---	------	------

SBI PSU Fund	1.00	1.00
--------------	------	------

PRINCIPAL BALANCED FUND	1.00	1.00
-------------------------	------	------

3,000 Bonds of IFCI @ Rs. 1,000/- Each	3.00	3.00
--	------	------

UNQUOTED

2,500 Equity Shares of Rs. 10/- each, Fully Paid Up In Saraswat Co-operative Bank Ltd.	0.03	0.03
---	------	------

Total "B"	6.34	6.34
------------------	-------------	-------------

Provision for Loss on Investment "C"	1.28	1.24
--------------------------------------	------	------

Net Current Investments "D" ("B" - "C")	5.05	5.10
--	-------------	-------------

Total Investment "A" + "D"	11.06	11.10
-----------------------------------	--------------	--------------

Market value of Quoted Investment Rs. 6.45 Millions (Previous Year Rs. 5.15 Millions)

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.5 "TRADE RECEIVABLES"

Unsecured consists of following

Non Current

Considered Good	48.09	36.81
Considered Doubtful	97.78	92.42
	145.87	129.23
Less: Provision For Doubtful Debts	97.78	92.42
Total - "A"	48.09	36.81

Current

Considered Good	5,613.79	6,121.15
Considered Doubtful	-	-
	5,613.79	6,121.15
Less: Provision For Doubtful Debts	-	-
Total - "B"	5,613.79	6,121.15

Total Trade Receivables ("A" + "B")	5,661.88	6,157.97
--	-----------------	-----------------

NOTE - 2.6 "OTHER FINANCIAL ASSETS"

Non Current

Balances Recoverable from Revenue Authorities	24.94	61.13
Insurance Claim Receivable :		
Considered Good	-	-
Considered Doubtful	21.15	21.15
	46.09	82.28
Less: Provision for Doubtful Insurance Claim	21.15	21.15
Total - "A"	24.94	61.13

Current

Export and Other Incentives Accrued	520.35	390.73
Balances with Revenue Authorities	429.10	661.09
Other Recoverables	10.27	6.18
Insurance Claim Receivable :		
Considered Good	59.33	64.32
Considered Doubtful	-	-
	1,019.06	1,122.31
Less: Provision for Doubtful Insurance Claim	-	-

Total - "B"	1,019.06	1,122.31
Total Other Financial Assets ("A" + "B")	1,044.00	1,183.44

NOTE - 2.7 "OTHER NON-CURRENT ASSETS"

Security Deposits	19.12	21.32
MAT Credit Entitlement	1,016.04	983.76
Others	5.00	5.00
	1,040.16	1,010.08

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.8 "INVENTORY"

(As Certified by The Management)

Raw Material	1,006.96	947.49
Work In Progress	5,993.30	6,970.22
Finished Goods	1,885.80	434.23
Stock in Trade	38.12	42.91
Other Miscellaneous Stocks	221.09	199.50
	9,145.27	8,594.35

NOTE - 2.9 "CASH & CASH EQUIVALENTS"

Balance with Banks	189.76	76.28
Balances in Dividend Accounts	0.38	0.39
Cash In Hand (Incl Staff Imprest)	15.66	12.42
	205.80	89.08

NOTE - 2.10 "LOANS"

Loans & Advances to Staff	3.82	3.79
	3.82	3.79

NOTE - 2.11 "OTHER CURRENT ASSETS"

Advances other than capital advances		
Payment to vendors for supply of goods	554.00	580.73
Others	128.08	86.99
	682.08	667.72

NOTE - 2.12 "SHARE CAPITAL"

Authorised Share Capital

35,00,00,000 Equity Shares Of Re. 1/- Each.

350.00

350.00

Issued, Subscribed & Paid up Capital

22,42,60,970 Equity Shares Of Re. 1/- Each Fully Paid up

224.26

224.26

(Also Refer Note 2.28)

224.26

224.26

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

NOTE - 2.13 "OTHER EQUITY"

Statement of Change in Equity (FY 2018-19)

Particulars	Equity Share Capital	Other Equity			Total equity attributable to equity holders
		Security Premium	General Reserves	Retained Earnings	
Balance as of April 1, 2018	224.26	3,287.98	141.02	6,933.02	10,586.29
Changes in equity for the year ended March 31, 2019					
<u>Add</u> : - Profit for the period	-	-	-	473.58	473.58
<u>Less</u> : - Final Dividend & Tax on Dividend	-	-	-	13.50	13.50
Balance as of March 31, 2019	224.26	3,287.98	141.02	7,393.11	11,046.37

Statement of Change in Equity (FY 2017-18)

Particulars	Equity Share Capital	Other Equity			Total equity attributable to equity holders
		Security Premium	General Reserves	Retained Earnings	
Balance as of April 1, 2017	224.26	3,287.98	141.02	6,414.00	10,067.27
Changes in equity for the year ended March 31, 2018					
<u>Add</u> : - Profit for the period	-	-	-	532.51	532.51
<u>Less</u> : - Final Dividend & Tax on Dividend	-	-	-	13.50	13.50
Balance as of March 31, 2018	224.26	3,287.98	141.02	6,933.02	10,586.29

Particulars	As At	As At
	March 31, 2019	March 31, 2018

NOTE - 2.14 "BORROWINGS"

Non Current

Secured

Term Loans

From Banks

1,644.00

2,182.09

Unsecured

Vehicle Loans

From Banks

11.62

17.39

From Others

0.28

1.28

1,655.90

2,200.76

(Also Refer Note 2.29)

Current

Secured

Working Capital Limits

From Banks

6,156.40

6,041.51

Unsecured

From Banks

203.29

299.32

6,359.69

6,340.83

Total Borrowings

8,015.58

8,541.59

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.15 "OTHER FINANCIAL LIABILITIES"

Non Current

Security from Customers	-	1.85
Other Capital Advances	119.25	173.79
	119.25	175.65

Current

Current Maturities of Long Term Debts	1,012.07	1,000.65
Current Maturities of Finance Lease obligations	6.85	8.30
Interest Accrued but not due on Borrowings	21.19	33.62
Unpaid Dividends	0.38	0.39
Accrued Compensation to Employees	55.66	52.20
Statutory dues payable	13.11	12.26
Accrued Expenses	20.69	15.95
	1,129.94	1,123.37
Total Other Financial Liabilities	1,129.94	1,123.37

NOTE - 2.16 "OTHER NON CURRENT LIABILITIES"

Non Current

Deferred Income	8.71	8.96
	8.71	8.96

NOTE - 2.17 "PROVISIONS"

Non Current

Provision for Employees Retirement Benefits	93.63	90.69
	93.63	90.69

Current

Provision for Employee Retirement Benefits	8.58	4.88
	8.58	4.88
Total Provisions	102.21	95.57

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.18 "DEFERRED TAX LIABILITY"

Tax Impact on Deferred Tax Liability arising on account of:
Depreciation

	1,189.04	1,146.83
Total - "A"	1,189.04	1,146.83

Tax Impact on Deferred Tax Assets arising on account of:

Employees Retirement Benefits	35.37	33.07
Other Expenses & Provisions	41.16	39.30

Total - "B"	76.53	72.38
--------------------	--------------	--------------

Net Deferred Tax Liability ("A" - "B")	1,112.50	1,074.45
---	-----------------	-----------------

Tax Impact of Other Comprehensive Income	9.08	8.94
--	------	------

Net Deferred Tax Liability	1,121.58	1,083.38
-----------------------------------	-----------------	-----------------

NOTE - 2.19 "TRADE PAYABLES"

Due to Micro ,Small & Medium Enterprises	44.43	29.67
Due to Others	5,263.39	5,364.57
	5,307.81	5,394.24

NOTE - 2.20 "OTHER CURRENT LIABILITIES"

Advances From Customers	96.23	110.66
	96.23	110.66

NOTE - 2.21 "REVENUE FROM OPERATIONS"

Sale of Manufactured Products		
Export	10,690.15	9,511.31
Domestic	19,935.63	11,191.73
Trading Sale		
Export	24.88	4.09
Domestic	498.57	216.07
	31,149.23	20,923.19

NOTE - 2.22 "OTHER INCOME"

Operating Income

Other Operating Income	0.60	4.26
Deferred Income - Govt. Grants	0.25	0.25

Other Income

Interest Income	59.59	52.21
Dividend From Investments	0.00	0.00
[Absolute amount Rs. 4,400 (Previous year Rs. 38)]		
Compensation on Sale of Land	-	3.62
Profit/ (Loss) on Restatement of Investment	(0.04)	0.01
	60.40	60.36

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.23 "RAW MATERIAL CONSUMED"

Opening Stock	947.49	1,211.33
Add:- Purchase of Raw Material	22,312.65	13,552.55
	23,260.13	14,763.88
Less :- Closing Stock	1,006.96	947.49
	22,253.17	13,816.39

NOTE - 2.24 "(INCREASE)/ DECREASE IN INVENTORIES OF FINISHED GOODS, STOCKS IN PROCESS & STOCK IN TRADE"

Inventory (At Close)

Finished Goods	1,885.80	434.23
Stock in Process	5,993.30	6,970.22
Stock in Trade	38.12	42.91
	7,917.22	7,447.36

Inventory (At Commencement)

Finished Goods	434.23	161.45
Stock in Process	6,970.22	6,915.57
Stock in Trade	42.91	66.01
	7,447.36	7,143.04
	(469.86)	(304.32)

NOTE - 2.25 "EMPLOYEE BENEFIT EXPENSES"

Salaries & Wages	642.53	608.44
Remuneration To Directors	33.56	37.54
Contribution to Provident and Other Funds	34.08	34.98
Staff Welfare	88.83	103.10
	799.00	784.05

NOTE - 2.26 "FINANCIAL EXPENSES"

Interest Expenses	878.23	883.67
Other Borrowing Costs & Foreign Exchange Fluctuation(Net)	603.11	268.36
	1,481.34	1,152.02

Standalone Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	Year Ended March 31, 2019	Year Ended March 31, 2018
-------------	------------------------------	------------------------------

NOTE - 2.27 "OTHER EXPENSES"

Manufacturing Expenses

Consumable Stores	158.20	143.88
Power, Fuel & Steam Expenses	1,032.41	916.28
Chemical Testing Expenses	25.96	19.26
Packing Expenses	170.72	203.97
Repairs & Maintenance		
Electricals	8.98	14.27
Machinery	124.10	131.64
Building	10.72	11.06
Total - "A"	1,531.08	1,440.36

Administrative Expenses

Travelling & Conveyance	27.96	32.38
Advertisement & Subscription	0.66	0.65
Books & Periodicals	0.18	0.13
Business Promotion	6.58	3.62
Insurance	39.62	24.95
Electricity Expenses (Office)	2.27	2.26
Postage, Telephone, Telegram	10.03	11.23
Printing & Stationery	5.97	9.51
Professional Fees	37.01	44.94
Rate, Fees & Taxes	36.45	43.19
Vehicle Running & Maintenance	5.15	4.96
Rent	13.05	13.92
Audit Fees	2.50	2.50
Office Expenses	7.49	5.24
Diwali & Pooja Expenses	3.67	4.44
Donation	22.75	15.22
Directors' Sitting Fees	0.22	0.18
Loss on Sale of Fixed Assets	2.23	0.19
Total - "B"	223.79	219.50

Selling & Distribution Expenses

Discount & Samples	40.55	21.92
Freight & Cartage Outward	282.80	160.96
Sales Commission	116.19	100.02
Provision for Doubtful Debts/ Insurance claim	5.36	3.30
Total - "C"	444.90	286.20
Grand Total ("A" + "B" + "C")	2,199.78	1,946.06

Standalone Financial Statements

2.28 DETAIL OF SHAREHOLDERS HOLDING MORE THAN 5% SHARES

Particulars	As at 31 st March, 2019		As at 31 st March, 2018	
	Number of shares held	Percentage of shares held	Number of shares held	Percentage of shares held
Mr. Sanjiv Goyal	55555600	24.77	55555600	24.77
NSR Direct PE Mauritius, LLC (Name changed to Isengard Direct PE LLC)	26000000	11.59	26000000	11.59
Depository of GDRs	46000000	20.51	46000000	20.51
Sanjiv (HUF)	43379400	19.34	43379400	19.34

Note: Since, the equity shares underlying GDRs are held by Deutsche Bank Trust Company Americas being depository of GDRs, hence disclosed per se.

Reconciliation of the number of shares outstanding:

Particulars	As at 31 st March, 2019	As at 31 st March, 2018
Equity shares at the beginning of the year	224260970	224260970
Add: Shares issued during the year	Nil	Nil
Equity shares at the end of the year	224260970	224260970

2.29 SECURED LOANS

- I. Term Loans from various banks are secured by way of First Pari Passu Charge on all the fixed assets of the Company and further secured by way of Second Pari Passu Charge on all the current assets of the Company and personal guarantee of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.
- II. Corporate Loans from Financial Institution are secured by way of personal guarantee/pledging of equity shares of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.

Repayment Schedule of Term Loans:

Year of Repayment	Amount (Rs. in Millions)
1-2	654.00
2-5	850.00
>5	140.00

Term Loans availed by the Company include term loans from various Banks/Financial Institutions.

Other Loans comprise of Vehicle Loans which are secured against hypothecation of respective vehicles.

Repayment Schedule of Vehicle Loans:

Year of Repayment	Amount (Rs. in Millions)
1-2	5.17
2-5	6.73
>5	-

- III. Working Capital Limits are secured by way of First Pari Passu Charge on all the current assets of the Company and further secured by way of Second Pari Passu Charge on all the fixed assets of the Company and personal guarantee of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.

2.30 CURRENT ASSETS, LOANS & ADVANCES

In the opinion of the management of the Company, the current assets, loans and advances are approximately of the value as stated, if realized in the ordinary course of business and are subject to confirmation/reconciliation.

2.31 CURRENT LIABILITIES

- I. The principal amount remaining unpaid as at 31st March 2019 in respect of enterprises covered under the "Micro, Small and Medium Enterprises Development Act, 2006" are Rs. 44.43 millions (Previous year Rs. 29.67 millions). The interest amount computed based on the provisions under Section 16 of the MSMED Act Rs. 3.25 millions (Previous year Rs. 2.21 millions) is remaining unpaid as at 31st March 2019. The principal amount that remained unpaid as at 31st March 2018 was paid during the year. The list of undertakings covered under MSMED Act was determined by the Company on the basis of information available with the Company and have been relied upon by the auditors.

- II. Investor Education and Protection Fund

Other liabilities include Rs. 0.38 millions (Previous year Rs. 0.34 millions) which relates to unclaimed dividend and share application money refundable. During the year, Rs. 0.05 millions was deposited relating to unclaimed dividend and share application money refundable with the Investor Education and Protection Fund (Previous year Nil).

2.32 CONTINGENT LIABILITIES AND COMMITMENTS

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
a)	Contingent Liabilities		
i)	Claims not acknowledged as debts:- *	114.31	5.97
	-Income Tax matters**	12.53	430.20#
	-Excise matters***	7.22#	7.22#
	-Service Tax matters****		
ii)	Bank Guarantees	14.14	13.11
iii)	Bills Discounted	-	47.91
iv)	Letter of Credit (Foreign / Inland)	286.12	222.42
b)	Commitments		
i)	Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advance)	97.35	31.31

* The matters are subject to legal proceedings in the ordinary course of business. In the opinion of the management, legal proceedings for above cases, when ultimately concluded will not have a material effect on the results of operation or financial position of the company.

** Amount deposited under protest Rs. 3.01 millions and MAT credit entitlement would be reduced by Rs. 108.34 millions, in case of adverse judgment.

*** Amount deposited under protest Rs. 5.90 millions

**** Amount deposited under protest Rs. 0.52 millions

In case demand is confirmed, penalty up to equivalent amount may be imposed.

2.33 PAYMENT TO AUDITORS

(Rs. in millions)

Particulars	2018-19	2017-18
Statutory Audit and Limited Review Fees	2.10	2.10
Tax Audit Fee	0.40	0.40
GST	0.45	0.45

Standalone Financial Statements

2.34 INCOME TAX

Current Tax

Provision for Current Income Tax has been made as per Income Tax Act, 1961, based on legal opinion obtained by the Company from its income tax consultant and the statutory auditors have relied upon the said legal opinion for the purpose of current income tax.

Deferred Tax

In compliance with Indian Accounting Standard (Ind AS 12) relating to "Income Taxes" issued under Companies (Indian Accounting Standards) Rules, 2016 as amended up to date, the Company has provided Deferred Tax Liability accruing during the year aggregating to Rs. 38.06 millions (Previous Year Rs. 40.89 millions) and it has been recognized in the Statement of Profit & Loss. In accordance with Indian Accounting Standard (Ind AS 12) Deferred Tax Assets and Deferred Tax Liabilities have been set off.

2.35 LEASES

Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable/cancellable at mutual consent. There are no restrictions imposed by lease arrangements. There are no sub leases. Lease payments recognized in the Statement of Profit & Loss are Rs. 13.05 millions (Previous Year Rs. 13.92 millions).

2.36 INTANGIBLE ASSETS

During the year, the Company incurred an amount of Rs. 91.60 millions (Previous Year Rs. 60.09 millions) on product development, product approval, US FDA Fees, Abbreviated New Drug Application (ANDA) Fees and such other related development expenses, recognized as Intangible Assets in the books of accounts and the same is amortized on straight line basis over a period of seven years.

2.37 EMPLOYEE RETIREMENT BENEFITS

- Benefits valued: Gratuity & Earned leave (both availment & encashment)
- Nature of the plans: Defined benefit; both gratuity & compensated absence
Liabilities are unfunded
- Valuation method: Projected Unit Credit Method

Changes in Present Value of Obligations

(Rs. in millions)

	Gratuity	Earned leave
Present Value of Obligations as at 1st April 2018	62.32	33.21
Acquisition adjustment	-	-
Interest Cost	5.28	2.01
Past Service Cost	-	-
Current Service Cost	9.75	1.0
Curtailment Cost/(Credit)	-	-
Settlement Cost/(Credit)	-	-
Benefits paid	(4.72)	(6.24)
Actuarial (gain)/loss on obligations	1.29	(1.69)
Present Value of obligations as at 31 st March 2019	73.91	28.29

Changes in the Fair Value of Plan Assets

(Rs. in millions)

	Gratuity	Earned leave
Fair Value of Plan Assets as at 1st April 2018	-	-
Acquisition Adjustments	-	-
Expected Return on Plan Assets	-	-
Contributions	-	-
Benefits Paid	-	-
Actuarial Gain/(loss) on Plan Assets	-	-
Fair Value of Plan Assets as at 31st March 2019	-	-

Fair Value of Plan Assets

(Rs. in millions)

	Gratuity	Earned leave
Fair Value of Plan Assets as at 1st April 2018	-	-
Acquisition Adjustments	-	-
Actual Return on Plan Assets	-	-
Contributions	-	-
Benefits Paid	-	-
Fair Value of Plan Assets as at 31st March 2019	-	-
Funded Status	73.91	28.29

Actuarial Gain/Loss Recognized

(Rs. in millions)

	Gratuity	Earned leave
Actuarial gain/(loss) for the year – Obligation	(1.29)	1.69
Actuarial gain/(loss) for the year – Plan Assets	-	-
Total gain/(loss) for the year	(1.29)	1.69
Actuarial (gain)/ loss recognized in the year	1.29	(1.69)
Unrecognized actuarial (gains)/losses at the end of year	-	-

Amount recognized in the Balance Sheet

(Rs. in millions)

	Gratuity	Earned leave
Present value of obligations as at 31 st March 2019	73.91	28.29
Fair value of plan assets as at 31 st March 2019	-	-
Funded Status	73.91	28.29
Unrecognized actuarial (gains)/losses	-	-
Net asset/(liability) recognized in the balance sheet	(73.91)	(28.29)

Expenses recognized in the Statement of Profit & Loss

(Rs. in millions)

	Gratuity	Earned leave
Current service cost	9.75	1.0
Past service cost	-	-
Interest cost	5.28	2.01
Expected return on plan assets	-	-
Curtailment cost/(credit)	-	-
Settlement cost/(credit)	-	-
Actuarial Loss/(gain) recognized in the year	-	(1.69)
Expenses recognized in the Statement of Profit & Loss	15.03	1.32

Standalone Financial Statements

Amount recognized as other comprehensive income

(Rs. in millions)

	Gratuity	Earned leave
Actuarial loss on DBO	1.29	-
Excess of interest on plan assets over actual return	-	-
Change in the effect of asset ceiling	-	-
Expense recognized as other comprehensive income	1.29	-

Valuation Assumptions

Discount Rate	7.7%
Estimated rate of increase in compensation levels	7%
Attrition Rate	Table A
Mortality Rates	Table B

The estimated rate of increase in compensation levels takes into account inflation, seniority, promotion and other relevant factors such as demand and supply in the employment market.

Table A

Age	Rates
Upto 30 years	3%
31-44 years	2%
Above 44 years	1%

Table B

Age	Mortality Rates	Age	Mortality Rates
20	0.000888	70	0.025855
30	0.001056	80	0.060558
40	0.001803	90	0.138895
50	0.004946	100	0.311628
60	0.011534	110	0.685737

2.38 TAX EXPENSE COMPRISES OF:

(Rs. in millions)

	2018-19	2017-18
- Current Tax	106.43	124.28
- Deferred Tax	38.06	40.89
- MAT Credit Entitlement (net)	(32.28)	(61.06)
	112.20	104.11

2.39 SEGMENT REPORTING

i) Primary Segment (Business Segment)

The Company operates only in the business segment of "Pharmaceuticals Products", and in the opinion of the management the inherent nature of activities in which it is engaged are governed by the same set of risks and reward. As such the activities are identified as single segment in accordance with the Indian Accounting Standard (Ind AS 108) issued under Companies (Indian Accounting Standards) Rules, 2016as amended up to date.

ii) Secondary Segment (By Geographical Segment)

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
(a)	India	20434.20	11407.80
(b)	Outside India	10715.03	9515.39
	Total Sales (inclusive of GST)	31149.23	20923.19

In view of the interwoven/intermix nature of business and manufacturing facility, other segmental information is not ascertainable.

2.40 RELATED PARTY DISCLOSURES

Related party disclosures as required under Indian Accounting Standard (Ind AS 24) on "Related Party Disclosures" issued under Companies (Indian Accounting Standards) Rule 2016, as amended up to date, are given below: -

a) Relationship

i) Subsidiary Companies

Nectar Lifesciences USA, LLC

Nectar Lifesciences UK Limited, United Kingdom (Inoperative during the year)

ii) Joint Ventures and Associates

None

iii) Key Management Personnel (Managing Director/Whole-time directors/CFO/Company Secretary)

Sh. Sanjiv Goyal, Chairman & Managing Director

Sh. Dinesh Dua, CEO & Whole time Director

Sh. Harprakash Singh Gill, President (upto 28.02.2019)

Sh. Sandeep Goel, Chief Financial Officer

Ms. Ankita Jain, Company Secretary

iv) Relatives of the Key Management Personnel*

Sh. Saurabh Goyal (upto 30.11.2018)

Sh. Aryan Goyal (upto 30.11.2018)

Smt. Raman Goyal

v) Entities over which key management personnel/their relatives are able to exercise significant influence*

Surya Narrow Fabrics (Proprietary concern)

Nectar Lifesciences Charitable Foundation (CSR vehicle of the company)

Nectar Biopharma Private Limited

* With whom the Company had transactions during the year.

b) The following transactions were carried out with related parties in the ordinary course of business.

i) Subsidiary Companies

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
i	Balance at the year end	100.49	22.80
ii	Sale during the year	289.83	30.94

ii) Key Management Personnel and their relatives

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
i.	Director Remuneration & Perquisites*	33.64	37.62
ii.	Salary & Perquisites*	15.02	20.08
iii.	Rent	1.20	-

*Includes Taxable value of Perquisites as per Income Tax Act 1961

iii) Entities over which key management personnel/their relatives are able to exercise significant influence

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
i.	Rent	-	0.72
ii	CSR expenditure through CSR vehicle	1.54	1.65
iii	Net Sales (inclusive of applicable indirect taxes)	472.57	205.09
iv	Net Purchases (inclusive of applicable indirect taxes)	13.03	12.50
v	Balance due at the year end (net receivable)	98.08	65.14

Standalone Financial Statements

2.41 DERIVATIVES

Currency derivatives

The Company uses foreign currency forward contracts and currency options to hedge its risks associated with foreign currency fluctuations relating to certain firm commitments and forecasted transactions. The use of foreign currency forward contracts and currency options is governed by Company's strategy. The Company does not use forward contracts and currency options for speculative purposes.

2.42 EARNINGS PER SHARE (EPS)

Particulars	Unit	Year Ended 31.03.2019	Year Ended 31.03.2018
Profit After Tax, before OCI	Rs. in millions	473.32	521.55
No of Shares Outstanding	Nos.	224260970	224260970
No of Weighted Average equity shares	Nos.	224260970	224260970
Diluted	Nos.	224260970	224260970
Nominal value of equity shares	Rs.	1.00	1.00
Earnings per Share			
-Basic	Rs.	2.11	2.33
-Diluted	Rs.	2.11	2.33

2.43 Other Borrowing Costs include Loss on account of foreign exchange fluctuation (net) amounting to Rs. 204.99 millions (Previous Year net gain of Rs. 46.55 millions).

2.44 DETAIL OF IMPORTED AND INDIGENOUS RAW MATERIAL AND STORES & SPARES CONSUMED

a) RAW MATERIAL CONSUMED (Rs. in millions)

S. No.	Particulars	2018-2019		2017-2018	
		Amount	(%age)	Amount	(%age)
1.	Imported	7355.70	33.05	6641.63	48.07
2.	Indigenous	14897.47	66.95	7174.76	51.93

b) STORES & SPARES CONSUMED (Rs. in millions)

S. No.	Particulars	2018-2019		2017-2018	
		Amount	(%age)	Amount	(%age)
1.	Imported	1.45	0.92	0.17	0.12
2.	Indigenous	156.75	99.08	143.71	99.88

2.45 OTHER INFORMATION (Rs. in millions)

	Particulars	2018-2019	2017-2018
(a)	CIF Value of Imports		
1.	Raw Material	7099.23	6293.56
2.	Traded Goods	380.12	61.43
3.	Capital Goods, Store & Spares, Packing Material etc.	22.24	11.68
(b)	Expenditure in Foreign Currency		
1.	Travelling Expenses	4.59	8.79
2.	Export Commission	98.19	82.09
3.	Other Expenses	22.02	15.08

	Particulars	2018-2019	2017-2018
(c)	Remittances in Foreign Currency		
1.	Raw Material	6996.35	6367.47
2.	Traded Goods	381.67	59.90
3.	Capital Goods and Stores & Spares	19.83	28.09
(d)	Expenditure in Foreign Currency on account of dividend		
1.	Number of Non Resident Shareholders	2	2
2.	Number of Equity Shares held by them	72000000	72000000
3.	(i) Amount of Dividend Paid	3.6	3.6
	(ii) Year to which dividend relates	2017-18	2016-17
(e)	Earning in Foreign Currency		
	FOB Value of Exports	10715.03	9473.22

2.46 CORPORATE SOCIAL RESPONSIBILITY EXPENSES

Donation includes an amount of Rs. 12.17 millions (Previous Year Rs. 14.06 millions) incurred by the Company on Corporate Social Responsibility (CSR) activities during the year, in addition to Rs. 13.97 millions (Previous Year Rs. 6.74 millions) capital expenditure incurred on power plant which is also eligible for CSR activities. In totality the Company incurred Rs. 26.14 millions (Previous Year Rs. 20.80 millions) on CSR activities against the requirement of Rs. 12.44 millions (Previous Year Rs. 13.67 millions).

2.47 The Company has re-grouped previous year's figures to confirm to current year's classification.

FOR NECTAR LIFESCIENCES LIMITED

Sanjiv Goyal
Chairman & Managing
Director

For Ashwani K. Gupta & Associates
Chartered Accountants
Firm Regn. No. 003803N

Dinesh Dua
CEO & Whole time
Director

Ashwani K. Gupta
Partner
M. No. : 082808

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

Place : Chandigarh
Dated : 25.05.2019

CONSOLIDATED INDEPENDENT AUDITOR'S REPORT

To the Members of

NECTAR LIFESCIENCES LIMITED

Report on the Audit of the Consolidated Financial Statements

1. Opinion

We have audited the accompanying consolidated financial statements of Nectar Lifesciences Limited (hereinafter referred to as "the Holding Company"), and its subsidiaries Nectar Lifesciences UK Limited, United Kingdom and Nectar Lifesciences USA LLC, USA (together referred to as "the Group"), which comprise the consolidated Balance sheet as at 31 March 2019, and the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31 March 2019, of its consolidated profit and other comprehensive income, consolidated changes in equity and consolidated cash flows for the year then ended.

2. Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI'), and we have fulfilled our other ethical responsibilities in accordance with the provisions of the Act. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

3. Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. In our opinion, there is no Key Audit Matter to be reported.

4. Other Information

The Holding Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Holding Company's Annual Report, but does not include the financial statements and our auditors' report thereon. Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

5. Management's Responsibility for the Consolidated Financial Statements

The Holding Company's management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in terms of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated profit/loss and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. The respective Board of Directors of the entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each entity and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective management and Board of Directors of the entities included in the Group are responsible for assessing the ability of each entity to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the entities included in the Group is responsible for overseeing the financial reporting process of each entity.

6. Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the

Consolidated Financial Statements

audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the entity has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group (Holding company and subsidiaries) to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to express an opinion on the consolidated financial statements.

We are responsible for the direction, supervision and performance of the audit of financial information of such entities.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

7. Other Matters

We have not carried out the audit of the subsidiary Companies namely Nectar Lifesciences UK Limited, United Kingdom (dormant/inoperative during the year) and Nectar Lifesciences USA LLC. We have relied on the audited financial statements

of the subsidiary namely Nectar Lifesciences USA LLC for the period ended 31st December, 2018, after duly accounting for the material transactions held during the quarter ended March 31, 2019, which have been incorporated in the consolidated financial statements. The financial statements of subsidiary reflects total assets of Rs. 115.91 millions as at March 31, 2019 (Previous year Rs. 7.15 millions), total revenues of Rs. 286.76 millions (Previous year Rs. 20.65 millions) and net cash inflows amounting Rs. 3.45 millions for the year ended on that date (Previous year Rs. 0.32 millions). These financial statements, as approved by the Board of Directors of the subsidiary companies, have been furnished to us by the management, and our report, in so far as it relates to the amounts included in respect of the subsidiaries, is based solely on such approved financial statements. However, the size of the subsidiaries is insignificant.

8. Report on Other Legal and Regulatory Requirements

- (A) As required by Section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.
 - c) The consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e) On the basis of the written representations received from the directors of the Holding Company and its subsidiaries which are incorporated in India, as on 31 March 2019 and taken on record by the Board of Directors of respective companies, none of the directors of the Group companies incorporated in India is disqualified as on 31 March 2019 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies incorporated in India and the operating effectiveness of such controls, refer to our separate report in Annexure A.
- (B) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Group has disclosed the impact of pending litigations on the consolidated financial position in consolidated financial statements as referred to in Note 2.32 to the financial statements.
 - ii. The Group has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, and as required on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company.

Consolidated Financial Statements

- (C) With respect to the matter to be included in the Auditors' Report under section 197(16):

In our opinion and according to the information and explanation given to us, the remuneration paid during the current year by the Holding Company and its subsidiaries which are incorporated in India is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director by the Holding Company and its subsidiaries which are incorporated in India, is not in excess of the limit laid down under Section 197 of the Act.

The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.

For **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(**Ashwani K. Gupta**)
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

ANNEXURE "A" TO THE AUDITORS' REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **NECTAR LIFESCIENCES LIMITED** ("the Company") as on 31 March 2019 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company and its subsidiaries which are incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding company and its subsidiaries, considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective entity's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Holding Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the

Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of change in conditions, or that the degree of compliance with the policies or procedure may deteriorate.

Opinion

In our opinion, the group has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Ashwani K. Gupta & Associates**
Chartered Accountants
Firm Regn. No. 003803N

(**Ashwani K. Gupta**)
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

CONSOLIDATED BALANCE SHEET As At 31st March 2019

Particulars	NOTE	As At March 31, 2019	As At March 31, 2018
ASSETS			
Non-Current Assets			
Property, plant and equipment	2.2	7,856.36	8,064.31
Capital work-in-progress		995.50	997.86
Intangible assets	2.3	391.82	459.24
Financial assets			
Investments	2.4	2.70	2.70
Trade receivables	2.5	48.09	36.81
Other financial assets	2.6	24.94	61.13
Other non-current assets	2.7	1,040.16	1,010.08
Total Non Current Assets		10,359.58	10,632.13
Current Assets			
Inventory	2.8	9,179.70	8,594.35
Financial assets			
Investments	2.4	5.05	5.10
Trade receivables	2.5	5,587.32	6,119.70
Cash and cash equivalents	2.9	213.27	93.11
Loans	2.10	3.82	3.79
Other financial assets	2.6	1,019.06	1,122.31
Other current assets	2.11	682.08	667.72
Total Current Assets		16,690.30	16,606.07
Total Assets		27,049.88	27,238.20
EQUITY AND LIABILITIES			
Equity			
Equity share capital	2.12	224.26	224.26
Other equity	2.13	10,827.35	10,362.34
Total Equity		11,051.61	10,586.60
Liabilities			
Non-Current Liabilities			
Financial liabilities			
Borrowings	2.14	1,655.90	2,200.76
Other financial liabilities	2.15	119.25	175.65
Other Non-Current Liability	2.16	8.71	8.96
Provisions	2.17	93.63	90.69
Deferred tax liabilities (net)	2.18	1,121.73	1,082.34
Total Non-Current Liabilities		2,999.22	3,558.39
Current Liabilities			
Financial liabilities			
Borrowings	2.14	6,359.69	6,340.83
Other financial liabilities	2.15	1,129.94	1,123.37
Trade payables	2.19		
Due to Micro, Small & Medium Enterprises		44.43	29.67
Due to Others		5,270.12	5,364.57
Other current liabilities	2.20	96.23	110.66
Provisions	2.17	8.58	4.88
Current tax liabilities (net)		90.07	119.23
Total Current Liabilities		12,999.05	13,093.21
Total Equity and Liabilities		27,049.88	27,238.20
Significant Accounting Policies	1		
Notes to Financial Statements	2		

For NECTAR LIFESCIENCES LIMITED

Sanjiv Goyal
Chairman & Managing Director

Dinesh Dua
CEO & Whole Time Director

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

CONSOLIDATED STATEMENT OF PROFIT AND LOSS ACCOUNT for the Year Ended March 31, 2019

Particulars	NOTE	Year Ended March 31, 2019	Year Ended March 31, 2018
Continuing Operations			
Revenue from Operations (Gross)	2.21	31,128.58	20,930.44
Less: GST Recovered		3,299.93	1,924.06
Revenue from Operations (Net of GST)		<u>27,828.65</u>	<u>19,006.37</u>
Other Income (Net)	2.22	60.40	60.41
		<u>27,889.05</u>	<u>19,066.78</u>
Expenses			
Raw Material Consumed	2.23	22,253.17	13,816.46
Purchase of Stock in Trade (Traded Goods)		428.17	152.73
(Increase)/ Decrease in Inventories of Finished Goods, Stock-in-Process and Stock in Trade	2.24	(504.28)	(299.09)
Excise duty		-	243.81
Employees Benefits Expense	2.25	799.00	784.05
Finance Cost	2.26	1,481.36	1,152.02
Depreciation & Amortization	2.2 & 2.3	632.57	643.09
Other Expenses	2.27	2,210.85	1,946.87
		<u>27,300.85</u>	<u>18,439.95</u>
Profit before exceptional items & tax		588.20	626.83
Exceptional items		-	-
Profit/(Loss) before tax		<u>588.20</u>	<u>626.83</u>
Tax Expenses		112.20	104.11
Profit for the period		<u>476.00</u>	<u>522.72</u>
Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
Remeasurement of the net defined benefit liability/asset (Net of Tax)		0.26	10.97
Items that will be reclassified subsequently to profit or loss			
Foreign Exchange Translation Reserve (Net of Tax)		2.25	(0.32)
Total Comprehensive income for the period		<u>478.51</u>	<u>533.37</u>
Earnings per equity share (Equity Shares of Re.1/- each fully paid up)			
Basic (Rs.)		2.12	2.33
Diluted (Rs.)		2.12	2.33
Significant Accounting Policies	1		
Notes to Financial Statements	2		

For NECTAR LIFESCIENCES LIMITED

Sanjiv Goyal
Chairman & Managing Director

Dinesh Dua
CEO & Whole Time Director

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

CONSOLIDATED CASH FLOW STATEMENT FOR YEAR ENDED 31st March 2019

PARTICULARS	As At March 31, 2019	As At March 31, 2018
CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before Tax & Extra Ordinary Items	588.20	626.83
Adjustments For :		
Depreciation & Amortization	632.57	643.09
Other Comprehensive Income (Net)	2.51	10.97
Other Comprehensive Income (Tax)	1.33	5.80
Provision for Doubtful debts/ Insurance Claims	4.58	3.64
Provision for Employees Retirement Benefits	6.64	4.36
Provision for Excise Duty On Finished Goods	-	(6.00)
Loss/ (Profit) on Sale of Fixed Assets	2.23	(3.43)
Loss/ (Profit) on Sale / Restatement of Investment	0.04	(0.01)
Interest on Borrowings	1,481.36	1,152.02
Other Non-Operating Income	(59.59)	(52.21)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	2,659.87	2,385.05
Adjustments For :		
(Increase)/Decrease in Current Assets	35.90	(1,685.68)
Increase/(Decrease) in Current Liabilities	(97.53)	109.17
Increase/(Decrease) in Long Term Liabilities	(56.39)	(12.18)
Increase/ (Decrease) in Non Current Liabilities	(0.25)	(0.25)
(Increase)/ Decrease in Non Current Assets	(13.66)	(18.26)
CASH GENERATED FROM OPERATIONS	2,527.94	777.87
Direct Taxes Paid	(135.59)	(126.20)
CASH FLOW BEFORE EXTRA-ORDINARY ITEMS	2,392.35	651.67
Extra-Ordinary Items	-	-
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	2,392.35	651.67
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(381.27)	(331.63)
Interest Received	59.59	52.21
Dividend Received	0.00	0.00
Sale of Fixed Assets	24.20	4.09
Sale/(Purchase) of Investments	0.00	(1.00)
Other Financial Assets Received/ (Paid)	36.18	(18.03)
NET CASH USED IN INVESTING ACTIVITIES (B)	(261.30)	(294.35)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds/(Repayment) from Term Loans from Banks	(526.67)	739.33
Proceeds/(Repayment) from Working Capital Limits from Banks	18.86	37.42
Proceeds/(Repayment) from Vehicle Loans	(8.22)	(7.26)
Dividend Paid	(13.50)	(13.50)
Interest Paid	(1,481.36)	(1,152.02)
NET CASH GENERATED FROM FINANCING ACTIVITIES (C)	(2,010.89)	(396.02)
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	120.16	(38.70)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	93.11	131.81
CASH & CASH EQUIVALENTS AT THE CLOSE OF THE YEAR	213.27	93.11

For NECTAR LIFESCIENCES LIMITED

Sanjiv Goyal
Chairman & Managing Director

Dinesh Dua
CEO & Whole Time Director

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019

Consolidated Financial Statements

1. SIGNIFICANT ACCOUNTING POLICIES

1.1 BASIS FOR PREPARATION OF FINANCIAL STATEMENTS

These financial statements have been prepared to comply with the Indian Accounting Standards (Ind AS). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

The financial statements are prepared on accrual basis under the historical cost convention. The financial statements are presented in Indian rupees rounded off to the nearest rupees in millions.

The Company has adopted all the Ind AS standards mandatorily applicable and the adoption was carried out in accordance with Ind AS 101 "First time adoption of Indian Accounting Standards". The transition was carried out from Indian Accounting Principles generally accepted in India as prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (IGAAP), which was the previous GAAP.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

1.2 USE OF ESTIMATES

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

1.3 PROPERTY, PLANT & EQUIPMENT

- i) Property, Plant & Equipment have been stated at cost, net of cenvat/ goods and service tax availed, but inclusive of attributable costs of bringing the assets to their working condition for their intended use, less depreciation and impairment loss, if any. Depreciation on assets is provided on straight line method in the manner prescribed in Schedule II to the Companies Act, 2013
- ii) Cost of leasehold assets is amortized over the period of the lease.

1.4 INTANGIBLE ASSETS

Intangible assets are stated at cost less accumulated amortization and impairment, wherever applicable. Intangible assets are amortized over their respective individual estimated useful lives on a straight line basis, from the date they are available for use. The estimated useful life of an identifiable asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances), and the level of maintenance expenditures required to obtain the expected future

cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The research costs are expensed as incurred. The development costs, which can be capitalized, include the cost of material, direct labour and overhead costs that are directly attributable to preparing the asset for its intended use.

1.5 INVESTMENTS

Investments are classified into current and long term investments. Long Term Investments are stated at cost and provision for diminution in value is made if decline is other than temporary in the opinion of the management. Current Investments are valued at cost and provision is made for decline in market value, if any.

1.6 REVENUE RECOGNITION

- i) Revenue from product sales is stated exclusive of returns, inter-division transfers, Sales Tax but includes Excise Duty and Goods and Service tax.
- ii) Dividend income is recognized as and when the right to receive is established.
- iii) Export benefits and other benefits are accounted for on accrual basis. Export entitlements are recognized as reduction from material consumption when the right to receive credit is established in respect of the exports made and when there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

1.7 FINANCIAL INSTRUMENTS

A. Initial recognition

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, that are not at fair value through profit or loss, are added to the fair value on initial recognition.

B. Subsequent measurement

a. Non-derivative financial instruments

- i. Financial assets carried at amortized cost

A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

- ii. Financial assets at fair value through other comprehensive income

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company has made an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income based on its business model. Further, in cases where the Company has made an irrevocable election based on its business model, for its investments which are classified as

Consolidated Financial Statements

equity instruments, the subsequent changes in fair value are recognized in other comprehensive income.

iii. Financial assets at fair value through profit or loss

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

iv. Financial liabilities

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

v. Investment in subsidiaries

Investment in subsidiaries is carried at cost in the separate financial statements.

b. *Derivative financial instruments*

The Company holds derivative financial instruments such as foreign exchange forward and option contracts to mitigate the risk of changes in exchange rates on foreign currency exposures. The counterparty for these contracts is generally a bank.

C. Derecognition of financial instruments

The company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognized from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

D. Fair value of financial instruments

In determining the fair value of its financial instruments, the Company uses a variety of methods and assumptions that are based on market conditions and risks existing at each reporting date. The methods used to determine fair value include discounted cash flow analysis, available quoted market prices and dealer quotes. All methods of assessing fair value result in general approximation of value, and such value may never actually be realized.

1.8 INVENTORIES

i) Raw materials, Stores and Spares and Packing material

Lower of cost and net realizable value. Cost of inventory comprises all cost of purchase and other cost incurred in bringing the inventories to their present location and condition.

ii) Finished Goods and work in process

Lower of cost and net realizable value. Cost includes direct material, labour and proportionate manufacturing overheads.

iii) Traded goods

Lower of Cost and Net Realizable Value. Cost includes the purchase price and other associated costs directly incurred in bringing the inventory to its present location. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

1.9 FOREIGN EXCHANGE TRANSACTIONS

i) Initial Recognition

Investments in foreign entities are recorded at the exchange rate prevailing on the date of making the investment. Transactions denominated in foreign currencies are recorded at the exchange rates prevailing on the date of the transaction.

ii) Conversion

Monetary assets and liabilities denominated in foreign currencies, as at the balance sheet date, not covered by forward exchange contracts, are translated at year end rates.

iii) Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in the previous financial statements, are recognized as income or expense in the year in which they arise and as per Ind AS 21, exchange differences arising on account of consolidation with foreign operation, are recognized in Other Comprehensive Income. The exchange difference on foreign currency denominated long term borrowings relating to the acquisition of depreciable capital assets are adjusted in the carrying cost of such assets for current year. The Company has opted for voluntary exemption given in Ind AS-101, which allows first time adopter to continue its Indian GAAP policy for accounting of exchange difference arising on translation of long term foreign currency monetary items recognized in the financial statements for the period ending immediately before the beginning of the first Ind AS financial reporting period.

1.10 EMPLOYEE BENEFITS

i) Short Term Employee Benefits:

Employee benefits payable fully within twelve months of rendering the service are classified as short term employee benefits and are recognized in the period in which the employee renders the related service.

Contribution to the Provident Fund, which is a defined contribution scheme, is recognized as an expense in the profit and loss account in the period in which the contribution is due.

ii) Long Term Employee Benefits

Post Employment Benefits (Defined Benefit Plans)

The employee gratuity scheme is a defined benefit plan. The present value of the obligation under such defined benefit plan is determined at Balance Sheet date based on an actuarial valuation carried out by an independent actuary using the projected unit credit method. Actuarial gains and losses and past service cost are recognized immediately in other comprehensive income.

Long term employee benefit also comprises of compensated absences. These are measured based on actuarial valuations carried out by an independent actuary using the projected unit method at balance sheet date unless they are insignificant. Actuarial gains and losses and past service cost are recognized immediately in other comprehensive income.

Consolidated Financial Statements

1.11 CASH FLOW STATEMENT

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

1.12 DIVIDENDS

Final dividends on shares are recorded as a liability on the date of approval by the shareholders.

1.13 OTHER INCOME

Other income is comprised primarily of interest income, dividend income and profit/ loss on sale of investment/ fixed assets. Dividend income is recognized when the right to receive payment is established.

1.14 BORROWING COSTS

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized. Other borrowing costs are recognized as an expense in the period in which they are incurred.

1.15 LEASES

Leases, where the lessor retains substantially all the risks and benefits of the ownership of the leased item are classified as operating leases. Lease rentals for assets taken on operating lease are charged to the profit and loss account in accordance with Indian Accounting Standard (Ind AS 19) on "Leases".

1.16 GOVERNMENT GRANTS AND SUBSIDIES

Grants and Subsidies are recognized when there is a reasonable assurance that the grant or subsidy will be received and that all underlying conditions will be complied with. When the grant or subsidy relates to an asset, such grant is recognized in Statement of Profit and Loss on a systematic basis over the useful life of the asset.

1.17 EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

1.18 IMPAIRMENT OF ASSETS

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired. Impairment occurs where the carrying value of future cash flows expected to arise from the continuing use of the assets and its eventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net sales price or present value as determined above.

1.19 INCOME TAXES

Income tax expense comprises current and deferred income tax. Income tax expense is recognized in net profit in the statement of profit and loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in other comprehensive income.

Current income tax for current and prior periods is recognized at the amount expected to be paid to or recovered from the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date. Deferred income tax assets and liabilities are recognized for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

2. NOTES TO FINANCIAL STATEMENTS

2.1 COMPANY OVERVIEW

Nectar Lifesciences Limited (CIN: L24232PB1995PLC016664) is an integrated pharmaceutical organization, incorporated in 1995, having its corporate office in Chandigarh and works in the states of Punjab and Himachal Pradesh. The Company has sustainable production systems to manufacture APIs and Formulations. With an expertise in R&D, the Company has been experiencing growth in this segment. The Company is also in the Menthol business and succeeded in both domestic and international markets. The Company has its primary listings on the BSE Limited and National Stock Exchange of India Limited.

NOTE - 2.2 “PROPERTY, PLANT AND EQUIPMENT”

Particulars	GROSS BLOCK			DEPRECIATION			NET BLOCK			
	As At 01-Apr-18	Additions	Sale/ Deletion	As At 31-Mar-19	Up To 31-Mar-18	During the Year	Deletion/ Adjustments	Up To 31-Mar-19	As At 31-Mar-19	As At 31-Mar-18
Freehold Land & Site Development	955.95	2.52	25.54	932.93	-	-	-	-	932.93	955.95
Leasehold Land	3.27	-	-	3.27	0.41	0.04	-	0.45	2.82	2.87
Buildings	1,615.01	34.07	-	1,649.07	462.37	50.42	-	512.79	1,136.28	1,152.64
Tube Well	22.66	-	-	22.66	15.40	2.33	-	17.73	4.93	7.26
Plant & Machinery *	8,646.43	221.88	-	8,868.31	3,708.42	315.67	-	4,024.08	4,844.22	4,938.01
Boiler	170.70	-	-	170.70	92.08	8.93	-	101.02	69.68	78.62
Pollution Control Equipment	75.25	-	-	75.25	58.90	5.68	-	64.58	10.67	16.35
Laboratory	110.05	1.27	-	111.32	77.21	5.57	-	82.78	28.54	32.84
Miscellaneous Fixed Assets	1,500.04	29.84	-	1,529.89	696.05	70.40	-	766.45	763.44	804.00
Furniture & Fixture	100.71	0.32	-	101.03	71.72	6.39	-	78.11	22.92	29.00
Motor Vehicles	111.69	0.60	16.68	95.61	68.22	7.21	15.80	59.63	35.98	43.47
Computer	44.57	1.53	-	46.10	41.25	0.90	-	42.14	3.95	3.32
GRAND TOTAL	13,356.33	292.02	42.22	13,606.13	5,292.02	473.55	15.80	5,749.76	7,856.36	8,064.31
Previous Year	13,062.24	294.82	0.73	13,356.33	4,824.27	467.81	0.06	5,292.02	8,064.31	8,237.97

*includes addition on account of foreign exchange fluctuation on ECB amounting to Rs. 53.03 Millions (Previous Year addition of Rs. 2.14 Millions)

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.3 "INTANGIBLE ASSETS"

Opening Gross Block	1,207.22	1,147.13
Additions during the year	91.60	60.09
Closing Gross Block	1,298.82	1,207.22
Opening Accumulated amortization	747.98	572.70
Amortization during the year	159.03	175.28
Closing Accumulated amortization	907.00	747.98
Net Intangible Assets	391.82	459.24

NOTE - 2.4 "INVESTMENTS"

Non Current Investments

Investment in Equity Instruments

UNQUOTED

In Others

2,20,000 (Previous Year 2,20,000) Equity Shares of Rs. 10/- each Fully paid up In Mohali Green Environment Private Limited	2.20	2.20
50,000 Equity Shares of RS. 10/- each, fully paid up in Nimbua Greenfield (Punjab) Ltd.	0.50	0.50
20 Equity Shares of Rs. 50/- each in The Thane Janta Sahakari Bank Ltd [Absolute amount Rs. 1,000 (Previous Year Rs.1,000)]	0.00	0.00

Total - "A"	2.70	2.70
--------------------	-------------	-------------

Current Investments

Investment in Equity Instruments

QUOTED

5 Equity Shares of Re. 1/- each, Fully Paid Up In Aurobindo Pharma Ltd. [Absolute amount Rs. 314 (Previous Year Rs. 314)]	0.00	0.00
4,700 Equity Shares of Rs. 5/- each, Fully Paid Up In Parsvanath Developers Ltd.	1.31	1.31
SBI PSU Fund	1.00	1.00
PRINCIPAL BALANCED FUND	1.00	1.00
3,000 Bonds of IFCI @ Rs. 1,000/- Each	3.00	3.00

UNQUOTED

2,500 Equity Shares of Rs. 10/- each, Fully Paid Up In Saraswat Co-operative Bank Ltd.	0.03	0.03
--	------	------

Total "B"	6.34	6.34
------------------	-------------	-------------

Provision for Loss on Investment "C"	1.28	1.24
--------------------------------------	------	------

Net Current Investments "D" ("B" - "C")	5.05	5.10
--	-------------	-------------

Total Investment "A" + "D"	7.76	7.80
-----------------------------------	-------------	-------------

Market value of Quoted Investment Rs. 6.45 Millions (Previous Year Rs. 5.15 Millions)

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
NOTE - 2.5 "TRADE RECEIVABLES"		
Unsecured consists of following		
Non Current		
Considered Good	48.09	36.81
Considered Doubtful	97.78	93.20
	145.87	130.01
Less: Provision For Doubtful Debts	97.78	93.20
Total - "A"	48.09	36.81
Current		
Considered Good	5,587.32	6,119.70
Considered Doubtful	-	-
	5,587.32	6,119.70
Less: Provision For Doubtful Debts	-	-
Total - "B"	5,587.32	6,119.70
Total Trade Receivables ("A" + "B")	5,635.41	6,156.51

NOTE - 2.6 "OTHER FINANCIAL ASSETS"

Non Current		
Balances Recoverable from Revenue Authorities	24.94	61.13
Insurance Claim Receivable :		
Considered Good	-	-
Considered Doubtful	21.15	21.15
	46.09	82.28
Less: Provision for Doubtful Insurance Claim	21.15	21.15
Total - "A"	24.94	61.13
Current		
Export and Other Incentives Accrued	520.35	390.73
Balances with Revenue Authorities	429.10	661.09
Other Recoverables	10.27	6.18
Insurance Claim Receivable :		
Considered Good	59.33	64.32
Considered Doubtful	-	-
	1,019.06	1,122.31
Less: Provision for Doubtful Insurance Claim	-	-
Total - "B"	1,019.06	1,122.31
Total Other Financial Assets ("A" + "B")	1,044.00	1,183.44

NOTE - 2.7 "OTHER NON-CURRENT ASSETS"

Security Deposits	19.12	21.32
MAT Credit Entitlement	1,016.04	983.76
Others	5.00	5.00
	1,040.16	1,010.08

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.8 "INVENTORY"

(As Certified by The Management)

Raw Material	1,006.96	947.49
Work In Progress	5,993.30	6,970.22
Finished Goods	1,920.22	434.23
Stock in Trade	38.12	42.91
Other Miscellaneous Stocks	221.09	199.50
	9,179.70	8,594.35

NOTE - 2.9 "CASH & CASH EQUIVALENTS"

Balance with Banks	197.23	80.30
Balances in Dividend Accounts	0.38	0.39
Cash In Hand (Incl Staff Imprest)	15.66	12.42
	213.27	93.11

NOTE - 2.10 "LOANS"

Loans & Advances to Staff	3.82	3.79
	3.82	3.79

NOTE - 2.11 "OTHER CURRENT ASSETS"

Advances other than capital advances		
Payment to vendors for supply of goods	554.00	580.73
Others	128.08	86.99
	682.08	667.72

NOTE - 2.12 "SHARE CAPITAL"

Authorised Share Capital

35,00,00,000 Equity Shares of Re. 1/- Each.	350.00	350.00
---	--------	--------

Issued, Subscribed & Paid up Capital

22,42,60,970 Equity Shares of Re. 1/- Each Fully Paid up	224.26	224.26
--	--------	--------

(Also Refer Note 2.28)

224.26	224.26
---------------	---------------

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

NOTE - 2.13 "OTHER EQUITY"

Statement of Change in Equity (FY 2018-19)

Particulars	Equity Share Capital	Other Equity			Total equity attributable to equity holders
		Security Premium	General Reserves	Retained Earnings	
Balance as of April 1, 2018	224.26	3,287.98	141.02	6,933.33	10,586.60
Changes in equity for the year ended March 31, 2019					
Add: - Profit for the period	-	-	-	478.51	478.51
Less: - Corporation tax of USA paid	-	-	-	-	-
Less: - Final Dividend & Tax on Dividend	-	-	-	13.50	13.50
Balance as of March 31, 2019	224.26	3,287.98	141.02	7,398.35	11,051.61

Statement of Change in Equity (FY 2017-18)

Particulars	Equity Share Capital	Other Equity			Total equity attributable to equity holders
		Security Premium	General Reserves	Retained Earnings	
Balance as of April 1, 2017	224.26	3,287.98	141.02	6,413.50	10,066.76
Changes in equity for the year ended March 31, 2018					
Add: - Profit for the period	-	-	-	533	533.37
Less: - Corporation tax of USA paid	-	-	-	0.03	0.03
Less: - Final Dividend & Tax on Dividend	-	-	-	13.50	13.50
Balance as of March 31, 2018	224.26	3,287.98	141.02	6,933.33	10,586.60

Particulars	As At	As At
	March 31, 2019	March 31, 2018

NOTE - 2.14 "BORROWINGS"

Non Current

Secured

Term Loans

From Banks

1,644.00

2,182.09

Unsecured

Vehicle Loans

From Banks

11.62

17.39

From Others

0.28

1.28

1,655.90

2,200.76

(Also Refer Note 2.30)

Current

Secured

Working Capital Limits

From Banks

6,156.40

6,041.51

Unsecured

From Banks

203.29

299.32

6,359.69

6,340.83

Total Borrowings

8,015.58

8,541.59

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.15 “OTHER FINANCIAL LIABILITIES”

Non Current

Security from Customers	-	1.85
Other Capital Advances	119.25	173.79
	119.25	175.65

Current

Current Maturities of Long Term Debts	1,012.07	1,000.65
Current Maturities of Finance Lease obligations	6.85	8.30
Interest Accrued but not due on Borrowings	21.19	33.62
Unpaid Dividends	0.38	0.39
Accrued Compensation to Employees	55.66	52.20
Statutory dues payable	13.11	12.26
Accrued Expenses	20.69	15.95
	1,129.94	1,123.37
Total Other Financial Liabilities	1,129.94	1,123.37

NOTE - 2.16 “OTHER NON CURRENT LIABILITIES”

Non Current

Deferred Income	8.71	8.96
	8.71	8.96

NOTE - 2.17 “PROVISIONS”

Non Current

Provision for Employees Retirement Benefits	93.63	90.69
	93.63	90.69

Current

Provision for Employee Retirement Benefits	8.58	4.88
	8.58	4.88
Total Provisions	102.21	95.57

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
--------------------	---------------------------------	---------------------------------

NOTE - 2.18 “DEFERRED TAX LIABILITY”

Tax Impact on Deferred Tax Liability arising on account of:
Depreciation

	<u>1,189.04</u>	<u>1,146.83</u>
Total - “A”	<u>1,189.04</u>	<u>1,146.83</u>

Tax Impact on Deferred Tax Assets arising on account of:

Employees Retirement Benefits	35.37	33.07
Other Expenses & Provisions	41.16	39.30

Total - “B”	<u>76.53</u>	<u>72.38</u>
--------------------	---------------------	---------------------

Net Deferred Tax Liability (“A” - “B”)	<u>1,112.50</u>	<u>1,074.45</u>
---	------------------------	------------------------

Impact of Other Comprehensive Income	9.08	8.94
Impact of Foreign Exchange Translation Reserve	0.15	(1.05)
Net Deferred Tax Liability	<u>1,121.73</u>	<u>1,082.34</u>

NOTE - 2.19 “TRADE PAYABLES”

Due to Micro, Small & Medium Enterprises	44.43	29.67
Due to Others	5,270.12	5,364.57
	<u>5,314.55</u>	<u>5,394.24</u>

NOTE - 2.20 “OTHER CURRENT LIABILITIES”

Advances From Customers	96.23	110.66
	<u>96.23</u>	<u>110.66</u>

NOTE - 2.21 “REVENUE FROM OPERATIONS”

Sale of Manufactured Products		
Export	10,669.50	9,518.55
Domestic	19,935.63	11,191.73
Trading Sale		
Export	24.88	4.09
Domestic	498.57	216.07
	<u>31,128.58</u>	<u>20,930.44</u>

NOTE - 2.22 “OTHER INCOME”

Operating Income

Other Operating Income	0.60	4.32
Deferred Income - Govt. Grants	0.25	0.25

Other Income

Interest Income	59.59	52.21
Dividend From Investments	0.00	0.00
[Absolute amount Rs. 4,400 (Previous year Rs. 38)]		
Compensation on Sale of Land	-	3.62
Profit/ (Loss) on Restatement of Investment	(0.04)	0.01
	<u>60.40</u>	<u>60.41</u>

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	As At March 31, 2019	As At March 31, 2018
-------------	-------------------------	-------------------------

NOTE - 2.23 "RAW MATERIAL CONSUMED"

Opening Stock	947.49	1,211.33
Add:- Purchase of Raw Material	22,312.65	13,552.62
	23,260.13	14,763.95
Less :- Closing Stock	1,006.96	947.49
	22,253.17	13,816.46

NOTE - 2.24 "(INCREASE)/ DECREASE IN INVENTORIES OF FINISHED GOODS, STOCKS IN PROCESS & STOCK IN TRADE"

Inventory (At Close)

Finished Goods	1,920.22	434.23
Stock in Process	5,993.30	6,970.22
Stock in Trade	38.12	42.91
	7,951.64	7,447.36

Inventory (At Commencement)

Finished Goods	434.23	166.69
Stock in Process	6,970.22	6,915.57
Stock in Trade	42.91	66.01
	7,447.36	7,148.28
	(504.28)	(299.09)

NOTE - 2.25 "EMPLOYEE BENEFIT EXPENSES"

Salaries & Wages	642.53	608.44
Remuneration To Directors	33.56	37.54
Contribution to Provident and Other Funds	34.08	34.98
Staff Welfare	88.83	103.10
	799.00	784.05

NOTE - 2.26 "FINANCIAL EXPENSES"

Interest Expenses	878.23	883.67
Other Borrowing Costs & Foreign Exchange Fluctuation(Net)	603.12	268.36
	1,481.36	1,152.02

Consolidated Financial Statements

Nectar Lifesciences Limited

(Rs. in Millions)

Particulars	Year Ended March 31, 2019	Year Ended March 31, 2018
-------------	------------------------------	------------------------------

NOTE - 2.27 "OTHER EXPENSES"

Manufacturing Expenses

Consumable Stores	158.20	143.88
Power, Fuel & Steam Expenses	1,032.41	916.28
Chemical Testing Expenses	25.96	19.26
Packing Expenses	170.72	203.97
Repairs & Maintenance		
Electricals	8.98	14.27
Machinery	124.10	131.64
Building	10.72	11.06
Total - "A"	1,531.08	1,440.36

Administrative Expenses

Travelling & Conveyance	27.96	32.38
Advertisement & Subscription	0.66	0.65
Books & Periodicals	0.18	0.13
Business Promotion	6.58	3.62
Insurance	39.62	24.95
Electricity Expenses (Office)	2.27	2.26
Postage, Telephone, Telegram	10.03	11.23
Printing & Stationery	5.97	9.51
Professional Fees	37.45	44.94
Rate, Fees & Taxes	36.45	43.19
Vehicle Running & Maintenance	5.15	4.96
Rent	13.05	13.92
Audit Fees	2.50	2.50
Office Expenses	7.49	5.28
Diwali & Pooja Expenses	3.67	4.44
Donation	22.75	15.22
Directors' Sitting Fees	0.22	0.18
Loss on Sale of Fixed Assets	2.23	0.19
Total - "B"	224.23	219.53

Selling & Distribution Expenses

Discount & Samples	40.55	21.92
Freight & Cartage Outward	292.61	160.96
Sales Commission	116.19	100.02
Provision for Doubtful Debts/ Insurance claim	6.19	4.08
Total - "C"	455.54	286.98
Grand Total ("A" + "B" + "C")	2,210.85	1,946.87

Consolidated Financial Statements

2.28 DETAIL OF SHAREHOLDERS HOLDING MORE THAN 5% SHARES

Particulars	As at 31 st March, 2019		As at 31 st March, 2018	
	Number of shares held	Percentage of shares held	Number of shares held	Percentage of shares held
Mr. Sanjiv Goyal	55555600	24.77	55555600	24.77
NSR Direct PE Mauritius, LLC (Name changed to Isengard Direct PE LLC)	26000000	11.59	26000000	11.59
Depository of GDRs	46000000	20.51	46000000	20.51
Sanjiv (HUF)	43379400	19.34	43379400	19.34

Note: Since, the equity shares underlying GDRs are held by Deutsche Bank Trust Company Americas being depository of GDRs, hence disclosed per se.

Reconciliation of the number of shares outstanding:

Particulars	As at	
	31 st March, 2019	31 st March, 2018
Equity shares at the beginning of the year	224260970	224260970
Add: Shares issued during the year	Nil	Nil
Equity shares at the end of the year	224260970	224260970

2.29 SECURED LOANS

- I. Term Loans from various banks are secured by way of First Pari Passu Charge on all the fixed assets of the Group and further secured by way of Second Pari Passu Charge on all the current assets of the Group and personal guarantee of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.
- II. Corporate Loans from Financial Institution are secured by way of personal guarantee/ pledging of equity shares of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.

Repayment Schedule of Term Loans:

Year of Repayment	Amount (Rs. in Millions)
1-2	654.00
2-5	850.00
>5	140.00

Term Loans availed by the Group include term loans from various Banks/Financial Institutions.

Other Loans comprise of Vehicle Loans which are secured against hypothecation of respective vehicles.

Repayment Schedule of Vehicle Loans:

Year of Repayment	Amount (Rs. in Millions)
1-2	5.17
2-5	6.73
>5	-

- III. Working Capital Limits are secured by way of First Pari Passu Charge on all the current assets of the Group and further secured by way of Second Pari Passu Charge on all the fixed assets of the Group and personal guarantee of directors/relative of a director namely Sh. Sanjiv Goyal and Sh. Aryan Goyal.

2.30 CURRENT ASSETS, LOANS & ADVANCES

In the opinion of the management of the Group, the current assets, loans and advances are approximately of the value as stated, if realized in the ordinary course of business and are subject to confirmation/reconciliation.

2.31 CURRENT LIABILITIES

- I. The principal amount remaining unpaid as at 31st March 2019 in respect of enterprises covered under the "Micro, Small and Medium Enterprises Development Act, 2006" are Rs.44.43millions (Previous year Rs.29.67millions). The interest amount computed based on the provisions under Section 16 of the MSMED Act Rs.3.25millions (Previous year Rs.2.21 millions) is remaining unpaid as at 31st March 2019. The principal amount that remained unpaid as at 31st March 2018 was paid during the year. The list of undertakings covered under MSMED Act was determined by the Company on the basis of information available with the Company and have been relied upon by the auditors.

- II. Investor Education and Protection Fund

Other liabilities include Rs. 0.38millions (previous year Rs.0.34million) which relates to unclaimed dividend and share application money refundable. During the year, Rs.0.05millions was deposited relating to unclaimed dividend and share application money refundable to the Investor Education and Protection Fund (Previous year Nil)

2.32 CONTINGENT LIABILITIES AND COMMITMENTS

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
a)	Contingent Liabilities		
i)	Claims not acknowledged as debts:- *		
	-Income Tax matters**	114.31	5.97
	-Excise matters***	12.53	430.20#
	-Service Tax matters****	7.22#	7.22#
ii)	Bank Guarantees	14.14	13.11
iii)	Bills Discounted	-	47.91
iv)	Letter of Credit (Foreign / Inland)	286.12	222.42
b)	Commitments		
i)	Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advance)	97.35	31.31

* The matters are subject to legal proceedings in the ordinary course of business. In the opinion of the management, legal proceedings for above cases, when ultimately concluded will not have a material effect on the results of operation or financial position of the company.

** Amount deposited under protest Rs. 3.01 millions and MAT credit entitlement would be reduced by Rs. 108.34 millions, in case of adverse judgment.

*** Amount deposited under protest Rs. 5.90 millions

**** Amount deposited under protest Rs. 0.52 millions

In case demand is confirmed, penalty up to equivalent amount may be imposed.

2.33 PAYMENT TO AUDITORS

(Rs. in millions)

Particulars	2018-19	2017-18
Statutory Audit and Limited Review Fees	2.10	2.10
Tax Audit Fee	0.40	0.40
GST	0.45	0.45

Consolidated Financial Statements

2.34 INCOME TAX

Current Tax

Provision for Current Income Tax has been made as per Income Tax Act, 1961, based on legal opinion obtained by the Company from its income tax consultant and the statutory auditors have relied upon the said legal opinion for the purpose of current income tax.

Deferred Tax

In compliance with Indian Accounting Standard (Ind AS 12) relating to "Income Taxes" issued under Companies (Indian Accounting Standards) Rules, 2016 as amended up to date, the Company has provided Deferred Tax Liability accruing during the year aggregating to Rs. 38.06 millions (Previous Year Rs. 40.89 millions) and it has been recognized in the Statement of Profit & Loss. In accordance with Indian Accounting Standard (Ind AS 12) Deferred Tax Assets and Deferred Tax Liabilities have been set off.

2.35 LEASES

Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable/ cancellable at mutual consent. There are no restrictions imposed by lease arrangements. There are no sub leases. Lease payments recognized in the Statement of Profit & Loss are Rs. 13.05 millions (Previous Year Rs. 13.92 millions).

2.36 INTANGIBLE ASSETS

During the year, Group incurred an amount of Rs. 91.60 millions (Previous Year Rs. 60.09 millions) on product development, product approval, US FDA Fees, Abbreviated New Drug Application (ANDA) Fees and such other related development expenses, recognized as Intangible Assets in the books of accounts, and the same is amortized on a straight line basis over a period of seven years.

2.37 EMPLOYEE RETIREMENT BENEFITS

- Benefits valued: Gratuity & Earned leave (both availment & encashment)
- Nature of the plans: Defined benefit; both gratuity & compensated absence
Liabilities are unfunded

- Valuation method: Projected Unit Credit Method

Changes in Present Value of Obligations

(Rs. in millions)

	Gratuity	Earned leave
Present Value of Obligations as at 1st April 2018	62.32	33.21
Acquisition adjustment	-	-
Interest Cost	5.28	2.01
Past Service Cost	-	-
Current Service Cost	9.75	1.0
Curtailment Cost/(Credit)	-	-
Settlement Cost/(Credit)	-	-
Benefits paid	(4.72)	(6.24)
Actuarial (gain)/loss on obligations	1.29	(1.69)
Present Value of obligations as at 31 st March 2019	73.91	28.29

Changes in the Fair Value of Plan Assets

(Rs. in millions)

	Gratuity	Earned leave
Fair Value of Plan Assets as at 1st April 2018	-	-
Acquisition Adjustments	-	-
Expected Return on Plan Assets	-	-
Contributions	-	-
Benefits Paid	-	-
Actuarial Gain/(loss) on Plan Assets	-	-
Fair Value of Plan Assets as at 31 st March 2019	-	-

Fair Value of Plan Assets

(Rs. in millions)

	Gratuity	Earned leave
Fair Value of Plan Assets as at 1st April 2018	-	-
Acquisition Adjustments	-	-
Actual Return on Plan Assets	-	-
Contributions	-	-
Benefits Paid	-	-
Fair Value of Plan Assets as at 31 st March 2019	-	-
Funded Status	73.91	28.29

Actuarial Gain/Loss Recognized

(Rs. in millions)

	Gratuity	Earned leave
Actuarial gain/(loss) for the year – Obligation	(1.29)	1.69
Actuarial gain/(loss) for the year – Plan Assets	-	-
Total gain/(loss) for the year	(1.29)	1.69
Actuarial (gain)/ loss recognized in the year	1.29	(1.69)
Unrecognized actuarial (gains)/losses at the end of year	-	-

Amount recognized in the Balance Sheet

(Rs. in millions)

	Gratuity	Earned leave
Present value of obligations as at 31 st March 2019	73.91	28.29
Fair value of plan assets as at 31 st March 2019	-	-
Funded Status	73.91	28.29
Unrecognized actuarial (gains)/losses	-	-
Net asset/(liability) recognized in the balance sheet	(73.91)	(28.29)

Expenses recognized in the Statement of Profit & Loss

(Rs. in millions)

	Gratuity	Earned leave
Current service cost	9.75	1.0
Past service cost	-	-
Interest cost	5.28	2.01
Expected return on plan assets	-	-
Curtailment cost/(credit)	-	-
Settlement cost/(credit)	-	-
Actuarial Loss/(gain) recognized in the year	-	(1.69)
Expenses recognized in the Statement of Profit & Loss	15.03	1.32

Consolidated Financial Statements

Amount recognized as other comprehensive income

(Rs. in millions)

	Gratuity	Earned leave
Actuarial loss on DBO	1.29	-
Excess of interest on plan assets over actual return	-	-
Change in the effect of asset ceiling	-	-
Expense recognized as other comprehensive income	1.29	-

Valuation Assumptions

Discount Rate	7.7%
Estimated rate of increase in compensation levels	7%
Attrition Rate	Table A
Mortality Rates	Table B

The estimated rate of increase in compensation levels takes into account inflation, seniority, promotion and other relevant factors such as demand and supply in the employment market.

Table A

Age	Rates
Upto 30 years	3%
31-44 years	2%
Above 44 years	1%

Table B

Age	Mortality Rates	Age	Mortality Rates
20	0.000888	70	0.025855
30	0.001056	80	0.060558
40	0.001803	90	0.138895
50	0.004946	100	0.311628
60	0.011534	110	0.685737

2.38 TAX EXPENSE COMPRISES OF:

(Rs. in millions)

	2018-19	2017-18
- Current Tax	106.43	124.28
- Deferred Tax	38.06	40.89
- MAT Credit Entitlement (net)	(32.28)	(61.06)
	112.20	104.11

2.39 SEGMENT REPORTING

i) Primary Segment (Business Segment)

The Group operates only in the business segment of "Pharmaceuticals Products", and in the opinion of the management the inherent nature of activities in which it is engaged are governed by the same set of risks and reward. As such the activities are identified as single segment in accordance with the Indian Accounting Standard (Ind AS 108) issued under Companies (Indian Accounting Standards) Rules, 2016 as amended up to date.

ii) Secondary Segment (By Geographical Segment)

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
(a)	India	20434.20	11407.80
(b)	Outside India	10694.38	9522.64
	Total Sales (inclusive of GST)	31128.58	20930.44

In view of the interwoven / intermix nature of business and manufacturing facility, other segmental information is not ascertainable.

2.40 RELATED PARTY DISCLOSURES

Related party disclosures as required under Indian Accounting Standard (Ind AS 24) on "Related Party Disclosures" issued under Companies (Indian Accounting Standards) Rules 2016, as amended upto date, are given below: -

a) Relationship

i) Joint Ventures and Associates

None

ii) Key Management Personnel (Managing Director/Whole-time directors/CFO/Company Secretary)

Sh. Sanjiv Goyal, Chairman & Managing Director

Sh. Dinesh Dua, CEO & Whole time Director

Sh. Harprakash Singh Gill, President (upto 28.02.2019)

Sh. Sandeep Goel, Chief Financial Officer

Ms. Ankita Jain, Company Secretary

iii) Relatives of the Key Management Personnel*

Sh. Saurabh Goyal (upto 30.11.2018)

Sh. Aryan Goyal (upto 30.11.2018)

Smt. Raman Goyal

** With whom the Group had transactions during the year

iv) Entities over which key management personnel/their relatives are able to exercise significant influence*

Surya Narrow Fabrics (Proprietary concern)

Nectar Lifesciences Charitable Foundation (CSR vehicle of the company)

Nectar Biopharma Private Limited

* With whom the Company had transactions during the year.

b) The following transactions were carried out with related parties in the ordinary course of business.

i) Key Management Personnel and their relatives

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
i.	Director Remuneration & Perquisites*	33.64	37.62
ii.	Salary & Perquisites*	15.02	20.08
iii.	Rent	1.20	-

*Includes Taxable Perquisites as per Income Tax Act 1961

ii) Entities over which key management personnel/their relatives are able to exercise significant influence

(Rs. in millions)

S. No.	Particulars	31.03.2019	31.03.2018
i.	Rent	-	0.72
ii.	CSR expenditure through CSR vehicle	1.54	1.65
iii.	Net Sales (inclusive of applicable indirect taxes)	472.57	205.09
iv.	Net Purchases (inclusive of applicable indirect taxes)	13.03	12.50
v.	Balance due at the year end (net receivable)	98.08	65.14

2.41 DERIVATIVES

Currency derivatives

The Group uses foreign currency forward contracts and currency options to hedge its risks associated with foreign currency

Consolidated Financial Statements

fluctuations relating to certain firm commitments and forecasted transactions. The use of foreign currency forward contracts and currency options is governed by Company's strategy. The Group does not use forward contracts and currency options for speculative purposes.

2.42 EARNINGS PER SHARE (EPS)

Particulars	Unit	Year Ended 31.03.2019	Year Ended 31.03.2018
Profit After Tax, before OCI	Rs. in millions	476.00	522.72
No of Shares Outstanding	Nos.	224260970	224260970
No of Weighted Average equity shares	Nos.	224260970	224260970
Diluted	Nos.	224260970	224260970
Nominal value of equity shares	Rs.	1.00	1.00
Earnings per Share			
-Basic	Rs.	2.12	2.33
-Diluted	Rs.	2.12	2.33

2.43 Other Borrowing Costs include Loss on account of foreign exchange fluctuation (net) amounting to Rs. 204.99 millions (Previous Year net gain of Rs. 46.55 millions).

2.44 DETAIL OF IMPORTED AND INDIGENOUS RAW MATERIAL AND STORES & SPARES CONSUMED

a) RAW MATERIAL CONSUMED (Rs. in millions)

S. No.	Particulars	2018-2019		2017-2018	
		Amount	(%age)	Amount	(%age)
1.	Imported	7355.70	33.05	6641.63	48.07
2.	Indigenous	14897.47	66.95	7174.83	51.93

b) STORES & SPARES CONSUMED (Rs. in millions)

S. No.	Particulars	2018-2019		2017-2018	
		Amount	(%age)	Amount	(%age)
1.	Imported	1.45	0.92	0.17	0.12
2.	Indigenous	156.75	99.08	143.71	99.88

2.45 OTHER INFORMATION (Rs. in millions)

	Particulars	2018-2019	2017-2018
(a)	CIF Value of Imports		
1.	Raw Material	7099.23	6293.56
2.	Traded Goods	380.12	61.43
3.	Capital Goods, Store & Spares, Packing Material etc.	22.24	11.68
(b)	Expenditure in Foreign Currency		
1.	Travelling Expenses	4.59	8.79
2.	Export Commission	98.19	82.09
3.	Other Expenses	22.02	15.08
(c)	Remittances in Foreign Currency		
1.	Raw Material	6996.35	6367.47
2.	Traded Goods	381.67	59.90

	Particulars	2018-2019	2017-2018
2.	Capital Goods and Stores & Spares	19.83	28.09
(d)	Expenditure in Foreign Currency		
1.	Number of Non Resident Shareholders	2	2
2.	Number of Equity Shares held by them	72000000	72000000
3.	(i) Amount of Dividend Paid	3.6	3.6
	(ii) Year to which dividend relates	2017-18	2016-17
(e)	Earning in Foreign Currency		
	FOB Value of Exports	10715.03	9473.22

2.46 CORPORATE SOCIAL RESPONSIBILITY EXPENSES

Donation includes an amount of Rs. 12.17 millions (Previous Year Rs. 14.06 millions) incurred by the Company on Corporate Social Responsibility (CSR) activities during the year, in addition to Rs. 13.97 millions (Previous Year Rs. 6.74 millions) capital expenditure incurred on power plant which is also eligible for CSR activities. In totality the Company incurred Rs. 26.14 millions (Previous Year Rs. 20.80 millions) on CSR activities against the requirement of Rs. 12.44 millions (Previous Year Rs. 13.67 millions).

2.47 The Company has re-grouped previous year's figures to confirm to current year's classification.

FOR NECTAR LIFESCIENCES LIMITED

Sanjiv Goyal
Chairman & Managing
Director

For Ashwani K. Gupta & Associates
Chartered Accountants
Firm Regn. No. 003803N

Dinesh Dua
CEO & Whole time
Director

Ashwani K. Gupta
Partner
M. No. : 082808

Sandeep Goel
Chief Financial Officer

R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

Place : Chandigarh
Dated : 25.05.2019

Nectar Lifesciences Limited

(CIN: L24232PB1995PLC016664)

Registered Office: Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab

Email: sunderlal@neclife.com, Website: www.neclife.com

Phone: +91-01762-308000, Fax: +91-01762- 308135

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs.)

S. No.	Particulars		
1.	Name of the subsidiary	Nectar Lifesciences UK Limited	Nectar Lifesciences USA, LLC
2.	The date since when subsidiary was acquired	1 st March 2011	29 th Oct 2014
3.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	N.A.	1 st January, 2018 to 31 st December 2018*
4.	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	GBP and Exchange rate is INR 90.4756 for 1 GBP	US\$ and Exchange rate is INR 69.1713 for 1 US\$
5.	Share capital	75	3,301,942
6.	Reserves & surplus	-	5,387,731
7.	Total assets	75	115,914,252
8.	Total Liabilities	-	107,224,579
9.	Investments	-	-
10.	Turnover	-	286,764,946
11.	Profit/ (Loss) before taxation	-	2,680,046
12.	Provision for taxation	-	-
13.	Profit after taxation	-	2,680,046
14.	Proposed Dividend	-	-
15.	% of shareholding	100	100

* Consolidated Financial statements of Nectar Lifesciences Limited have been prepared based on the unaudited financial statements of Nectar Lifesciences USA, LLC for the year ended 31st Dec 2018, after duly incorporating the material transactions of Nectar Lifesciences USA, LLC held during the quarter ended March 31, 2019.

Notes: The following information shall be furnished at the end of the statement:

- 1) Names of subsidiaries which are yet to commence operations:
 - a) Nectar Lifesciences UK Limited
- 2) Names of subsidiaries which have been liquidated or sold during the year: N.A.

Part “B”: Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Name of associates/Joint Ventures	N.A.	N.A.	N.A.
1. Latest audited Balance Sheet Date	N.A.	N.A.	N.A.
2. Date on which the Associate or Joint Venture was associated or acquired	N.A.	N.A.	N.A.
3. Shares of Associate/Joint Ventures held by the company on the year end	N.A.	N.A.	N.A.
No.	N.A.	N.A.	N.A.
Amount of Investment in Associates/Joint Venture	N.A.	N.A.	N.A.
Extend of Holding%	N.A.	N.A.	N.A.
4. Description of how there is significant influence	N.A.	N.A.	N.A.
5. Reason why the associate/joint venture is not consolidated	N.A.	N.A.	N.A.
6. Net worth attributable to shareholding as per latest audited Balance Sheet	N.A.	N.A.	N.A.
7. Profit/Loss for the year	N.A.	N.A.	N.A.
i. Considered in Consolidation	N.A.	N.A.	N.A.
ii. Not Considered in Consolidation	N.A.	N.A.	N.A.

1. Names of associates or joint ventures which are yet to commence operations: N.A.

2. Names of associates or joint ventures which have been liquidated or sold during the year: N.A.

Note: This Form is to be certified in the same manner in which the Balance Sheet is to be certified.

For **NECTAR LIFESCIENCES LIMITED**

Sanjiv Goyal
Chairman & Managing Director

Dinesh Dua
CEO & Whole Time Director

Sandeep Goel
Chief Financial Officer


R.K. Aggarwal
Vice President Accounts

Ankita Jain
Company Secretary

As per our report of even date
For **Ashwani K. Gupta & Associates**
CHARTERED ACCOUNTANTS
Firm Regn. No. 003803N

Ashwani K. Gupta
Partner
M. No. 082808

Place : Chandigarh
Dated : 25.05.2019



Notes

A series of horizontal dotted lines for taking notes.

Form No. MGT-11

Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the company: NECTAR LIFESCIENCES LIMITED

CIN: L24232PB1995PLC016664

Registered office: Village Saidpura, Tehsil Derabassi,

Distt. S.A.S. Nagar (Mohali) Punjab – 140 507

Name of the member (s): _____ DP ID: _____

E-mail Id: _____ Folio No/ Client Id: _____

Registered address: _____

I/We, being the member (s) of shares of the above named company, hereby appoint:

1. Name _____ E-mail Id: _____

Registered address: _____

Signature: _____ or failing him

2. Name _____ E-mail Id: _____

Registered address: _____

Signature: _____ or failing him

3. Name _____ E-mail Id: _____

Registered address: _____

Signature: _____

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 24th Annual general meeting of the company, to be held on the September 28, 2019 at 10.00 a.m. at registered office and works of the company at Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) (Punjab) and at any adjournment thereof in respect of all or such resolutions as are indicated below:

Resolution Nos.

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.

**Affix
Revenue
Stamp**

Dated :

Signature of shareholder: _____


Signature of Proxy holder(s): _____

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Route map of loaction of 24th AGM.

A – Ambala Chandigarh Expressway (NH-22) at Derabassi.

B – Nectar Lifesciences Limited, Works and Registered Office at Village Saidpura, Derabassi, Punjab.



CORPORATE INFORMATION

BOARD OF DIRECTORS

1. Mr. Sanjiv Goyal	:	Chairman & Managing Director
2. Dr. Dinesh Dua	:	Chief Executive Officer & Director
3. Mr. Ajay Swaroop	:	Independent Director
4. Ms. Guljit Sethi	:	Independent Director
5. Mr. Rupinder Tewari	:	Independent Director
6. Dr. (Maj. Gen.) S.S. Chauhan, VSM (Retd.)	:	Independent Director
7. Ms. Meena Verma	:	Nominee Director
8. Mr. Vivek Seth	:	Director

◆ Chief Financial Officer

Mr. Sandeep Goel

◆ Vice President (Accounts)

Mr. R.K. Aggarwal

◆ Auditors

M/s Ashwani K. Gupta & Associates
Chartered Accountants
H.No. 1044-A, Sector-2, Panchkula

◆ Bankers

1. Punjab National Bank, Chandigarh
2. State Bank of India, Chandigarh
3. EXIM Bank, Mumbai
4. Axis Bank, Mumbai
5. Jammu and Kashmir Bank Limited, Chandigarh
6. Shinhan Bank, Delhi

◆ REGISTERED OFFICE

Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Punjab), INDIA
Ph: 01762-308000, 308001 Fax: 01762-281187

◆ CORPORATE OFFICE

SCO-38-39, Sec-9-D Chandigarh 160009 (UT), INDIA
Ph: 0172-3047777, 3047701
Fax: 0172-3037755
Website: <http://www.neclife.com>

◆ HEAD OFFICE

F-66, 6th Floor, Himalaya House
23 KG Marg, C.P. New Delhi-110001, INDIA
Ph: 91-11-42403311-22

◆ Plant Locations

1. Nectar Lifesciences Limited-Unit-1

Village Saidpura, Tehsil Derabassi Distt.
S.A.S Nagar, (Punjab)

2. Nectar Lifesciences Limited-Unit-2

Village Saidpura, Tehsil Derabassi
Distt. S.A.S Nagar, (Punjab)

3. Empty Hard Gelatin Capsule Unit

Village Bhatoli Kalan, Pargana Dharampur
Tehsil Nalagarh, Distt. Solan (H.P)

4. Formulation Unit

Village Bhatoli Kalan, Pargana Dharampur
Tehsil Nalagarh, Distt. Solan (H.P)

5. Narbada Industries


Plot no-2, Lane no-4, Phase-2,
SIDCO Industrial Complex,
Bari Barhmana, Jammu (J & K)

6. Guar Gum Unit

Village - Basauli, Near Lalru, Tehsil - Derabassi
Distt. S.A.S. Nagar, (Punjab)

◆ Registrar & Share Transfer Agent

Karvy Fintech Pvt Limited
Unit: Nectar Lifesciences Ltd.
Karvy Selenium Tower-B
Plot No.31-32, Gachibowli, Financial District,
Nanakramguda, Serilingampally, Hyderabad- 500032
Ph. 040-67161527 Fax. 040-23311968



Nectar Lifesciences Ltd.

SCO 38-39, Sector 9D, Madhya Marg, Chandigarh 160009(India)

www.necLife.com



NECTAR LIFESCIENCES LIMITED

CIN: L24232PB1995PLC016664

Regd. Office: Village Saidpura, Tehsil – Derabassi, Distt. S.A.S Nagar (Mohali) Punjab – 140507, India.
Phone: 01762-308000, 308001; **Fax:** 01762-308135, **Email:** cs@neclife.com, **Website:** www.neclife.com

ATTENDANCE SLIP

Sr. No.:

Registered Folio No. / DP No. / Client No. :	
Name and Address of the Shareholder :	
Name(s) of the Joint Holder(s) if any :	
No. of shares held :	
Full name of Proxy (IN BLOCK LETTERS) :	

I hereby record my presence at the ANNUAL GENERAL MEETING (AGM) of the Company held on Saturday, September 28, 2019 at Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S Nagar (Mohali) Punjab – 140507, at 10.00 a.m.

Member's / Proxy Signature

Notes:

1. Members/Proxy holders are requested to produce the attendance slip duly signed for entry to the AGM hall.
2. Members are requested to bring their copy of AGM Notice for the reference at the Meeting.

ELECTRONIC VOTING PARTICULARS

EVEN(E Voting Event Number)	User ID	PASSWORD
4860		

GENERAL INSTRUCTIONS

1. The Members, whose names appear in the Register of Members / list of Beneficial Owners on the close of the day on Saturday, September 21, 2019 (cut-off date), i.e. the date prior to the commencement of book closure, are entitled to vote on the Resolutions set forth in this Notice.
2. The voting rights of the Members for e-voting shall be in proportion to the paid up value of their shares in the equity share capital of the Company as on the cut-off date.
3. The Board has appointed Mr. Prince Chadha of M/s. P. Chadha & Associates, Company Secretaries, Chandigarh as a Scrutinizer to scrutinize the physical voting and e-voting process in a fair and transparent manner and he has communicated his willingness to be appointed and will be available for same purpose.
4. After the conclusion of voting at the AGM, the scrutinizer shall, immediately first count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses (who shall not be in the employment of the company). Thereafter, Scrutinizer shall give a consolidated report, specifying the total votes cast in favour or against, if any, within forty eight hours of conclusion of the meeting, to the Chairman or a person authorised by him in writing who shall countersign the same. The Chairman or a person authorised by him in writing shall declare the result of the voting forthwith. The results declared shall be available on the website of the Company (www.neclife.com) and on the website of the Karvy (<https://evoting.karvy.com>). The results shall simultaneously be communicated to the Stock Exchanges. The resolutions will be deemed to be passed on the date of AGM subject to receipt of the requisite number of votes in favour of the resolutions.

Instructions and other information relating to remote e-voting (e-voting) are as under:

1. The remote e-voting facility will be available at the link <https://evoting.karvy.com> during the following voting period:
Commencement of remote e-voting: FROM 9.00 a.m. on Wednesday, September 25, 2019.
End of remote e-voting: TO 5.00 p.m. on Friday, September 27, 2019.
2. In case a Member receives an email from Karvy (for Members whose email Ids are registered with the Company/Depository Participant(s)):
 - a) Launch internet browser by typing the URL: <https://evoting.karvy.com>.
 - b) Enter the login credentials (i.e. User id and password mentioned in e-mail). Your Folio No./ DP ID / Client ID will be your User ID. However, if you are already registered with Karvy for e-voting, you can use your existing User ID and password for casting your vote.
 - c) After entering these details appropriately, click on "LOGIN".
 - d) You will now reach password change menu wherein you are required to mandatorily change your password. The new password shall comprise minimum 8 characters with at least one upper case (A-Z), one lower case (a-z), one numeric (0-9) and a special character (@,#,\$,etc.). The system will prompt you to change your password and update your contact details like mobile number, email ID etc. on first login. You may also enter a secret question and answer of your choice to retrieve your password in case you forget it. *It is strongly recommended that you do not share your password with any other person and take utmost care to keep your password confidential.*
 - e) You need to login again with the new credentials.
 - f) On successful login, the system will prompt you to select the E-Voting Event Number (EVEN) for Nectar Lifesciences Limited.
 - g) On the voting page enter the number of shares (which represents the number of votes) as on the cut-off Date under each of the heading of the resolution and cast your vote by choosing the "FOR / AGAINST" or alternatively, you may partially enter any number in "FOR" and partially in "AGAINST" but the total number in "FOR / AGAINST" taken together should not exceed your total shareholding as mentioned overleaf. You may also choose the option "ABSTAIN" and the shares held will not be counted under either head. Option "FOR" implies assent to the resolution and "AGAINST" implies dissent to the resolution.
 - h) Members holding multiple folios / demat accounts shall choose the voting process separately for each of the folios / demat accounts.
 - i) Voting has to be done for each item of the Notice separately. In case you do not desire to cast your vote on any specific item it will be treated as abstained.
 - j) You may then cast your vote by selecting an appropriate option and click on "Submit".
 - k) A confirmation box will be displayed. Click "OK" to confirm else "CANCEL" to modify. Once you confirm, you will not be allowed to modify your vote. **During the voting period, Members can login any number of times till they have voted on the Resolution(s).**
 - l) Corporate / Institutional Members (i.e. other than Individuals, HUF, NRI, etc.) are also required to send scanned certified true copy (PDF / JPEG Format) of the Board Resolution / Authority Letter etc. together with attested specimen signature(s) of the duly authorised representative(s), to the Scrutinizer at e-mail id: prince.chadha88@gmail.com. They may also upload the same in the e-voting module in their login. The scanned image of the above mentioned documents should be in the naming format "Corporate Name_EVENT NO."
3. In case a Member receives physical copy of the Annual General Meeting Notice by courier (for members whose email Ids are not registered with the Company/Depository Participant(s)).
 - a) User ID and initial password are provided overleaf.
 - b) Please follow all steps from Sr. No. (a) to (l) as mentioned in (1) above, to cast your vote.
4. Once the vote on a resolution is cast by a Member, the Member shall not be allowed to change it subsequently or cast the vote again.
5. In case of any query pertaining to e-voting, please visit Help & FAQ's section available at Karvy's website <https://evoting.karvy.com> or call Karvy on 040-67161616 or send an e-mail request to evoting@karvy.com.
6. The facility for ballot / polling paper shall be made available at the Annual General Meeting (AGM) and the members attending AGM who have not cast their vote by e-voting shall be able to vote at the AGM through ballot / polling paper. The members who have cast their vote by e-voting may also attend AGM, but shall not be entitled to cast their vote again.
7. Any person who becomes member of the Company after dispatch of the Notice of the meeting and holding shares as on the cut-off date may obtain the User Id and password in the manner as mentioned below:
 - a) If the mobile number of the member is registered against Folio No./ DPID Client ID, the member may send SMS:
MYEPWD<space> E-Voting Event Number +Folio no. or DPID Client ID to +91-9212993399
Example for NSDL: MYEPWD<SPACE>IN12345612345678
Example for CDSL: MYEPWD<SPACE>1402345612345678
Example for Physical: MYEPWD<SPACE> XXXX1234567890
 - b) If e-mail address or mobile number of the member is registered against Folio No. / DPID Client ID, then on the home page of <https://evoting.karvy.com>, the member may click "Forgot Password" and enter Folio No. or DPID Client ID and PAN to generate a password.
If the member is already registered with Karvy for e-voting, he can use his existing User ID and password for casting the vote through e-voting.